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DIANA BRIDGET FULMER. Ciliogenesis and Cilia-Mediated Signaling in Cardiac 
Valve Development and Disease. (Under the direction of RUSSELL A. NORRIS) 
 
ABSTRACT 
 Mitral valve prolapse (MVP) and bicuspid aortic valve (BAV) are serious heart 
conditions that affect a combined 3-4% of the world population. These diseases carry 
high risk for secondary complications including arrhythmia, blood regurgitation, and 
sudden cardiac death. Often, valve diseases are heritable and have complex origins that 
are not fully understood. The lack of knowledge about valve disease causation likely 
contributes to the absence of non-surgical treatment options for this patient population. 
 Recent work by our lab and others has demonstrated a link between defects in 
primary cilia and the development of heart valve disease in humans. Primary cilia are 
singular, non-motile, microtubule-derived, signaling organelles that are ubiquitous to 
most cell types. In cardiac valves, they are spatially and temporally regulated, appearing 
primarily on interstitial cells during valvulogenesis. This dissertation presents evidence 
that ciliogenesis in the valves is dependent on a highly conserved octameric protein 
trafficking complex known as the exocyst. We demonstrate that defects in exocyst 
trafficking result in shorter, less prevalent cilia, the development of bicuspid aortic valves 
and myxomatous mitral valves in mice, and arterial stenosis in zebrafish. We also 
uncovered links between ciliome variants and BAV in humans through GWAS analysis. 
Additionally, we present findings that establish Desert Hedgehog (DHH) signaling as a 
necessary ciliary signaling pathway in valvulogenesis. Through morphometric analysis of 
murine mitral valves and biochemical in vitro studies with embryonic chicken valve cells, 
we describe a novel paracrine crosstalk mechanism emanating from the DHH expressing 
 xiii 
endocardium that influences the production of alpha smooth muscle actin (a-SMA) by 
the ciliated valve interstitial cells to promote valve remodeling. This newly generated 
hypothesis will guide future studies and may provide mechanistic insights of ciliopathies 
in other tissues. 
 This project led to a new understanding of valve development and highlights the 
importance of the exocyst, primary cilia, and Desert Hedgehog signaling in valve 
morphogenesis. Genetic defects in any portion of this system result in faulty valve 
architecture and disease progression. Insights from this work will inform future 
discoveries into disease origins and progression and potentially lead to the identification 









Chapter 1: Introduction 
  
 15 
1.1 Heart Anatomy and Evolution 
The heart is the first organ to function in a developing vertebrate embryo, and its 
earliest cellular contractions can be detected in the cardiac crescent even before the 
fusion of the primitive heart tube1. Most animals, including humans, have body plans that 
are too complex for simple diffusion and thus require a heart for all but the earliest stages 
of embryonic growth to circulate nutrients and support cellular gas exchange. Even 
insects with their open circulatory system and disparate tracheal system require a heart to 
circulate hemolymph to their wings and throughout their bodies2. As would be expected 
by its indispensable raison d’être, the permanent arrest of this vital organ is also a clinical 
determination of death3. Sufficing to say that despite millennia of human chorus and 
composition to the contrary, it is nearly impossible to thrive as a chordate and truly be 
“heartless”, though as will be discussed in subsequent chapters, it is quite possible to 
suffer from a “broken” heart. 
Though functionally similar in rudiments of circulation, cardiac anatomy varies 
greatly between classes of the phylum Chordata. For example, Osteichthyes (bony fish) 
have a two-chambered heart consisting of a singular ventricle and atrium, while members 
of Amphibia have three chambers consisting of two atria and a common ventricle. 
Although a two chambered anatomy is sufficient for the needs of a fish, it lacks the 
advantage of a secondary pumping force to deliver blood to the brain and body after 
oxygenation, limiting its metabolic efficiency4. This problem is circumvented in 
amphibians with the return of blood to the heart prior to somatic distribution. However, 
even though some amphibian hearts have a primitive septum principale at the arterial 
pole of the ventricle and a spiraled valve in the common truncus arteriosus to limit the 
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mixing of oxygenated and deoxygenated blood5, they lack the complete outflow tract 
(OFT) separation and muscular ventricular septum that emerged to varying degrees in the 
class Reptilia6. The metabolic advantages of reduced blood mixing offered by the 
reptilian heart were then further improved with the divergence of the classes Aves and 
Mammalia, which convergently evolved a fully septate, four-chambered heart7, affording 
both groups greater circulation efficiency and thermoregulation than their distant 
ancestors8. 
In addition to variance in gross anatomy, cardiac tissue differs in cellular structure, 
progenitor population proportions, and extracellular composition between even more 
closely related mammals such as humans, mice and rats9. Logically, this makes sense as 
humans and rodents are separated by more than 90 million years of divergent evolution, 
and have been subjected to vastly different selection forces over that time. Just one 
example of these tissue disparities is that the human mitral valve has at least six distinct 
matrix layers whereas the smaller murine counterpart contains only two or three10. 
Further, mice develop atherosclerotic lesions in different vessels than humans, and can 
even have complete blockage of the vessel lumen without evidence of a heart attack11. 
These compositional and molecular differences place limitations on data interpretation, 
and broader application of findings from small animal models must be rigorously 
confirmed in the translation to human disease treatment12,13. 
However, despite the anatomical and biochemical differences between species, 
humans share 95% of their DNA with mice14 and there is much that can be learned about 
heart development and function from a variety of model systems. Broadly, the molecular 
environments of endocardium, myocardium, and epicardium are similar in corresponding 
 17 
tissues between animals. Gene composition, regulation, and expression are often highly 
conserved across the boundaries of genus, and can be teased apart in vitro, in vivo, and in 
silico through a variety of manipulations and perturbations that would not be possible in 
human patients. There is also remarked similarity in cardiogenesis between animal 
species as a result of their shared evolutionary origins. 
In mammalian and avian hearts, development begins when the first cardiac progenitor 
cells arise at gastrulation from the anterior lateral plate mesoderm15,16. These progenitor 
cells then migrate along the cranial rim of the embryo to form two populations on either 
side of the primitive streak, and then extend along the midline to create the cardiac 
crescent17-19. The cardiac crescent is comprised of two distinct progenitor populations 
known as the first heart field (FHF) and second heart field (SHF)20. The FHF, as its name 
implies, is the first region to show differentiation towards the cardiac cell-fate, and its 
cells primarily contribute to the formation of the left ventricle and both atria21. Cells from 
the SHF differentiate slightly later than FHF cells, and contribute primarily to the 
formation of the right ventricle and the OFT22-24. Both FHF and SHF progenitor 
populations express cardiac specific markers such as GATA4, NKX2.5, and MEF2C, but 
they also have lineage-specific markers such as TBX5 (FHF) and ISL1 (SHF) which 
distinguish their origins21,25. 
Embryonic folding during gastrulation causes the cardiac crescent to fuse and 
restructure into an inverted Y-shaped heart tube that consists of a lumen surrounded by 
endothelial cells that are covered by myocardium26 (E7.5-E8 in the mouse). After the 
formation of the linear heart tube, SHF cell contribution at the arterial and venous poles 
cause the tube to lengthen and subsequently bend to form a right-handed cardiac loop 
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(E8.5)27,28. Asymmetry is an essential step to cardiogenesis, and is tightly controlled by a 
Left-Right Organizer (LRO) in which ciliated cells direct extraembryonic fluid flow to 
transduce temporal-spatial activation of genes including nodal, lefty, and Pitx229. Once 
the heart tube has looped, distinct atrial, ventricular, and OFT components can be 
identified, and additional contributions are made to cardiac structures by cell migration 
from the neural crest and proepicardium at approximately E10.525,30. Heart tube looping 
also signals for the secretion of cardiac jelly by the myocardium and the beginning stages 
of valvulogenesis10. 
1.2 Heart Valve Growth and Development 
Mammalian and avian hearts contain four sets of unidirectional valves that act to 
maintain sequential blood flow through the cardiac chambers, pulmonary circuit, and 
systemic circulation. These valves can be further divided into the atrioventricular (AV) 
aka inlet valves, which regulate blood flow into the ventricles from the atria, and the 
semilunar (SL) or outlet valves, which control the exit of blood from the heart. Though 
the AV and SL valves arise in different regions of the heart and are composed of different 
cell population proportions, their geneses progress through the same basic stages. In both 
cases, valves begin their journey in the acellular layer of hyaluronic acid, 
glycosaminoglycans and sulfates, termed “cardiac jelly” that exists between the 
myocardium and endothelial layer of the linear heart tube10,31 . As the heart tube loops to 
create its asymmetrical form, the myocardium produces growth factors that engorge the 
cardiac jelly and expand it to generate small pouches that line the annular regions of both 
the AV junction and OFT. These pillowy expansions of tissue encroach into their 
respective cardiac lumens to produce structures known as endocardial cushions32.  
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As the endocardial cushions fill with extracellular matrix (ECM), some of the 
endothelial cells lining the luminal surface of the primordial heart lose the expression of 
the adhesion proteins that maintain their connection to the surrounding endothelium33. 
This leads to the delamination of these cells from the endothelial lining of the cardiac 
cushions and results in a regulated migration with other freed cells into the expanded 
cardiac jelly34. This process is known as endothelial to mesenchymal transition (EMT), 
and is a critical step to the cellularization of the primitive valves. As these cells migrate 
into the developing cushions, they also rapidly proliferate and increase in size33,35.  
In the common AV canal, the expansion of the superior (dorsal) and inferior 
(ventral) endocardial cushions continues until they make contact and fuse to form the 
atrioventricular cushion (AVC), beginning the process of cardiac septation and dividing 
the heart into right and left halves36. An additional endocardial cushion extends from each 
lateral wall of the heart at the AV annulus to form the posterior mitral and lateral mural 
tricuspid leaflets on the left and right respectively37,38. Similarly, in the OFT, the conal 
and truncal cushions expand and fuse prompting the creation of a spiraled 
aorticpulmonary septum that bifurcates the common OFT into pulmonary and aortic 
vessels33. Here also two additional endocardial cushions develop, known as the 
intercalating cushions, that extend into the base of both major outlet vessels, giving the 
SL valves a tricuspid conformation and contributing the non-coronary (NC) cusp and 
anterior leaflet of the aortic and pulmonary valves respectively36.  
Both inlet and outlet valves are colonized through the early stages of development 
by cells from different linages. While delaminated endocardial cells and their derivatives 
from the FHF make the major contribution to cardiac valves in general39, additional 
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contributions are received from epicardial derived cells (EPDCs)40,41 and cells migrating 
from the neural crest42,43 through similar EMT processes36. The contribution of these cells 
to the mesenchymal population of each valve cushion is variable with the majority of 
EPDCs contributing to the lateral leaflets of the inlet valves and the neural crest cells 
(NCCs) making a major contribution to the truncal cushions of the outlet valves. 
However, NCCs and EPDCs both also make minor contributions to the septal leaflets of 
the inlet valves44. NCCs first begin their migration by leaving the dorsal neural tube at 
E9.545. They colonize the SL cushions by E11.5, and can be detected in the 
atrioventricular cushion (AVC) by E12.546. EPDCs similarly arrive at the lateral leaflets 
of the AV valves at approximately E12 by migrating through the AV junction, and they 
comprise the majority cell population in the lateral leaflets by E1547. Defects in the 
migration and behavior of both of these cell types have been of interest to researchers due 
to their potential association with the development of cardiac valve defects. For example, 
EPDCs replace the majority of endocardial cell derivatives in the lateral AV leaflets, 
which are the leaflets most commonly affected in diseases such as Ebstein’s anomaly, 
mitral valve prolapse, and tricuspid stenosis36,37,48. Likewise, deficiencies in NCC 
behavior have been attributed to the development of right-left coronary cusp fusion 
patterns observed in BAV49.  
Both inlet and outlet valves also receive additional mesenchymal cell 
contributions from the Isl1+ SHF. In the case of the inlet valves, this happens through the 
SHF creation of the dorsal mesenchymal protrusion (DMP), which fuses with the major 
endocardial cushions during early cardiac septation50,51. During this process the DMP acts 
to bridge the dorsal region of the superior and inferior AV cushions, contributing to the 
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creation of the atrioventricular mesenchymal complex52. The DMP eventually becomes 
muscularized, and few, if any cells, from this structure permanently incorporate into the 
atrioventricular cushion as valve interstitial or endocardial cells. However, studies have 
indicated there is a contribution of SHF cells to the formation of the intercalating 
cushions of the outlet valves. This is reported to happen directly by SHF mesenchymal 
cells that join the cushion to become valve cells53 and SHF cells that first differentiate 
into other cell types such as endothelial cells that then join the valve population54,55.  
In addition to endocardial cells, their derivatives, EPDCs, NCCs, and SHF cells, 
there are also contributions to valve cell populations from circulating bone marrow 
derived cells (BMDCs)10. Studies have shown that BMDCs contribute to valves from late 
embryonic56 to adult57 timepoints, and localize specifically to a subepicardial layer of the 
atrialis of inlet valves and the ventricularis of outlet valves58. The function of this cell 
population is still being investigated, but it is known that their contribution to valve 
populations increases with age56, and that they have collagen producing properties similar 
to fibroblasts58. It is thought that these cells contribute to valve homeostasis59 as well as 
the remodeling in response to disease60, and their properties have been of particular 
interest to bioengineers in their endeavors to create tissue-engineered heart valves61,62. 
Once the endocardial cushions have been colonized by EMT and expanded 
through rapid cellular proliferation, the mesenchymal population begins a terminal 
differentiation into valvular interstitial cells (VICs) that further remodel ECM to stratify, 
elongate, and thin the developing valves into their mature form10. VICs help to facilitate 
these structural changes through the production, alignment and regional organization of 
vast quantities of matrix proteins such as collagens, versican, and elastin63. This ECM 
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turnover transitions the endocardial cushions from a gelatinous environment to a tightly 
compacted fibrous tissue. However, the mechanisms by which VICs contribute to the 
compression of the valves are largely unknown. What is clear, is that VICs can remodel 
the ECM and drive shape changes in the valve through tissue remodeling64-67.  
Before remodeling, the endocardial cushions are soft and pillowy, and they lack 
the sturdy rigidity of mature valves. As the hemodynamic forces increase during valve 
development, the atrioventricular cushions need support, which is provided by 
myocardium as they elongate into the ventricular lumen68,69. The tricuspid septal leaflet 
remains fixed to the ventricular septum until it delaminates at E17.570, but the lateral 
leaflets of both the tricuspid and mitral valves develop along a myocardial scaffold36. The 
anterior mitral leaflet does not have a myocardial template like the other AV leaflets, but 
does have connections to the mitral gully along its margins71. The myocardium 
underlying the inlet valves is eventually degraded and remodeled to liberate the leaflets 
and likely contributes to the formation of the chordae and papillary muscles10,36. Rather 
than developing on muscular template like the AV valves, the SL valves are excavated to 
form depressions on the arterial side of the cushions72. They then experience regionalized 
growth along the luminal edges of the cusps that elongates them further and forms ridges 
where the cusps meet during diastole36. 
These physiological changes in both AV and SL valves are highly regulated 
processes, coordinated through precisely timed cell signaling events. Immense volumes 
of literature have been dedicated to the dissection of these events, and it is universally 
recognized that major pathways such as the TGFb, Wnt, and Notch signaling cascades 
have important roles in each stage of valvulogenesis. However, many cilia-mediated 
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pathways such as the Hedgehog pathway, have yet to be adequately explored in the 
context of valve development. Given the growing evidence of a role for primary cilia in 
valvulogenesis, it is increasingly important to understand more about the generation of 
these organelles and their downstream signaling consequences. 
1.3 Primary Cilia 
Previous work by our lab and others have implicated organelles known as primary 
cilia as essential regulators of heart valve development. Primary cilia are singular, 
membrane-bound bundles of microtubules that project from the surface of cells to interact 
with the extracellular environment and transduce signaling. The microtubule skeleton of a 
primary cilium is arranged in a 9+0 configuration, and the lack of a central microtubule 
doublet, radial spokes, and inner and outer dynein arms renders these organelles immotile 
(Figure 1.1). However, these inert structures are far from inactive. Primary cilia are 
dynamic signaling hubs whose membranes are studded with an array of receptors that 
respond to cues for cellular differentiation, proliferation, matrix deposition, and other 
critical developmental and homeostatic functions73. They are ubiquitous to most cell 
types74, and can respond to physical mechanical forces such as fluid flow and sheer 





Figure 1.1: Cilia Structure. Cilia are microtubule derived organelles, and consist of a 
motile or immotile axoneme contingent on the presence or absence of a central 
microtubule doublet and associated motor proteins such as the outer dynein arm (ODA), 
inner dynein arm (IDA), and radial spokes. The basal body is made from the mother 
centriole docked to the plasma membrane and is surrounded by a network of proteins 
called the pericentriolar matrix (PCM). Vesicles from the Golgi dock at the distal 
appendages and a tightly controlled transition zone (TZ) regulates traffic into and out of 
the ciliary axoneme. 
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 The foundation of every primary cilium is the mother centriole, which serves as 
an anchoring basal body during G0/G1 and until reentry of the cell cycle at which time 
the cilium is disassembled78,79. The basal body initiates ciliogenesis through attachment 
to the plasma membrane80. It is embedded in a pericentriolar matrix (PCM), which is an 
intricate mass of receptors and cytoskeletal proteins that influence signaling and tubulin 
nucleation81. The PCM also provides a network of cytoskeletal highways for protein 
trafficking complexes to help guide the delivery of Golgi derived vesicles82. These 
vesicles dock at the distal appendages of the basal body to deliver their cargo of 
ciliogenic proteins, such as intraflagellar transport (IFT) proteins, which are required to 
build the ciliary axoneme (Figure 1.1). The axoneme is constructed of a microtubule-
based scaffold and covered by a PI(4)P phosphoinositide-rich membrane that is 
contiguous with, but distinct from the PI(4,5)P2 phosphoinositide membrane of the ciliary 
transition zone and cell plasma membrane83. The axoneme can be thought of as the 
“antenna” portion of the cilium as it protrudes from the cell surface and houses the 
receptors that transduce extracellular signals. Between the basal body and axoneme is a 
transition zone (TZ), which governs the entry and exit of proteins from the axoneme. 
 In cardiac valves, primary cilia are broadly expressed by mesenchymal and 
valvular interstitial cells (VICs) throughout embryonic development84-86. The presence of 
primary cilia has been noted in this cell population at the earliest stages of valvulogenesis 
in both the aortic and mitral cushions, but their expression is almost completely absent in 
adult cardiac valves. Valvular endocardial cells (VECs) are also generally devoid of cilia 
at most time points84-86, but have been reported during the early stages (E9.5-E12.5) of 
valvulogenesis29. The loss of VEC cilia expression later in valvulogenesis coincides with 
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a period of increased hemodynamic force in the heart and likely represents a resorption 
response to sheer stress as has been documented in other cell types. Conditional ablation 
of primary cilia in cardiac valves through deletion of the necessary cilia gene, Ift88, has 
been shown to result in increased prevalence of bicuspid aortic valves and myxomatous 
mitral valves in mice85,86. The temporal and spatial expression patterns of primary cilia 
during valvulogenesis and the association of cilia mutations with valve disease supports 
their role as signaling coordinators that influence valve morphogenesis. Teasing apart the 
signaling mechanisms of primary cilia in valve development was a major aim of this 
dissertation and a core focus of the Norris Lab. 
There are hundreds, if not thousands, of proteins that comprise the “ciliome”87, 
and mutations in the genes that produce them are associated with diseases known as 
ciliopathies. Ciliopathies have a wide range of phenotypes including obesity, cystic 
kidneys, blindness, and cognitive impairment. Work by our lab and others has identified 
cilia gene mutations in families with non-syndromic mitral valve prolapse and cilia 
variants associated with human bicuspid aortic valve disease. The associations between 
cilia and the heart is supported by the fact that patients with recognized ciliopathies have 
a higher than average rate of heart diseases88. For example, individuals with polycystic 
kidney disease (PKD) have a 10-fold greater risk of developing mitral valve prolapse89. 
Understanding the signaling pathways involved in ciliary regulation of tissue 
development is critical to developing new therapeutics and could improve the outcome 




1.4 Hedgehog Signaling 
Hedgehog (HH) signaling is a well-characterized, cilia-dependent90 pathway that 
is closely associated with regulation of embryonic development and adult tissue 
homeostasis. It was first discovered in Drosophila in 1980 by the Nüsslein-Volhard and 
Wieschaus groups, and contributed to the work that garnered their Nobel Prize with 
Edward Lewis in Physiology or Medicine in 1995. Components of this pathway are 
highly conserved between species91, and expression of Hedgehog ligands, receptors, and 
cofactors is tightly controlled by cells in temporal and spatial patterns that vary between 
tissues92-94. There are three different HH ligands, Sonic (SHH), Indian (IHH), and Desert 
(DHH), the first of which was named by a British postdoc in the lab of Cliff Tabin after a 
then unknown comic book character. Indian and Desert Hedgehog were discovered first, 
and they were named after two species of hedgehogs due to the mutant Drosophila 
larvae’s supposed resemblance to the prickly mammals. All of these ligands are 
processed by autocatalytic cleavage to produce the bioactive N-terminal peptide and then 
undergo modification by cholesterol which leads to their secretion at the plasma 
membrane95.  
 Once secreted, HH ligands are able to bind to Patched receptors96 (PTCH1 and 
PTCH2), which reside near the base of the ciliary axoneme. In the absence of HH 
signaling, PTCH1/2 proteins function to inhibit the entry of a G-protein coupled receptor 
(GPCR) named Smoothened (SMO) into the ciliary axoneme97 (Figure 1.2A). When 
bound to HH ligand, the inhibition by PTCH is removed, and SMO is able to translocate 
into the axoneme where it signals to prevent the cleavage of the transcription factor, 
GLI3, and activates Hedgehog target gene transcription (Figure 1.2B). Though the exact 
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mechanism of PTCH-mediated SMO inhibition is not fully understood, it has been 
hypothesized that PTCH is able to allosterically inhibit interactions between SMO and 
oxysterols, which are required for SMO activation98. In fact, multiple steps in the 
Hedgehog signaling cascade are known to require interaction with oxysterols that serve 
as cofactors that modify the conformations of PTCH and SMO through mechanisms that 
are still being explored99.  
The Hedgehog pathway is complex, and in addition to interactions with 
cholesterol derivatives, requires signaling inputs from a variety of other cofactors and 
receptors. While many of these interactions are still being described, strong evidence 
suggests the involvement of protein kinase A (PKA) signaling as a negative regulator of 
the Hedgehog pathway. PKA signaling is initiated in the absence of Hedgehog by the 
GPCR, GPR161, which maintains high cAMP levels that lead to PKA activation100,101. 
Under these conditions, PKA phosphorylates GLI3, which marks it for proteolytic 
cleavage and results in its repressor form (GLI3R) translocating to the nucleus to 
suppress the transcription of HH target genes102 (Figure 1.2A). As part of this 
mechanism, a protein known as, SuFu, also acts as a negative HH regulator by forming a 
complex with GLI factors and inhibiting GLI3 trafficking it to the ciliary axoneme103. 
However, upon Hedgehog signaling, SuFu is recruited to the axoneme and the complex is 
dissociated, releasing GLI3 activator (GLI3A), which then translocates to the nucleus to 
promote the transcription of HH target genes104,105. Interestingly, in addition to its role as 
a negative regulator of Hedgehog signaling, studies have indicated that PKA may 
promote downstream signaling upon Hedgehog stimulation through phosphorylation of 
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Figure 1.2: Simplified Canonical Hedgehog Signaling Model. (A) In the absence of 
Hedgehog (HH) ligand, Patched1 (PTCH1) receptor acts to suppress the entry of 
Smoothened (SMO) into the ciliary axoneme. Concurrently, GPR161 signaling maintains 
high cAMP levels that activate PKA. PKA is then able to phosphorylate full length GLI3 
(GLI3FL) to inhibit the accumulation of SuFu/GLI3 complexes in the axoneme. This 
results in the cleavage of GLI3 in to its repressor form (GLI3R), which acts to suppress 
the transcription of Hedgehog (HH) targeted genes. (B) However, when present, HH 
ligand binds to PTCH1 and releases the inhibition against SMO. SMO interacts with 
oxysterols that allow it to change conformation and translocate to the ciliary axoneme. 
This promotes the endocytosis of GPR161 receptors and SuFu/GLI3 accumulation into 
the axoneme. GLI3 then dissociates from SuFu and is modified into its activator form 





Hedgehog signaling that activates GLI3-dependent transcription through a HH-
PTCH1-SMO mechanism is known as the “canonical” Hedgehog pathway. This pathway 
has been shown to be critical in embryo patterning, and is most commonly associated 
with the SHH ligand. All three HH ligands bind to PTCH1 with equivalent affinity, 
however SHH has a greater ability to activate GLI signaling than either IHH or DHH108. 
SHH and IHH are closer in homology than DHH, and commensurately DHH has less 
ability to induce canonical signaling than the other two ligands109. It has been 
hypothesized that the differences between ligand signaling affinity could be due to cell 
type specific expression patterns and minor disparities in their N-terminal motifs which 
lead them to interact with different sets of accessory proteins109. 
 It is logical to consider that these differences between the HH ligands could 
indicate discrete signaling behavior in vivo. It is thus also not surprising that in addition 
to canonical signaling, several types of non-canonical signaling have also been identified 
for the Hedgehog pathway. Type I non-canonical signaling is a PTCH-dependent but 
SMO and GLI-independent pathway which induces apoptosis108 (Figure 1.3A). It has 
been reported that the Type I pathway also regulates cell cycle progression through 
PTCH1 binding with Cyclin B1 in its phosphorylated form to reduce cell proliferation110. 
Mutations in PTCH1 are also known to be responsible for most forms of basal cell 
carcinoma and nevoid basal cell carcinoma syndrome91, emphasizing the importance of 
this receptor in regulating cell turn over and survival. Type II non-canonical signaling is a 
SMO-dependent, GLI-independent pathway, which is known to induce cytoskeletal 
reorganization through activation of members of the RHO GTPase protein family108,111,112 
(Figure 1.3B). Unlike canonical HH signaling, all three ligands seem able to participate 
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equally in non-canonical pathways108,109. However, unlike SHH and IHH, cell-type seems 
to be particularly important to DHH binding efficiency. It has been speculated that this is 
because unidentified accessory molecules are required to amplify cell response to DHH 
signaling, and thus DHH sensitivity varies by cell lineage109.  
 Very little has been written about Hedgehog signaling in valve development, 
though several studies exist that examine SHH expression and signaling in the posterior 
SHF113, DMP114, and ventricular septum115. These studies disrupt different portions of the 
SHH signaling pathway with lineage-specific cres, resulting in atrial septal defects 
(ASDs)113 and atrioventricular septal defects (AVSDs)113,114 with the ablation of 
Smoothened, and ventricular septal defects (VSDs) with the disruption of Sufu115 in mice. 
These studies provide evidence for a relationship between SHH signaling disturbance and 
the prevalence of human cardiac defects such as AVSDs in Trisomy 21 patients115. It is 
thus logical to hypothesize that Hedgehog signaling could have a role to play in 
valvulogenesis as well, and examination of this pathway and its association with a disease 




Figure 1.3: Non-canonical Hedgehog Signaling. (A) Type I non-canonical Hedgehog 
signaling (HH) is Patched1 (PTCH1) dependent and results in alterations in cell cycle and 
apoptosis. (B) Type II non-canonical HH signaling is Smoothened (SMO) dependent and 
results in changes to cytoskeletal reorganization. 
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1.5 Mitral Valve: Structure and Disease 
The mitral valve (MV) is the inlet valve of the left side of the heart that regulates 
the blood flow between the left atrium and left ventricle. It is composed of two leaflets, 
the septal, aortic, or anterior leaflet (AL) and the mural, lateral or posterior leaflet (PL). 
Both mitral leaflets are connected by chordae tendineae to papillary muscles which 
coordinate their operation116. In humans the mitral leaflets consist of three main layers: 
the atrialis (nearest the atrium), the spongiosa (the middle region of the leaflet), and the 
fibrosa (nearest the ventricle)117. However, these layers can be subdivided further into six 
“molecularly distinct zones” including an elastin rich region nearest the endocardium of 
the atrialis, followed by a proteoglycan enriched zone and successive collagen I enriched 
zone in the spongiosa, and three subsequent laminae in the fibrosa consisting of a zone of 
collagen I and hyaluronan, followed by another region of collagen I devoid of 
hyaluronan, and bounded by a final area rich in periostin, hyaluronan, and collagen I10. 
Disruption to the anatomical structure of the mitral leaflets or in their connections to the 
ventricular walls can result in a valvular disease known as mitral valve prolapse. 
Mitral valve prolapse (MVP) is a common cardiac condition that affects 
approximately 2.5% of the world population. It is clinically classified as the displacement 
of one or both of the mitral leaflets greater than 2mm above the annular plane during 
systole and a leaflet thickness of 5mm or more116,118. It is molecularly characterized by a 
deleterious remodeling of the extracellular matrix known as myxomatous degeneration, 
and carries the risk of serious secondary complications including arrhythmia, 
thromboembolism, and sudden cardiac death. Myxomatous valves are thickened and 
mechanically incompetent, often resulting in blood regurgitation from the left ventricle 
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back into the left atrium, detrimentally altering cardiac hemodynamics. These changes to 
blood flow and left atrial pressure can further damage the valve and eventually advance 
to the need for surgical intervention in 1 out of 10 MVP patients. There are no non-
surgical interventions available to treat this patient population. The lack of therapeutic 
alternatives to surgery for this disease carries a particularly high burden as MVP is 
typically diagnosed in the elderly and is known to affect greater than 11% of those over 
the age of 75119.  
 Mitral valve prolapse is commonly diagnosed when a primary care physician 
initially notices the characteristic mid-systolic clicking sound in the stethoscope during a 
patient examination. This is then followed by a variety of confirmational procedures, 
frequently including an echocardiogram. Diagnosis by echocardiogram was advanced in 
part by the work of Dr. Robert Levine in 1986, who redefined knowledge about the shape 
of the mitral annulus as “saddle shaped” rather than planar as previously thought120. At 
the time of Dr. Levine’s discovery, 20-40% of the general population was found to have 
MVP, and his insights not only lead to new criteria for echo examination, but also a 
dramatic reduction in erroneous MVP diagnosis.  
 While this condition has been recognized by cardiologists for over 50 years, 
surprisingly little is known about the molecular origins and mechanistic progression of 
this disorder. However, it is known that MVP can stem from a variety of biological 
insults. MVP can exist as part of a syndrome of co-occurring symptoms, such as in 
Marfan’s syndrome, which is a connective tissue disorder that affects multiple cardiac 
structures, the eyes, and bones. MVP can also have a non-syndromic presentation in 
which the mitral valve is the only tissue affected. Non-syndromic MVP can have several 
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causes, including genetic and non-genetic etiologies. Myxomatous degeneration is 
considered the idiopathic form of the disease, and accounts for the majority of cases. 
Additionally, MVP can result from immune responses to pathological conditions such as 
in rheumatic valvulitis or bacterial endocarditis. It can also be associated with structural 
deficiencies in elastin or rupture of the chords or papillary muscles associated with 
cardiac infarction. 
Histologically, a Movat’s pentachrome stain is used to identify myxomatous 
degeneration in mitral valves. Movat’s staining shows collagen as yellow, proteoglycans 
as blue, elastin and nuclei as black, muscle as red, and fibrin as bright red. Normally the 
fibrosa has definitive collagen expression, the spongiosa shows discrete proteoglycans 
concentrated at the leaflet tip, and organized elastin staining in the atrialis. In MVP, 
Movat’s staining is characterized by loosely packed collagen in the fibrosa, dramatically 
increased proteoglycan staining in the spongiosa, and a loss of defined elastin staining in 
the atrialis116. The overall architecture of the valve is expanded and tissue layers are 
disrupted. Studies by our lab and our Leducq collaborators from around the world have 
identified several congenital defects associated with human families with non-syndromic 
mitral valve prolapse86,121. These discoveries are important in defining this disease as 
having a developmental origin. 
As previously mentioned, 10% of MVP patients will progress to require surgical 
intervention to repair or replace their faulty valve leaflet(s). However, half of these 
patients are not eligible for standard mitral valve surgery due to complicating health 
factors122. Less invasive surgeries employing transcatheter valve replacement have 
recently been tested and are largely successful in this patient population, but mortality 
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rates still remain variable and possibly as high as 28% over 1 year123. Patients receiving 
valve replacement generally also have to maintain an ongoing course of anticoagulant 
medication to prevent clots from forming on the replacement valve, which leaves them 
vulnerable to other medical complications. Great efforts are being put into creating better 
synthetic and biological valve replacements to improve longevity and functionality of 
future implants. However, understanding the molecular pathways involved in MVP will 
be necessary to create pharmaceutical therapies. 
1.6 Aortic Valve: Structure and Disease 
The aortic valve is the last valve that blood encounters as it exits the heart and 
begins somatic distribution. Like the mitral valve, it consists of three main layers: the 
fibrosa (nearest the aorta), the spongiosa, and the ventricularis (nearest the ventricle), 
which are rich in collagen, proteoglycans, and elastin fibers respectively72. Unlike the 
mitral valve, however, the aortic valve has three rounded cusps that give rise to the 
“semilunar” name of this outlet valve. These are the right coronary (RC), left coronary 
(LC), and non-coronary (NC) cusps. The NC cusp of the aortic valve is located dorsally 
to the RC and LC cusps, and most proximal to the tricuspid valve. As their names imply 
the RC cusp is located to the right side of the heart, and the LC cusp is located to the left, 
and both are situated just below coronary sinuses which serve as the openings for the 
coronary arteries that distribute blood to the myocardium. Genetic mutations can lead to 
malformation of this normally tricuspid valve, resulting in disease. 
Bicuspid aortic valve (BAV) disease is the most common congenital cardiac valve 
disease, affecting approximately 1 to 2% of individuals worldwide124. Classically, BAV 
refers to the development of two aortic cusps, rather than the normal tricuspid 
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conformation. However, BAV is really an umbrella term for a spectrum of dysmorphic 
valve phenotypes (Figure 1.4). These phenotypes can include one or more “raphe” 
regions, which are full or partial fusion points along two of the three aortic cusps that 
result in loss of a commissure between them125. Raphe valves are much more common in 
BAV presentation than full fusion between two cusps, which is considered the “pure” 
form of BAV125. Raphe between the right and left cusps is the most common fusion 
pattern and occurs in ~80% of cases126. Right and non-coronary (RNC) cusp fusion is the 
second most common raphe (~17% of cases), and left non-coronary (LNC) fusion is the 
least common occurring in only ~2% of BAV cases126. Even more rare is the 




Figure 1.4 Aortic Valve Cusp Conformations. (A) Normal aortic valve morphology 
includes the formation of three cusps: the right coronary (RC), left coronary (LC), and 
non-coronary (NC) cusps. All three cusps should be present and distinct. (B) The 
majority (~80%) of bicuspid aortic valves are full or partial fusions (“Raphes”) between 
the right and left coronary (RLC) cusps. (C) The next most common fusion pattern is 
between the right and non-coronary (RNC) cusps. (D) The least common bicuspid 
arrangement is a fusion between the left and non-coronary (LNC) cusps. The aortic valve 





There is debate in the field as to whether the bicuspid aortic arrangement arises 
from excessive tissue growth that causes the cusps to fuse together (the more commonly 
accepted mechanism), or if BAV represents a failure of cusps to separate during 
development. Regardless of the actual mechanics of cusp raphe in BAV development, it 
is well established that there is the potential for affected individuals to develop serious 
secondary compilations, and that the severity of the cusp fusion pattern influences patient 
outcomes. These BAV-related sequelae can include valve stenosis, coarctation of the 
aorta, aortic dissection, aortic root dilation, and calcification of the aortic valves 
occurring 10-20 years before population norms72,127-129. Calcific aortic valve disease 
(CAVD) is particularly common and problematic in the BAV population, and it results in 
more than 80,000 surgeries each year in the United States alone130. Calcified valves 
display increased levels of fibrosis and the growth of dense calcified nodules on the aortic 
face of the valve cusps131. This fibrotic mineralization alters the biomechanics of the 
valves, resulting in stiff, inflexible tissue that is unable to maintain unidirectional blood 
flow and alters the hemodynamics in the heart and aorta. 
Most cases of BAV are sporadic, indicating there are likely non-genetic 
environmental factors that play a role in its development. However, there is also a strong 
link to genetic inheritance, and in 20-30% of BAV cases, additional affected family 
members are identified72. Work with pedigrees from large affected families have 
identified some mono-allelic causes of BAV in the disruption of genes that code for the 
production of extracellular matrix proteins, or have involvement in critical regulatory 
pathways such as Notch and TGFb signaling, but these mutations can only account for a 
small subset of BAV cases132. Given the familial inheritance patterns, but incomplete 
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penetrance and variability of the aortic phenotype, it is much more likely that the 
variation seen in BAV is indicative of complex network of multigenic variations and de 
novo mutations that produce a combined effect on valve development.  
BAV can be diagnosed at any age, though it is more commonly recognized in 
association with the issues that present in older patients. Similar to the diagnosis in MVP, 
BAV can be initially recognized during a physician’s examination with the discovery of 
clicking sound during aortic ejection. This is then usually followed by additional 
confirmation from ECG and Doppler echocardiography analysis, but definitive diagnosis 
by echo can be obscured by excessive fibrosis133. In these cases, MRI is a more sensitive 
and specific diagnostic tool because it can offer higher resolution visualization of the 
cusps and commissures.  
The existence of bicuspid valves has been recognized for over 500 years based 
upon early sketches by Leonardo da Vinci, but the association between BAV and 
complications such as stenosis and regurgitation was not widely recognized until the mid-
1800s. As with mitral surgery, aortic valve surgery was first made possible with the 
introduction of the heart-lung bypass machine in 1953, and the first mechanical and 
corpse-derived transplants were performed in the early 1960s. Major advancements to 
surgical techniques were then made in the late 1980s with the introduction of 
transcatheter aortic valve replacements (TAVR), and a variety of improvements have 
built upon this technology through the 2000s. However, despite the long history of 
bicuspid aortic valve knowledge, surgical replacement or repair of the valve is still the 
standard of care for patients with diminished functionality. Non-surgical treatments are 
unavailable for this patient population, likely due to little being known about the 
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molecular mechanisms of this congenital disorder. However, data obtained in the course 
of this dissertation project have uncovered an association between the development of 
bicuspid aortic valves and variations in the genes affecting ciliogenesis and a protein 
trafficking complex known as the exocyst. 
1.7  The Exocyst 
 The exocyst is an octameric protein trafficking complex that is responsible for 
shuttling vesicles from the Golgi apparatus to other locations in the cell (Figure 1.5). It is 
highly conserved in organisms ranging from plants to mammals, indicating its importance 
in cellular viability. It is known to play a role in a diverse array of functions including 
plasma membrane tethering of vesicles for exocytosis, cell migration, autophagy, 
cytokinesis, cell junction maintenance, apical-basolateral polarity, and primary 
ciliogenesis134. The exocyst was first discovered as part of the secretory pathway in 
yeasts, and in this organism its eight subunits are referred to as Sec3, Sec5, Sec 6, Sec8, 
Sec10, Sec15, Exo70 and Exo84. In mammals, the equivalent nomenclature is simplified 
as EXOC1-EXOC8. Despite the discrepancies of name, in all organisms, the exocyst 
subunits primarily assemble to form a holocomplex than interacts with the family of 
RHO-GTPases to perform its functions135. Some evidence exists for the formation of sub-
complexes in specific spatiotemporal patterns in flies and zebrafish, but further studies 




Figure 1.5: The Exocyst. The exocyst is an octameric protein trafficking complex. It is 
responsible for trafficking vesicles from the Golgi to the plasma membrane. By 
interacting with proteins such as CDC42 and DZIP1, the exocyst localizes to the basal 
body to deliver ciliogenic proteins. EXOC6 interacts with small GTPases (such as RAB8) 
on the surface of incoming vesicles to bind them. EXOC5 acts as a linker protein between 




However, it is known that disruption of a key linker protein, EXOC5 (Sec10), 
impairs the assembly of the exocyst complex and interferes with its ability to build 
cilia136. EXOC5 serves as a bridge that joins EXOC6 (Sec15), which physically interacts 
with the small GTPases on the surface of incoming vesicles, and the rest of the exocyst 
complex that mediate its localization and functionality137. There is also evidence to 
suggest that perturbation of EXOC5 results in the degradation or lack of expression of 
other exocyst complex members such as EXOC4 (Sec8)138. The regulatory role for 
EXOC5 in complex assembly makes in an ideal target for genetic manipulation, and 
conditional knockout mice were first developed for studies of kidney development and 
disease139. These mice have since been utilized in the study of other organ systems such 
as retina development and degradation in the eye140, and the study of cardiac 
valvulogenesis as in the case of this dissertation84. Global knockouts of EXOC5 (and 
other exocyst components) are early embryonic lethal shortly after the start of 
gastrulation141, and some exocyst mutations, such as in the case of EXOC1 (Sec3), are 
even lethal prior to uterine implantation142. 
Mutations in members of the exocyst complex have also been linked to the 
development of human disease. For example, recent reports have shown a link between 
mutations in EXOC8 (Exo84) and a ciliopathy known as Joubert syndrome143, which 
affects neuromuscular coordination, as well as ocular motor function and the 
development of other organs such as the heart, kidneys and liver. Studies have also linked 
mutations in other exocyst components to the development of metastatic cancers through 
its role in ARP2/3-mediated actin polymerization and its secretion of matrix 
metalloproteinases (MMPs) to promote an invasive cellular phenotype141. A further role 
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for exocyst-mediated disease has been reported in association with neurocognitive 
diseases through a role in neuroblast migration and axon extension in brain development. 
Given its importance in organogenesis and cilia trafficking, we chose to explore its 











Congenital heart disease (CHD) is one of the most common birth defects, 
affecting approximately 1% of live births144-146. Twenty-five percent of CHD births are 
classified as “critical”, meaning the infant will require surgical intervention to survive147. 
Bicuspid aortic valve (BAV) disease is the most frequently observed congenital valve 
defect, and is present in 0.5-2%72 of the population. BAV results from abnormal aortic 
cusp formation during valvulogenesis, whereby cusps fail to form or adjacent cusps fuse 
into a single large cusp. As previously described, the fusion events are phenotypically 
heterogeneous with significant variability in fusion patterns (Figure 1.4). However, 
regardless of the specific fusion pattern, patients with BAV frequently have profound 
deleterious long-term consequences on heart function and can develop progressive aortic 
valve calcification and stenosis as well as thoracic aortic aneurysm and dissection148. As 
such, patients with BAV frequently require surgeries to repair or replace damaged valve 
tissue in the cardiac outlet segment. Though not currently considered a congenital 
disease, some cases of non-syndromic mitral valve prolapse (MVP) are also associated 
with familial inheritance patterns, and biomechanical incompetence will require surgical 
intervention in 10% of MVP cases. Both BAV and MVP lack non-surgical interventions, 
and thus represent a significant health and economic burden for affected individuals. 
Due to their clinical prevalence and severity, concerted efforts by numerous 
scientific groups have led to genetic discoveries underlying BAV and MVP etiologies in 
humans149,150. Both diseases are known phenotypic components in patients with rare 
syndromic disease such as Marfan, Loeys-Dietz and Turner Syndromes for which causal 
genes are known151. Genetic studies on families displaying inherited non-syndromic BAV 
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or MVP have proven fruitful and have revealed causative mutations in specific 
transcription factors149, signaling molecules150, and structural genes152. However, no 
single-gene model clearly explains valve disease etiology in patients, thus supporting a 
complex network of interacting genes and pathways. We therefore hypothesized that 
population-based genetic studies would identify new pathways involved in valve disease 
origins and focused our efforts on BAV. Thus, genome wide association studies (GWAS) 
were undertaken and revealed modest association with genes involved in the generation 
of primary cilia. Although previously viewed as vestigial, recent studies have clearly 
demonstrated the functional importance of primary cilia in human disease. These 
diseases, termed ciliopathies, are a collection of congenital syndromic diseases (e.g. 
Joubert Syndrome, Bardet-Biedl Syndrome, Meckel-Gruber Syndrome and Autosomal 
Dominant Polycystic Kidney Disease) that affect many tissues, including the heart. 
Cardiac phenotypes are observed in most types of ciliopathy and are most commonly 
associated with BAV and MVP. Additionally, our previous work has shown that 
knockout of intraflagellar transport protein 88 (IFT88) in mice leads to loss of cilia85,86, a 
70% penetrant BAV phenotype85, and the development of myxomatous mitral valves86. 
These clinical data support our hypothesis that cilia gene variants are associated with 
valve disease in the population and are critical for aortic and mitral valve development. 
Genetic studies in humans, mice, and zebrafish identified a molecular trafficking 
complex (known as the exocyst) that is critical for cilia biogenesis in cardiac valves, and 
when dysregulated, can cause outflow tract defects, BAV, and calcific aortic stenosis153. 
Though, not the main focus of this study, a MVP phenotype was also observed in mice, 
indicating a broader role for the exocyst and ciliogenesis in heart valve disease. 
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2.2 Results 
We performed a GWAS study using a Discovery cohort of 452 BAV patients and 
1,834 Caucasian population-controls (Figure 2.1A), examining a common set of 
1,355,128 SNPs (demographic data, and clinical variables are shown in Figure 2.1B). A 
total of 734,104 SNPs were assigned to 26,290 coding genes, and we identified 1,889 
SNPs associated with BAV at p<1x10-4. Working on the hypothesis that SNPs in or near 
cilia genes may be over-represented in the BAV population, we analyzed the ciliome in 
the context of our dataset. A large number of cilia genes (28/303, or 9.2%), from the 
SysCilia set (http://www.syscilia.org), were found +/-150 kb from the 1,889 most 
significant SNPs, including members of the exocyst complex, required for promoting 
cilia biogenesis (EXOC4, EXOC6, and EXOC8 (Figure 2.2A)). Another well-
characterized cilia list154, yielded 156 cilia genes (156/1,925, or 8.1%) within 150 kb of 
the 1,889 SNPs (Figure 2.2B), also including exocyst members: EXOC4, EXOC6, and 
EXOC8. From the Discovery GWAS, three of the eight exocyst members (EXOC4, 
p=7.78 X 10-7; EXOC6, p=5.63 X 10-5; and EXOC8, p=6.64 X 10-5) and an exocyst 
regulator, CDC42135,155,156 (p=5.88 X 10-5) were associated with BAV at p<1x10-4. 
EXOC4, EXOC6, EXOC8 were 17.11 kb, 148.4 kb, and 79.41 kb from their respective 
SNPs (Figure 2.3). Hypergeometric probability analysis showed that the overlap between 
the exocyst genes and the genes located within 150 kb of the 1,889 SNPs most associated 
with BAV (using the cutoff p<1x10-4) was significantly higher than expected by chance 
alone (p=0.033).  
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Figure 2.1. GWAS quality control, demographic data, and clinical variables. (A) 
From dbGaP (FHS) we used 2,477 Caucasian controls genotyped using the 
HumanOmni5.0 bead chip with 4,271,233 genetic markers. Quality control (QC) of the 
genotype data for this cohort was performed using GenomeStudio and PLINK as 
outlined. We considered markers with a MAF>1% and performed extensive principal 
components-based filtering for population stratification. After merging cases and controls 
and further QC, we used 452 BAV cases and 1,834 Caucasian controls with a common 
set of 1,355,128 single nucleotide polymorphisms (SNPs). (B) Population description for 





Figure 2.2 Cilia genes identified from the GWAS. 734,104 SNPs were assigned to 
26,290 coding genes. We identified 1,889 SNPs associated to BAV at p<1x10-4. (A) 
From the SysCilia gene list, 28 cilia genes were found within 150 kb of the 1,889 most 
significant SNPs, including two exocyst genes (shown in red). (B) From the Liu, et al. 
cilia list, 156 (out of 1,925 total) cilia genes were found within 150 kb of the 1,889 most 
significant SNPs, including three exocyst genes, and its effector CDC42, which are 




Figure 2.3: Regional plots of GWAS show SNP proximity to exocyst genes. The 
regional plot +/- 500 kb is shown for the exocyst genes (EXOC4, EXOC6, and EXOC8) 
identified in the GWAS. 
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Genotyping of the 15 most significant SNPs identified in the Discovery cohort, 
including those containing EXOC4/6/8, was performed upon a replication cohort of 1,679 
BAV cases and 894 controls (Table 2.1). The combined p-value for the exocyst 
components was 3.63 X 10-4. As these data suggested a modest association between 
BAV, the exocyst, and ciliogenesis, we performed additional analyses in animal models 




Table 2.1 GWAS Studies. Fifteen top BAV GWAS hits from the Discovery Study of 
452 patients with BAV and 1834 white population controls were used in the Replication 
Study, with a separate cohort of 1679 patients with BAV and 894 control patients 





The exocyst complex is generally considered a holocomplex comprised of eight 
unique subunits157. Disruption of a key linker protein, EXOC5, is known to effectively 
dismantle this complex and impair ciliogenesis136. Using zebrafish, we generated 
homozygous exoc5 mutants (Figure 2.4A) to test whether disruption of the exocyst 
complex results in impaired cardiac outlet development (Figures 2.4, 2.5). By Western 
blot analysis, we confirmed that exoc5 protein was virtually undetectable in exoc5 mutant 
larvae, and that exoc4 protein was also significantly decreased, when compared to WT 
siblings (Figure 2.4B). Mutant exoc5 zebrafish displayed gross phenotypes consistent 
with defects in other ciliary genes158. At 3.5 days post fertilization (dpf), all exoc5 
mutants had a similar phenotype to previous studies in exoc5 morphants135,159, including 
pericardial edema, when compared to wild-type (WT) siblings (Figure 2.4A). The 
morphologic phenotype was consistently observed in ~25% of the progeny from 
heterozygous crosses, as would be expected by Mendelian inheritance. The exoc5 
homozygous mutants only survived to 4 dpf and exhibited severe cardiac outflow 
obstruction (Figure 2.4C, D), as well as disruption of cardiac function (data not shown). 
The outflow tract of the exoc5 mutants appeared stenotic with dramatic narrowing of the 
arterial lumen, as is observed in patients with aortic stenosis. To ensure exoc5 loss caused 
the phenotype, an additional exoc5 mutant was generated using CRISPR gene editing140, 
and the resulting phenotype was identical to the exoc5 mutant described above (Figure 
2.5).  
 To confirm that the ciliary phenotypes observed in exoc5 mutants were caused 
specifically by loss of exoc5, we performed rescue experiments by injecting WT human 
EXOC5 mRNA into control and exoc5 mutant embryos at the 1-2 cell stage. At 3.5 dpf, 
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we found that low dose (150 pg) reconstitution of EXOC5 mRNA, in exoc5 mutant 
embryos, partially rescued the mutant phenotypes, including cardiac edema; while high 
dose (250 pg) EXOC5 mRNA showed near complete phenotypic rescue (Figure 2.4E). 
EXOC5 contains a highly-conserved VxPx ciliary targeting sequence160 (Figure 2.6). To 
further strengthen the link between primary cilia and the cardiac phenotype, we used site-
directed mutagenesis to disrupt the ciliary targeting sequence of human EXOC5 (Figure 
2.6). Rescue of the exoc5 mutant zebrafish was significantly decreased using the mutated 
ciliary targeting sequence EXOC5 mRNA compared to WT EXOC5 mRNA (Figure 
2.4F). Mutagenesis of the ciliary targeting sequence did not affect the stability of the 
EXOC5 protein, or its ability to bind other exocyst components138. These data 
demonstrate that dismantling the exocyst ciliary-trafficking complex during zebrafish 





Figure 2.4: Exoc5 mutant zebrafish display ciliopathic phenotypes and cardiac 
outflow tract stenosis. (A) Lateral view of representative wild-type (exoc5+/+) and exoc5 
homozygous mutant (exoc5–/–) zebrafish at 3.5 dpf. Exoc5 mutants showed cilia defects, 
including pericardial edema (arrowheads indicate pericardium). Scale bars=0.171μm. 
Chromatograms of Sanger sequencing reactions from each genotype are shown below. A 
stop codon has been introduced in the exoc5 mutant zebrafish. (B) By Western blot 
analysis, exoc5 protein was virtually undetectable in exoc5 mutant larvae, and exoc4 
protein was also significantly decreased, in comparison to wild-type siblings. 
Quantification is shown below. (C,D) Low magnification (left) and high magnification 
(right) of hematoxylin and eosin–stained hearts of 3.5 dpf wild-type (C) and mutant (D) 
zebrafish. Orange arrowheads indicate the outflow tract between the ventricle and bulbus 
arteriosus, highlighting the severe stenosis in the exoc5 mutant. (E) Injection of wild-type 
human EXOC5 mRNA rescued the exoc5 mutant phenotype in zebrafish in a dose 
dependent manner. (F) Human EXOC5 mRNA with a mutated ciliary-targeting sequence 
(VxPx to VxAx), in contrast to wild-type EXOC5 mRNA, was unable to efficiently 





Figure 2.5: A second exoc5 mutant zebrafish line, generated using CRISPR, shows 
ciliopathy phenotypes. (A) Chromatograms of Sanger sequencing reactions of wild-type 
(exoc5+/+) and homozygous exoc5 mutant (exoc5-/-) zebrafish showing the 13 bp insertion 
from CRISPR gene editing that leads to a stop codon. (B) Lateral view of representative 
WT and exoc5 homozygous mutant zebrafish at 3.5 dpf. Exoc5 homozygous CRISPR 
mutants phenocopied the homozygous exoc5 mutants we received from ZIRC (Figure 
2.4), with ciliary defects that included pericardial edema, hydrocephalus, and small eyes. 
(C) Western blot analysis showing decreased exoc5 and exoc4 protein in the CRISPR 
KO compared to WT zebrafish at 3.5 dpf. (D) Low magnification (left) and high 
magnification (right) of hematoxylin and eosin (H&E)-stained hearts of 3.5 dpf wild-type 
(top row) and mutant (bottom row) zebrafish. BA=bulbus arteriosus, V=ventricle, 






Figure 2.6: Site-directed mutagenesis of the ciliary targeting sequence in human 
EXOC5 cDNA. (A) The EXOC5 VxPx ciliary targeting sequence is highly-conserved 
from yeast to humans. (B) Site-directed mutagenesis of cytosine at position 2002, results 




Based on our zebrafish findings, and our previous report that loss of cilia in outlet 
valves can cause a BAV phenotype in mice85, we decided to conditionally ablate the 
Exoc5 gene, using Exoc5f/f mice that were previously generated139. Aortic valves are built 
through integration of various cell types (endothelial, anterior heart field, and neural 
crest), with endothelial-derivatives providing the largest contribution to the aortic cusps72. 
Thus, knocking out Exoc5 in endocardial and endocardial-derived cells, using an NfatC1-
Cre driver161, permits analyses of the function of the exocyst in a majority of cells that 
make up the aortic valves. Conditional homozygous knockout in Exoc5 mice 
(NfatC1Cre(+);Exoc5f/f) resulted in zero out of fifty-eight pups surviving to birth, and 
genotyping data revealed non-Mendelian birth ratios consistent with embryonic lethality 
(Figure 2.7A). Lethality of the NfatC1Cre(+);Exoc5f/f embryos occurred between E13.5 
and E15.5. At these timepoints, NfatC1Cre(+);Exoc5f/f conditional knockout mice exhibited 
ventricular septal defects with large cellular voids at the junction between the 
interventricular membranous septum and atrioventricular septal complex (Figures 2.7B, 
2.8), as well as evidence of apical coronary vascular hemorrhaging (Figure 2.7B) and 
increased caspase 3 activity compared to controls (Figure 2.8). Due to the lack of P0 
NfatC1Cre(+);Exoc5f/f mice, subsequent analyses were performed on conditional 
heterozygous animals (NfatC1Cre(+);Exoc5f/+). Three-dimensional reconstruction of P0 
aortic valves revealed increased incidence of bicuspid aortic valves resulting from the 
fusion of the right and non-coronary cusps in conditional heterozygous 
(NfatC1Cre(+);Exoc5f/+) mice (Figure 2.7C). Five out of eleven (45%) 
NfatC1Cre(+);Exoc5f/+ mice displayed some degree of BAV, with 4/5 being right non-
coronary (RNC) fusions and 1/5 with left non-coronary (LNC) fusions. High-resolution 
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confocal microscopy of E13.5 aortic cushions, confirmed a significant effect of exocyst 
loss on ciliogenesis, which preceded the BAV phenotype observed at P0 (Figure 2.9). 
Similarly, investigation of cilia in the atrioventricular cushion showed significant loss of 





Figure 2.7: Exoc5 endocardial-specific knockout mice display homozygous 
embryonic lethality and BAV. (A) Conditional heterozygous (cHet) breeding failed to 
produce Mendelian ratios of conditional homozygous knockout (cKO) mice. A second 
breeding strategy between cHet and doubly floxed Exoc5 mice (Exocf/f) also failed to 
produce cKO pups, indicating the condition is embryonic lethal (B) Homozygous cKO 
embryos died between E13.5 and E15.5, most likely because of ventricular septal defects 
(first row, indicated by black arrows and dotted line) and progressive vascular 
hemorrhage (third row, indicated by black arrows). Embryos also showed anomalous 
attachment of the heart to the body cavity (second row, indicated by black arrows). (C) 
Representative 3-dimensional reconstructions of H&E stained control and cHet P0 aortic 
valves. Conditional heterozygous mice had an increased prevalence of bicuspid and 
partially fused aortic valves (45%, n=11). LA=left atrium, LC=left coronary, LV=left 
ventricle, NC=non-coronary, RA=right atrium, RC=right coronary, RNC=right non-





Figure 2.8 Endocardial-specific Exoc5 knockouts display ventricular septal defects 
and increases in apoptosis. Conditional Exoc5 knockouts (cKO, bottom row) had 
ventricular septal defects with large cellular voids (boxed area) at E14-E15. Ventricular 
defects in the cKO mice were also caspase3 positive (red channel), indicating an increase 
in apoptotic activity. The overall width of the ventricular septum was also increased and 




Figure 2.9: Exoc5 endocardial-specific knockout mice show disrupted ciliogenesis. 
(A) Representative high-resolution confocal microscopy images of E13.5 aortic cushion 
cells. Axonemes (acetylated α-tubulin) are shown in green and basal bodies (γ-tubulin) 
are shown in red. The bottom row is a higher magnification of the boxed area from the 
top row. (B) Quantification of cilia length. Each gray dot represents the cilia length from 
a single cell (including dots at 0, which are indicative of no cilia). The blue boxes show 
the cilia length lower, median, and upper quartiles for each genotype, and the red dot is 
the mean cilia length. WT control mice had longer and more prevalent cilia than 
conditional heterozygous and homozygous Exoc5 knockout mice, indicating that ablation 
of Exoc5 disrupts ciliogenesis. The mean cilia length was statistically significant between 
all genotypes. The number of cells without cilia was also significant between the controls 
and knockouts (p<0.007) and between controls and heterozygotes (p<0.05). n=3 animals 
per genotype and >1500 cells.  
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Figure 2.10: Conditional Exoc5 ablation disrupts ciliogenesis in atrioventricular 
cushion mesenchyme. (A) Representative high-resolution confocal microscopy images 
of E13.5 atrioventricular cushion cells. Axonemes (acetylated a-tubulin) are shown in 
green for both control and conditional knockout animals. (B) Quantification of cilia 
length and number of ciliated cells. Each gray dot represents the cilia length from a single 
cell (including dots at 0, which are indicative of no cilia). The blue boxes show the cilia 
length lower, median, and upper quartiles for each genotype, and the red dot is the mean 
cilia length. Both the average cilia length and number of ciliated cells were statistically 




 Cilia and the exocyst are known to regulate MAPK signaling and disruption of 
exocyst-mediated ciliogenesis leads to MAPK pathway activation137,139,159. Additionally, 
recent work has shown involvement of the MAPK pathway in murine162,163 and human 
BAV and calcific aortic stenosis164. As a readout for altered ciliogenic signaling, we 
analyzed whether the final downstream component of MAPK signaling, ERK (pERK1/2) 
was altered in the EXOC5 BAV model. In E13.5 control aortic valves, ERK 
phosphorylation was prominent in valve endocardium and interstitial cells, while in 
NfatC1Cre(+);Exoc5f/+ and NfatC1Cre(+);Exoc5f/f valves, ERK1/2 activation was 
significantly downregulated (Figure 2.11). Human BAV and CAVS samples have shown 
elevation of the MAPK pathway as a potential marker for disease progression164. Thus, 
we examined time points after which BAV is evident (P0) and CAVS is observed in the 
adult. As shown in Figure 2.12, pERK1/2 is elevated at neonatal and adult time points in 
conditional mice, indicating aberrant activation of the MAPK pathway, similar to results 
observed in human disease. Additional examination of P0 mitral valves also revealed an 





Figure 2.11: Embryonic Exoc5 conditional knockout mice show aberrant MAPK 
signaling. (A) At E13.5, control mice displayed prominent ERK activation (pERK, red 
cells) on their aortic cusps (outlined with dashed lines). In contrast, at the same stage, (B) 
conditional heterozygous and (C) conditional homozygous Exoc5 knockouts have less 
robust pERK expression. (D) Graphic quantification of the average fold change in the 
percentage of pERK positive aortic cusps cells between the genotypes (n=3/genotype). 
White arrowheads indicate areas of highest pERK expression on the RC. RC=right 





Figure 2.12: Exoc5 deficient mice have elevated MAPK signaling after birth. (A) At 
postnatal day 0 (P0), conditional heterozygous mice (NfatC1Cre(+);Exoc5f/+) have elevated 
ERK activation (pERK, red cells indicated by white arrows). (B) Graph of average pERK 
fold change at P0. (C) Aberrant MAPK activation persists through to adulthood. (D) 
Quantification of pERK fold change between adult control mice and conditional 





Figure 2.13: Exoc5 deficient mice have elevated pERK in mitral leaflets after birth. 
Qualitative analysis of exploratory immunohistochemical stains shows that P0 Exoc5 





As our model of EXOC5 deficiency demonstrated fusion of the aortic cusps and 
molecular signatures consistent with the disease process observed in humans with calcific 
aortic stenosis, we evaluated long-term effects of the aortic valve phenotype on cardiac 
function. Echocardiography was performed on aged (18-month) NfatC1Cre(+);Exoc5f/+ 
mice and demonstrated evidence of stenosis and calcification (Figure 2.14A), biphasic 
depolarization in the QRS complex (Figure 2.14B), and significant aortic root dilation 
(Figure 2.14C). As the histological, molecular and echocardiographic data in both the 
mouse and zebrafish models suggested aortic stenosis, we further analyzed aged mice for 
evidence of calcification. Adult NfatC1Cre(+);Exoc5f/+ (six with TAV, five with RNC and 
two with LNC) and four control aortic valves were isolated from our aged mice and 
processed for histology and immunohistochemistry. In contrast to control valves (Figure 
2.14D), 4/7 (57%) BAV and 3/6 (50%) TAV showed evidence of calcification, being 
positive for alizarin red (Figure 2.14E). Aortic valves were further analyzed for evidence 
of calcification by performing IHC staining for RUNX2 sequential histological sections 
on control (NfatC1Cre(-);Exoc5f/f) and alizarin red-positive conditional heterozygote 
(NfatC1Cre(+);Exoc5f/+) aortic valves (n=3). RUNX2 signal by IHC was below the level of 
detection in control aortic valves (n=3). However, in each conditional heterozygote 
analyzed, positive RUNX2 expression was detected in areas of alizarin-red, indicating 




Figure 2.14: Conditionally heterozygous Exoc5 adult mice have calcific valves. 
Echocardiographic images were acquired in five conditional heterozygous mice and 
eleven controls, revealing several functional abnormalities in aortic blood flow in 
the NfatC1Cre(+);Exoc5f/+mice. (A) Color Doppler images of the aortic valve in an aged 
(18 month) NfatC1Cre(+);Exoc5f/+ mouse and a control sibling from a 2D short axis view 
(within the dashed circle). Blood flow through the aortic valve in the control mouse was 
uniform (laminar; shown in blue) and was initiated soon after the QRS complex of the 
electrocardiogram (ECG; green trace (B)). In contrast, in the conditional heterozygous 
mice, aortic blood flow during the same phase of the cardiac cycle showed jets of high 
velocity flow around the aortic cusps (red and blue mixing highlighted by white 
arrowheads) providing evidence of stenosis and calcification. (B) The biphasic 
depolarization pattern seen in the QRS complex of the conditional heterozygous mouse 
(right) could be suggestive of slower electrical conduction through one of the bundle 
branches. (C) Aortic root diameters of conditional heterozygous mice were around 24% 
larger than control mice. (D) Control valves did not stain positive for alizarin red or 
RUNX2. (E) In contrast, NfatC1Cre(+);Exoc5f/+ adult (6 weeks old) aortic valves stained 
positive for alizarin red along the cusps and showed positive RUNX2 staining on 
sequential histological sections indicating areas of valve calcification. Brightfield images 
were taken to ensure melanocyte autofluorescence was not responsible for the positive 
staining.  
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As a final measure of Exoc5 influence on valve disease, we examined mitral 
valves of control and conditional heterozygous mice (NfatC1Cre(+);Exoc5f/+). At P0, 
conditional heterozygous mice displayed mitral valves that were enlarged compared to 
controls (Figure 2.15A). Though volume changes were not statistically significant 
between control mice and conditional heterozygous (cHet) mice, measurements of leaflet 
thickness revealed a statistically significant increase in thickness and an overall increase 
in the range of thickness in the anterior leaflets of cHets compared to controls (Figure 
2.15B). In adult (12 month old) mice, mitral leaflets were enlarged compared to controls, 
and showed changes in ECM expression, such as increases in versican and less organized 
collagen (Figure 2.16). These mice also displayed a loss of molecular boundaries 
between valve layers, which is characteristic of myxomatous degeneration (Figure 2.16). 
Taken together, these data are indicative that loss of Exoc5 is associated with a phenotype 
that is similar to that seen in MVP patients, and demonstrates the potential usefulness of 




Figure 2.15: Exoc5 deficient mice have enlarged mitral vales at P0 compared to 
controls. (A) Representative 3D reconstructions and H&E images of control and 
conditional Exoc5 heterozygotes show enlarged anterior leaflets. (B) Quantification of 
leaflet thickness shows statistically significant differences in anterior leaflet thickness, 
but not in the posterior leaflet. AL=anterior leaflet, PL=posterior leaflet, WT= wildtype, 
cHet=conditional heterozygote, n.s.=not significant. Dots on scatter plot are colored by 
mouse, larger red dot is average leaflet thickness, and blue boxes denote the quartiles. 
Error bars=95% confidence interval. 
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Figure 2.16: Exoc5 deficient mice have a myxomatous mitral phenotype. Adult 
Exoc5 deficient mice have disrupted extracellular matrix (ECM) including increased 
versican expression (top row), reduced collagen organization (middle row), and 
myxomatous valves (bottom row). Movats stains show collagen in yellow, proteoglycans 
in blue, and conditional heterozygous Exoc5 mice have a loss of molecular boundaries 





Bicuspid aortic valve disease is a frequent valvular abnormality that can lead to 
calcific aortic valve stenosis (CAVS). CAVS is the most prevalent acquired valvular 
heart disorder in the Western world and accounts for greater than $10 billion in health 
care costs in the U.S. each year130. Aortic stenosis displays increased severity and 
prevalence with age, with >12% of individuals over the age of 75 having CAVS129. 30-
50% of CAVS patients have a BAV165, consistent with our GWAS patient population, in 
which 42% were diagnosed with aortic stenosis (data not shown). The genetic, molecular 
and cellular mechanisms that contribute to BAV and CAVS are poorly understood and 
few applicable models have been developed to study this disease149,150. This paucity of 
data is likely reflected in the fact that there are currently no preventative medical 
therapies for CAVS and, in North America alone, 80,000 patients progress annually to 
severe symptomatic CAVS requiring aortic valve replacement (AVR). 
Similarly, mitral valve prolapse is a common heart valve condition that can lead 
to serious secondary consequences for affected patients and disproportionally affects the 
elderly. In 1 out of 10 MVP patients, valve incompetence will progress to require surgical 
intervention for patient survival through a valve replacement or repair. While many 
studies have found causative genes in the context of syndromic MVP, much remains to 
be discovered about the molecular origins and progression of the non-syndromic forms of 
this disorder. However, work by our lab and others has indicated that disturbance to the 
ciliogenic pathway may contribute to MVP development.  
We initiated our studies with patients that have BAV as a unifying disease 
phenotype. We hypothesized that BAV in the population may not commonly be caused 
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by single damaging variants, but rather by an association of various SNPs in converged 
genetic pathways. This appears to be the case from our current study, whereby the most 
significant SNPs generated from GWAS analyses fit within a cilia biogenesis regulatory 
network. Although these data do not provide definitive genetic evidence, they do support 
cilia and the exocyst as a target worthy of further validation. Additionally, these data 
suggest that this population of BAV patients may not harbor single damaging SNPs as is 
evident in inherited BAV families, but rather it is the combination of genetic variants in 
this pathway that lead to disease. Thus, it is possible that the combination of multiple 
SNPs in/near cilia genes is more relevant to BAV pathology than any one individual 
SNP. 
Prior reports support cilia and the exocyst in the etiology of left-heart valve 
disease based on the following observations. First, patients with ciliopathies, which are 
syndromic diseases caused by mutations in functional components of primary cilia (e.g., 
Meckel-Gruber, Joubert and Bardet-Biedl Syndromes, autosomal dominant polycystic 
kidney disease), frequently present with BAV, MVP and/or calcific aortic valve 
stenosis153. In fact, a family with Joubert Syndrome, a well-described ciliopathy, has 
recently been identified with a damaging mutation in EXOC8143, one of the exocyst genes 
identified in our GWAS analysis. Second, NOTCH1, the first gene identified in patients 
with inherited forms of aortic valve disease and CAVS, depends on primary cilia for 
cleavage and proper function77,150,166,167. However, our analysis of NOTCH1 cleavage 
within the EXOC5 deficient valves failed to reveal any changes in NOTCH1 activation 




Figure 2.17: Notch signaling is unchanged in Exoc5 deficient mice. Staining of the 
cleaved notch intracellular domain (NICD, red cells) showed no difference in expression 
at E13.5 or P0 between Exoc5 deficient mice versus controls. CD31 (green cells) marks 




Third, primary cilia are expressed during aortic and mitral valve development, and 
genetic ablation of cilia, by removal of IFT88, results in a highly penetrant myxomatous 
mitral valves and a (>70%) BAV phenotype85, the single most important predictor of 
aortic valve disease and aortic stenosis. Combined with the supportive GWAS-driven 
finding of the exocyst in BAV etiology, we sought to confirm these genetic findings and 
bolster support for this protein complex and pathway in human BAV by performing 
genetic ablation and rescue experiments in zebrafish and mice. Here we show that 
disrupting the exocyst through deletion of the key linker protein, EXOC5, results in a 
severe cardiac phenotype in zebrafish and mice, highlighting the importance of this 
trafficking pathway in normal heart development across species. Deletion of Exoc5 in 
mice results in shorter and less abundant cilia within the aortic and mitral valves, 
increased incidence of BAV, myxomatous degeneration, and calcification of aortic valves 
concomitant with elevation of pERK1/2, a marker of disease phenotype. We also 
demonstrated that the exocyst interacts with other cilia proteins, such as DZIP1 (Figure 
2.18). DZIP1 is known to locate to the base of the cilia and deleterious mutations in its 
gene have been identified in large families with non-syndromic MVP86. The interaction 
of the exocyst with known cilia regulating proteins such as DZIP1, could help to explain 





Figure 2.18: Exocyst components interact with known cilia protein, DZIP1. (A) 
Hek293T cells were transfected with two different Dzip1 plasmid constructs containing 
flag-tag sequences and then lysates were co-immunoprecipitated with either generic IgG 
or anti-Flag antibody. DZIP1 was able to pull down EXOC5 protein. (B) Transfected 





Further genomic analysis of the exocyst GWAS data also supports a role for the 
exocyst in BAV. GenoCanyon1 was used to measure the functional importance of 
genomic loci. GenoCanyon scores for BAV-associated SNPs near EXOC4, EXOC6, and 
EXOC8 were 0.94, 0.92, and 1.00, respectively, implying potential functional impact. We 
examined the functional role of all associated SNPs using the Human Enhancer Disease 
Database (HEDD)2, identifying the EXOC4 SNP (rs10279531) as a putative enhancer3. 
Pathway analysis using GeNets4 for the 33 genes +/-150 kb from the 15 SNPs that were 
used for the Replication study, showed that the ARF6 trafficking pathway was 
significantly associated at p=1.48 X 10-5. We have previously shown that ARF proteins 
interact with the exocyst to control ciliogenesis and MAPK signaling, and others have 
shown that EXOC5 interacts directly with ARF6168. 
The embryonic lethality in the context of deletion of the exocyst from 
endocardium and endocardial-derived cells is intriguing and implicates a role for primary 
cilia not only in valvulogenesis, but also in endothelial cells within the interventricular 
septum and ventricular myocardium. Unlike the valve endocardium, primary cilia are 
present on ventricular endocardial cells (Figure 2.19), which may help to explain the 
vascular hemorrhaging that is the likely cause of death by E15.5.  
 
1 GenoCanyon. http://genocanyon.med.yale.edu/. Accessed May 17, 2019. 
2 HEDD: Human Enhancer Disease Database. http://zdzlab.einstein.yu.edu/1/hedd.php. Accessed 
May 17, 2019. 
3 Detail results of enhancer. Human Enhancer Disease Database. 
http://zdzlab.einstein.yu.edu/1/hedd/detail.action.php?idno=1269828. Accessed May 17, 2019. 




Figure 2.19: Ventricular endocardial cells express primary cilia. Unlike valve 
endocardium, ventricular endocardial cells have primary cilia. Ciliary axonemes are 
shown in green and endothelial cells are in red. White arrows point to endocardial cells 
with cilia in the higher magnification images. Primary cilia were observed on ventricular 




The developmental origins of cardiac valve diseases are still poorly understood. 
Motivated by the severity and high prevalence of MVP/BAV/CAVS, numerous groups 
have endeavoured to understand the embryological development of the aortic and mitral 
valves in an attempt to relate these findings back to patients. Included in the findings are 
the temporal-spatial mapping of various cell lineages that make up the valves, as well as 
the identification of molecular and biomechanical pathways that regulate cell phenotype 
and function during the organization and maturation of the aortic cusps and mitral 
leaflets. It is now clear that formation of the valvular cushions requires an interplay 
between mechanical forces and the cell types that contribute to their development, 
including: neural crest, endocardial, epicardial, myocardial, and circulating cells. The 
majority of cells within the aortic and mitral valves originate from endothelial cells that 
undergo endothelial to mesenchymal transformation (EMT). Consistent with this finding, 
endocardial-specific removal of Exoc5 in mice is sufficient to generate a highly penetrant 
BAV phenotype that proceeds to CAVS in adulthood and dysmorphic neonatal mitral 
valves that progress to severe myxomatous degeneration. A similar phenotype was 
observed when we genetically removed Exoc5 with the pan-endothelial Cre, Tie2Cre, 
demonstrating that the BAV phenotypes and lethality are due to defects in endothelial 




Figure 2.20: Tie2Cre(+);Exoc5f/+ mice phenocopy NfatC1Cre(+);Exoc5f/+ mice and have 
BAV. Tie2 Cre(+);Exoc5f/+ mice were crossed with Exoc5f/f mice. 24 pups were born over 
three litters, and, by genotyping, included 13 WT (Tie2Cre(-);Exoc5f/+, Tie2Cre(-);Exoc5f/f, 
or Tie2Cre(-);Exoc5+/+) and 11 conditional heterozygous (Tie2Cre(+);Exoc5f/+) mice. No 
conditional homozygous KO (Tie2Cre(+);Exoc5f/f) mice survived to birth. Hearts from 
three cHet (Tie2Cre(+);Exoc5f/+) and control (Tie2Cre(-);Exoc5f/+) mice were sectioned and 
3D reconstruction performed. Two of the three heterozygous (Tie2Cre(+);Exoc5f/+) mice 




Currently, only a few, human genetic-based models of BAV/CAVS or MVP have 
been reported. Here, we report the EXOC5 model as an applicable model to study 
mechanisms underlying BAV formation and its progression to a stenotic valve as well as 
MVP and its associated sequelae. Through the use of zebrafish, mouse, and human 
genetics, we have demonstrated that BAV, and its related phenotypes, which affect 
between 38 to 91 million people worldwide72, can occur in association with defects in 
exocyst-mediated ciliogenic programs. As included in this study, GWAS analyses on 
BAV populations may need to invoke combinatorial SNP analyses to define convergent, 
parallel, or overlapping pathways that contribute to disease etiology. We have also 
demonstrated preliminary evidence for the role of the exocyst in the development of 
mitral valves and mitral disease. Future studies will take advantage of these new data and 
animal models to further tease apart the underlying mechanisms that could inform new, 












 Hedgehog (HH) signaling is a powerful regulator of organogenesis and tissue 
homeostasis. It is also a well-established growth factor signaling pathway that requires 
the primary cilium for its function. The initial input for this signaling cascade is at least 
one of three Hedgehog ligands, Sonic Hedgehog (SHH), Indian Hedgehog (IHH), and/or 
Desert Hedgehog (DHH). These ligands interact with their cognate receptor, Patched 
(PTCH) along the ciliary axoneme, which results in de-repression of the G protein 
coupled receptor, Smoothened (SMO), at the cilia base. The canonical signaling pathway 
culminates with nuclear translocation of GLI transcriptional activators and/or repressors 
to modify expression of target genes primarily involved in cell cycle regulation. Due to 
the broad expression domains of Hedgehog ligands and the presence of primary cilia on 
nearly every cell-type during development, it is not surprising that defects in ciliogenesis 
and its downstream signaling can cause a wide variety of congenital defects in humans. 
In the heart, primary cilia are observed in the majority of cell types and have been 
associated with various congenital cardiac defects. Recent genetic and molecular studies 
have established primary cilia as important in forming both the mitral and aortic valves. 
However, how primary cilia function and whether Hedgehog ligands are involved in cilia 
signaling during valve morphogenesis is currently unknown. Through a combination of in 
vivo and in vitro analyses, we show that among the three Hedgehog ligands, only Desert 
Hedgehog (DHH) functions during fetal gestation to regulate cytoskeletal organization of 
the valve leaflets through a non-canonical, cilia-dependent pathway. The Hedgehog 
signal emanates from the endocardium and is received by ciliated mesenchymal cells. 
This paracrine cross-talk is specific to developmental time points and is critical for 
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shaping the valve into a thin, attenuated structure. Genetic perturbation of this pathway 
results in valvular defects during fetal gestation and leads to the generation of 
myxomatous valves later in life. Our studies establish a molecular and developmental 
origin for myxomatous mitral valves through a novel cross-talk mechanism and further 
implicate MVP as a congenital defect. 
Mitral valve prolapse (MVP) is a progressive cardiac tissue disorder that affects 1 
in 40 individuals worldwide169-174. It is characterized by destruction of the extracellular 
matrix (ECM), which disrupts the valvular tissue architecture and renders the valves 
biomechanically incompetent. These valves prolapse, or “billow” above the line of the 
mitral annulus, which can lead to blood regurgitation and significant cardiovascular 
remodeling. These changes to cardiac hemodynamics often result in patient development 
of secondary complications including arrhythmias, thromboembolisms, heart failure and 
sudden cardiac death unless surgically corrected175-177. Understanding the pathways 
underlying this disease is critically important to the development of new therapies for 
those affected, with the goal of the creation of non-surgical interventions for this 
population. 
3.2 Results 
 Previous studies have reported the expression of Hedgehog ligand in the 
developing atrioventricular cushion, but little is known about its role in mitral valve 
development. To explore the potential influence of this signaling pathway, we first began 
by investigating its expression patterns. RT-PCR of immortalized mouse atrioventricular 
mesenchymal cells demonstrated expression of the HH signaling genes, Smoothened 
(SMO), Patched1 (PTCH1), and their downstream messages for GLI proteins (GLI1, 
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GLI2, GLI3) (Figure 3.1A). However, message for the three HH ligands, Sonic (Shh), 
Indian (IHH), and Desert (Dhh) were below the level of detection in this assay, indicating 
little or no expression of these genes in this cell population (Figure 3.1A). This was 
somewhat unexpected because the atrioventricular mesenchymal cells are the population 
in developing mitral valves that express the primary cilia required to transduce HH 
signaling. To explore the expression of HH ligands in vivo, RNAseq was performed on 
the anterior leaflets of three wildtype P0 mitral valves. These data revealed the expression 
of message for DHH ligand, but not SHH or IHH (Figure 3.1B). This is consistent with 
previous reports (Bitgood & McMahon, 1995), and prompted us to explore Dhh 
expression in vivo. In situ hybridization (Figure 3.1C) and IHC (Figure 3.1D) revealed 
that DHH message and protein can be detected in endocardial cells as early as E13.5 and 
persists to P0 but is absent in adults (Figure 3.1D), notably similar to the expression 
patterns of primary cilia (Toomer, Dev Dyn, 2017). As shown in Figure 3.1C, Dhh is 
expressed primarily within the valve endocardium at E15.5 with lower levels of 
expression within the trabeculated endothelium, primary atrial septum and epicardium. 
By the P0 neonatal timepoint, valvular Dhh mRNA expression shows regionalization 
within the mitral leaflet and is primarily restricted to the atrialis endocardium. 
Immunohistochemistry (IHC) confirmed the presence of DHH protein within the valve 
endocardium at embryonic, fetal and neonatal timepoints with evidence of protein 
diffusion into the interstitium (Figure 3.1D). Similar to the mRNA expression, DHH 
protein is primarily evident within the atrialis aspect of the anterior and posterior mitral 
leaflets with the highest signal present at the valve tip (Figure 3.1D and Figure 3.2A). 
Expression of DHH protein was not detected in the adult mitral leaflets (Figure 3.1D), 
 89 
indicating a likely developmental role for this growth factor. To test whether Hedgehog 
signaling was active in the valve interstitium, IHC was performed for axonemes and the 
G protein coupled receptor (GPCR), Smoothened. In the presence of HH ligand, 
Smoothened undergoes a variety of modifications on its C-terminal tail, including 
phosphorylation and cholesterol adducts, which change its structural confirmation leading 
to translocation from the membrane into the primary cilium178,179. Thus, localization of 
Smoothened serves as a marker for Hedgehog signaling. Using high resolution confocal 
microscopy, Smoothened was found both at the ciliary base and within the axoneme, 
strongly supporting active HH signaling within the valve (Figure 3.1E.) Taken together, 
our RNA and protein expression studies support a paracrine cross-talk mechanism in 
which valve endocardial-produced DHH communicates with valve interstitial cells 




Figure 3.1: DHH ligand is expressed by the endocardium and activates Smoothened 
ciliary translocation in interstitial cells (A) RT-PCR analyses of immortalized AV 
cushion mesenchyme showing expression of Smo, Gli1, Gli2, Gli3 and Patched 1 (P1) but 
not Shh, Ihh, or Dhh. Hprt was used as a control for the RT reaction. (B) mRNA reads 
from RNAseq datasets of isolated anterior mitral valve leaflets at P0 showing Dhh is the 
only Hedgehog ligand present within the mitral valves. (C) Section in situ for Dhh 
mRNA at E15.5 and P0 showing expression in valve endocardium (arrows), primary 
atrial septum (PAS), dorsal mesenchymal protrusion (DMP), epicardium (epi), 
ventricular endothelium (blue arrowheads) and endothelium of forming chordae 
tendineae (black arrowheads). (D) IHC shows the expression of DHH protein by 
endocardial cells of the developing mitral valve (white arrows), epicardium (epi) and 
ventricular endothelium (white arrows). Expression within the valve is more concentrated 
along the atrialis. No discernible expression is observed at adult timepoint (**). (E) High 
resolution confocal microscopy and 3D reconstruction of IHC of the anterior leaflet of P0 
mitral valves show Smoothened (red) translocation onto ciliary axoneme (green-
acetylated tubulin) indicating active HH signaling (arrowheads). AVC = atrioventricular 





Figure 3.2: DHH antibody validation. (A) P0 Tie2Cre(-); Dhhf/+ control hearts were 
stained with a DHH antibody and show endocardial staining primarily at the tip of the 
anterior and posterior mitral leaflets. (B) IHC for DHH on the Dhh conditional knockout 
mice (Tie2Cre(+);Dhhf/f) shows a loss of DHH staining in endocardial cells, thus validating 




DHH conditional mice (Dhhf/f) were used180 to assay the cell-specific function of 
DHH during valve development and to validate the DHH antibody (Figure 3.2). We 
initially examined Dhhf/f mice maintained on either the Tie2Cre or NfatC1Cre backgrounds. 
Both of these Cre lines genetically remove Dhh in endothelial and endothelial-derived 
cells. As the mitral valves are initially built through an endothelial-to-mesenchymal 
transformation (EMT), these Cre lines will remove Dhh from a majority of cells that 
make up the mitral valves in its entirety. Although subtle phenotypic differences were 
observed between each of these Cre-lines, the mitral leaflets from both lines displayed 
quantifiably altered valve morphology in both length and thickness (Figure 3.3). In all 
animals examined, the valves exhibited regional thickness, width and length alterations, 
resulting in enlarged valve leaflets at P0. To test whether the DHH signal emanating from 
the endocardium is responsible for regulating valve morphogenesis as suggested by its 
expression pattern (Figure 3.1A-D), Dhh floxed mice were bred onto the NfatC1enCre(+) 
line. This Cre is specifically expressed in valve endocardial cells that do not undergo 
EMT and thus, enables deletion of Dhh only in the valve endocardium181 without 
disrupting any expression in the ciliated VIC population. Depletion of Dhh in valve 
endocardial cells resulted in a phenotype similar to the Tie2Cre(+);Dhhf/f and 
NfatC1Cre(+);Dhhf/f mice. Morphometric analyses of 3D reconstructions and 
measurements obtained from H&E sections demonstrated that mitral valve leaflets in the 
NfatC1en-Cre(+);Dhhf/f mice had abnormal valve morphology with significant increases in 





Figure 3.3: Conditional ablation of Dhh in mitral valves results in abnormal 
morphology. (A) 3D reconstructions (top row) of H&E stains (bottom row) for P0 Dhh 
conditional knockout mice (Tie2Cre(+);Dhhf/f) compared to controls (Tie2Cre(-);Dhh+/+). (B) 
Morphometric quantification from 3D and H&E stains showing that loss of Dhh resulted 
in significantly longer and thicker leaflets than controls. n=5/genotype (C) 3D 
reconstructions (top row) of H&E stains (bottom row) for P0 Dhh conditional knockout 
mice (NfatC1Cre(+);Dhhf/f) compared to controls (NfatC1Cre(-);Dhh+/+). (D) Morphometric 
quantification from 3D and H&E stains showing that loss of Dhh using the NfatC1Cre 
resulted in significantly longer and thicker anterior and posterior leaflets than controls. 
n=4/genotype. AL = anterior leaflet, PL = posterior leaflet, WT = control valves, cKO = 





Figure 3.4: DHH signals through a paracrine mechanism and its loss results in 
myxomatous degeneration. (A) 3D reconstructions of P0 mitral valves (top row) created 
from H&E images (bottom row) showed that conditional knockout (cKO) of Dhh from 
endocardial cells (NfatC1enCre(+);Dhhf/f) resulted in enlarged valves compared to controls. 
AL, PL = anterior and posterior leaflets, respectively. (B) Quantification of volumes from 
panel A revealed a statistically significant increase in cKO volume compared to controls 
(WT). (C) The lengths of the AL and PL were significantly increased in cKOs compared 
to WT. (D) Box plots of mitral valve thickness values between WT and cKO. The blue 
boxes show the distribution of the thickness values. The bottom of the box is the 25th 
percentile, the middle line is the median value, and the top of the box is the 75th 
percentile. The red dot denotes the mean. Conditional KOs showed an increased range of 
thicknesses in both AL and PL, and the average thickness was statistically increased in 
both leaflets compared to controls. Each dot is an individual thickness measurement and 
the each color correspond to measurements from individual mice. n=5 animals/genotype. 
(E) Adult Dhh conditional knockout mice (NfatC1enCre(+);Dhhf/f) and control littermates 
were stained for Movats pentachrome (proteoglycans (blue), collagen (yellow), nuclei & 
elastin (black), muscle (red), and fibrin (bright red). NfatC1enCre(+);Dhhf/f mice showed 
enlarged AL and PL with blurring of molecular boundaries, increased proteoglycans and 
enlarged valve tissue compared to controls, indicating a myxomatous phenotype. n=3 
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To define whether loss of Dhh could result in a myxomatous valve as seen in 
patients with MVP, adult NfatC1en-Cre(+);Dhhf/f adult mice were examined histologically 
by Movats Pentachrome stains. As shown in Figure 3.4E, developmental depletion of 
Dhh in the valve endocardium resulted in adult myxomatous anterior and posterior 
leaflets in 100% of animals examined. This phenotype was consistent with the 
myxomatous valves observed in global Dhh deletion adult animals (Figure 3.5). Both 
global and conditional knockout models for Dhh exhibit excess leaflet tissue and have 
disrupted ECM boundaries including loss of fibrillar collagen and increased 




Figure 3.5: Global Dhh ablation results in a myxomatous phenotype in adult mice. 
(A) Movats pentachrome and IHC staining for collagen, versican and elastin on adult 
control mitral valve show thin, elongated valve leaflets with defined molecular regions. 
(B) The anterior and posterior leaflets (AL, PL, respectively) from adult Dhh knockout 
mice (Dhh-/-) are enlarged and show blurring of molecular boundaries as is typical in a 
myxomatous phenotype. Movats staining: proteoglycans (blue), collagen (yellow), nuclei 




To begin exploring the mechanisms by which DHH signaling through primary 
cilia can regulate valve development and lead to myxomatous valves later in life, we 
initially examined whether Dhh ablation had an effect on the construction of the cilia 
themselves. However, careful analysis showed there was no change in cilia length or 
prevalence in NfatC1en-Cre(+);Dhhf/f mice compared to controls (Figure 3.6). Once we had 
eliminated a possible mechanism of ciliogenesis disruption, we next turned our attention 
to examine if canonical Hedgehog signaling is impacted by primary cilia. Following a 
Hedgehog signal through the primary cilium, GLI3 is cleaved into activator and/or 
repressor transcription factors182-184. Thus, the ratios of GLI3 activator vs repressor are 
well established readouts for active Hedgehog signaling through the primary cilium. In 
our study, isolated mitral valves from two independent models of cilia deficiency (Ift88 
and Dzip1), were assayed by Western analyses for differences in these cleavage products 
(Figure 3.7). Western analyses of isolated mitral leaflets from wildtype, conditional 
heterozygote, and knockout mice revealed no statistically significant change in the ratios 
between full length (GLI3 transcriptional activator) or GLI3 repressor (Figure 3.7A, B). 
As transcription of GLI factors and Patched1 is under the control of GLI transcription 
regulators through an autocrine feedback loop, we examined whether mRNA of Gli1, 
Gli2, Gli3 and Patched 1 was changed as a global readout for altered canonical 
Hedgehog signaling in the valves. In mitral leaflets isolated from cilia-deficient Dzip1 
and Ift88 conditional knockout mice, no statistically significant change in mRNA levels 
for these Gli transcriptional targets were observed (Figure 3.7C). Although Gli 
transcription factor mRNAs are expressed by mitral valve interstitial cells, our data 
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suggest that canonical Hedgehog signaling does not impact GLI cleavage or transcription 




Figure 3.6: Dhh disruption does not affect ciliogenesis. (A) Representative 
immunostaining of ciliary axonemes (acetylated a-tubulin, green) and nuclei (Hoechst, 
blue) from P0 mitral anterior leaflets. (B) Quantification of cilia length measurements 
showed no statistical differences between conditional knockouts and controls. (C) There 






Figure 3.7: Primary cilia loss fails to reveal statistically significant differences in 
GLI3 processing or in GLI transcriptional targets. (A) Western blots and 
quantification from cilia deficient P0 valves of NfatC1Cre(+); Dzip1f/f or (B) NfatC1Cre(+); 
Ift88f/f do not show statistical differences in the ratio of GLI3 full length (Gli3FL) to 
GLI3 repressor (Gli3R) compared to controls. n=3/genotype. (C) RNAseq for Gli 
transcriptional target genes are also statistically insignificant. n.s. = not significant. 
n=3/genotype. p-values for each panel are listed below their respective graphs. Error bars 




There are currently two known non-canonical signaling pathways in which 
Hedgehog can function. The first (type I) is a Patched-dependent, Gli-independent 
pathway regulates apoptosis and the cell cycle. However, previous reports have shown 
that loss of cilia either through Ift88 or Dzip1 deletion in the valves does not result in a 
significant change in proliferation or apoptosis85,86. Consistent with these prior reports, 
we do not see a change in total cell number in the Dhh conditional knockout mitral 
leaflets (Figure 3.8A, C). These data suggest that DHH signaling and/or primary cilia 
have little impact on cell proliferation during valve morphogenesis and type I non-
canonical signaling is unlikely the major mechanism impacting valve development. The 
second (type II) non-canonical Hedgehog pathway is Smoothened-dependent, Gli-
independent and involves cytoskeletal remodeling111 as the major functional readout. 
During mitral valve development, VICs are activated to reorganize their cytoskeleton and 
become aligned within the tissue10,33,121,185. This results in the attached ECM becoming 
structured into distinct laminae in a process called “ECM compaction or ECM 
remodeling”. Thus, we hypothesized that DHH-signaling, through a type II non-canonical 
mechanism, activates the VIC cytoskeleton and results in ECM compaction, ultimately 
leading to leaflet attenuation and thinning. We initially tested this by assaying cellular 
density within the Dhh conditional knockout valves. Consistent with our previous 
findings in the Ift88 and Dzip1 conditional knockout mice84-86, there is a reduction in cell 
density in the mitral leaflets at P0 (Figure 3.8A, B) and an increase in extracellular space 
between cells compared to control littermates. This indicates a potential failure for the 




Figure 3.8: DHH does not regulate total cell number but does affect cell density. (A) 
H&E of control (NfatC1Cre(-); Dhhf/f) and conditional knockout (NfatC1Cre(+);Dhhf/f) 
showing boxed regions where measurements were taken for cell density n=3 sampling 
squares/section, 3sections/animal, 4 animals/genotype (B) and total cell numbers. n=3 
sections/animal, 4 animals/genotype (C) Cell density is decreased in the conditional 




To directly test the effect of DHH signaling and the role of primary cilia in ECM 
remodeling through activation of the cytoskeleton, we employed 3D collagen gel 
compaction assays. In these assays, cells are embedded within free-floating collagen gels 
and upon treatment with drug or control media, will compact the gel over time. These 
assays are commonly used as an efficient and reproducible method for quantifying 
cytoskeletal dynamics and ECM compaction in vitro185. Embryonic chicken valvular 
interstitial cells (cVICs) during stages of active valve remodeling (HH30-31) were 
dissected, cultured, and entombed with collagen hydrogels (1.5mg/ml), released from the 
side and bottom of the wells and subsequently treated with DHH ligand (mouse C23II, 
1µg/ml). While the results showed that DHH treated cells had significantly smaller 
hydrogel diameters at 2-6 hours post treatment, the results were modest and there was no 
difference in hydrogel compaction after 7 hours of treatment (Figure 3.9A, B). This 
prompted us to investigate whether Hedgehog ligands were present within the media, 
potentially masking the effect of exogenously added ligand. Western blotting of 
unconditioned media confirmed the presence of each of the three Hedgehog ligands 
present within the media (Figure 3.9C). To test whether Hedgehog ligands were 
responsible for promoting collagen remodeling in this gel system, antibodies directed 
against each of the Hedgehog ligands were added to the culture media. Addition of these 
blocking antibodies significantly impacted the rate of collagen remodeling in the gels at 
every timepoint investigated (Figure 3.9D-F) demonstrating a crucial role for Hedgehog 
signaling in cell-driven ECM compaction. As DHH is the only Hedgehog ligand 
expressed during cardiac valve development, the data strongly support that this growth 
factor is driving valve ECM compaction. This was further confirmed in serum free media 
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stimulated with DHH ligand. As shown in Figure 3.10, DHH alone was sufficient to 





Figure 3.9: DHH treatment promotes VIC contraction in 3D collagen hydrogel in 
vitro assays. (A) Representative images of Untreated and DHH treated hydrogels seeded 
with embryonic chicken VICs (cVICs, HH30-31) over the course of 24 hours. (B) Graph 
of hydrogel diameter change from (panel A) over time shows DHH treatment increased 
hydrogel contraction from hours 2-6 compared to control, but there was no statistical 
(n.s.) difference by 24 hours. ns= not significant, *=p<0.05, **=p<0.005 (C) Westerns 
revealed that HH ligands were present in serum samples from untreated media. (D) 
Antibodies against HH ligands blunted compaction of collagen gels compared to the 
DHH treated group. (E) Quantification of hydrogel diameters from panel D showed 
antibodies against HH ligands significantly reduced contraction rate compared DHH 
treatment. d=p<0.0005 (F) Quantification of percent increase in compaction compared 
between DHH stimulated and antibody treated showing that over time, DHH treated gels 





Figure 3.10: DHH stimulates collagen remodeling. (A) Bright field images taken at 
one hour increments over 8 hours of compacting collagen gels entombed with chicken 
VICs in full media supplemented with antibodies against SHH, DHH and IHH compared 
or in serum free (SF) media supplemented with DHH protein. (B) Quantification of gels 
shown in A demonstrating a significant increase in DHH-dependent collagen remodeling 




To test whether DHH signaling is dependent on primary cilia, chicken VICs were 
treated with cyclopamine (Figure 3.11A). Cyclopamine is a Hedgehog-specific inhibitor 
that binds to Smoothened to prevent its signaling through the primary cilium186. VICs 
stimulated with cyclopamine (25µM) displayed a pronounced delay in their ability to 
remodel the collagen ECM compared to control and DHH treated gels. Results from 
combinatorial treatment of DHH and cyclopamine were similar to those obtained from 
cyclopamine-only treated gels, suggesting a DHH-dependency on Smoothened at the 
primary cilium. Cytochalasin D (CytoD), an actin depolymerizing agent was used as a 
control to validate that gel compaction is due to actin organization. Chicken VICs, that 
were stimulated with CytoD failed to compact collagen gels over a 24-hour timepoint. 
The addition of DHH to CytoD treated cultures had no impact on the cells ability to 
remodel the ECM as anticipated (Figure 3.11C). Brightfield images of the hydrogels 
taken at the 24-hour timepoint confirmed that cell viability was likely not a factor in the 
differences in hydrogel remodeling (Figure 3.12A). 3D reconstructions of cVICs from 
the hydrogels also showed that cells treated with DHH exhibited a different pattern of a-
SMA staining compared to cyclopamine and CytoD treated cells (Figure 3.12B). In the 
cyclopamine treated cultures, the cells exhibited a rounded morphology and perturbed a-
SMA organization with no evidence of linearly organized actin filaments. The a-SMA 
staining in the cytochalasin D treated cells appears jagged and consistent with 
depolymerized actin cables. Conversely, the DHH treated cells have elongated filopodia 
with organized smooth muscle actin and appear to make syncytial networks with 
neighboring cells. These data strongly support DHH as regulating smooth muscle actin 
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organization and ultimately, ECM remodeling, through a Type II (Smoothened-




Figure 3.11: ECM remodeling is dependent on cilia/Smoothened signaling. (A) 
Cyclopamine, a Smoothened-specific HH inhibitor, reduced hydrogel contraction 
compared to the DHH treated group. (B) Graph depicting the quantification of hydrogels 
from the groups in panel A. There was no significant difference between cyclopamine 
alone versus cyclopamine plus DHH ligand. *=p<0.05, **=p<0.005 (C) Treatment with 
the actin polymerization inhibitor, Cytochalasin D (CytoD), prevented hydrogel 
contraction. (D) Quantification of CytoD vs DHH treatment from gels in panel C shows 
CytoD significantly reduced contraction of hydrogels, demonstrating that collagen 
remodeling is dependent on an intact and active actin cytoskeleton. *=p<0.05, 





Figure 3.12: cVIC grown in 3D culture show changes in SMA expression when 
treated with DHH. (A) Low and high magnification of brightfield images of chicken 
cVICs after 24 hours in 3D culture reveal that treatment with DHH, cyclopamine, or 
cytochalasin D did not impede cell viability. (B) 3D reconstructions of cVICs in 
sectioned collagen hydrogels showed that DHH induced elongation of cells and robust 
SMA expression compared to cVICs treated with cyclopamine and cytochalasin D. Cells 
treated with cyclopamine had rounded nuclei, indicative of low intercellular tension and 
very little SMA expression, indicative of cVIC inactivity. Cells treated with cytochalasin 
D also had rounded nuclei, and jagged/blebbed SMA protrusions, indicative of inhibited 




Our data showing that DHH can regulate a-SMA organization in vitro, combined 
with the observation that DHH and cilia are only present during developmental 
timepoints in vivo indicates that a-SMA activation may represent a unique DHH-driven 
cell phenotype within the mitral valves during development. Immunohistochemical stains 
revealed that a-SMA is expressed by VICs within specific regions of the valve during 
timepoints of active valve remodeling. During early stages of valve morphogenesis 
(E10.5), a-SMA is not observed in newly transformed mesenchymal cells, but is robustly 
expressed by developing myocytes187 (Figure 3.13A). Within the valves at E13.5, 
expression of a-SMA is confined to a small group of cells at the junction where superior 
and inferior AV cushions have fused as well as in a few mesenchymal cells within the 
distal regions of the anterior and posterior leaflets (Figure 3.13A). By E15.5, expression 
becomes more pronounced within VICs localized to the distal tips of the mitral leaflets. 
The expression of a-SMA continues to increase in this region of the leaflet at P0 and 
correlates with the timepoints of active valve compaction/remodeling, the expression of 
primary cilia and the presence of DHH protein (Figure 3.13B, C, and Figure 3.2). To 
test whether expression of a-SMA is affected by DHH, we performed IHC and 3D-
reconstructions of immunostains throughout the entire valve of control and NfatC1Cre(+) 
mice (Figure 3.13C). In control mitral leaflets at P0, expression of a-SMA is expressed 
primarily in regions of apposition between the anterior and posterior mitral leaflets. This 
pattern of expression was significantly attenuated in the NfatC1Cre(+);Dhhf/f valves 
(Figure 3.13C). Loss of cilia resulted in a similar change in a-SMA expression and its 
spatial distribution (Figure 3.13D).  
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Figure 3.13: Temporal-spatial a-SMA is regulated by Dhh and primary cilia in vivo. 
(A) IHC showed that a-smooth muscle actin begins to be expressed in the 
atrioventricular cushion (AVC) by E13.5 and continues to increase in later stages of 
valvulgenesis. a-SMA is robustly expressed within the myocardium at all timepoints 
analyzed. The expression within the valves is restricted to a core of cells localized to the 
fusion region of the superior and inferior cushions (arrow) as well as within the tip of the 
anterior and posterior leaflets (arrowheads). (B) 3D reconstruction created from z-stack 
of high-resolution confocal image of wildtype anterior leaflet shows primary cilia (green) 
are present throughout a-SMA rich regions (red) within the valve tip. (C) 3D 
reconstruction (top row) of control (NfatC1Cre(-);Dhh+/+) and Dhh conditional knockout 
(NfatC1Cre(+);Dhhf/f) P0 mitral valves show reduced SMA (red) expression compared to 
wildtype controls. White arrow heads indicate areas of high SMA expression on the 
wildtype anterior leaflet on IHC stains from which the 3D reconstructions were created 
(bottom row). (D) Mitral valves of cilia conditional knock outs (NfatC1Cre(+);Ift88f/f) also 
show an apparent reduction in SMA expression (red) compared to controls. AVC = 
atrioventricular cushion, AL = anterior leaflet, PL = posterior leaflet, n=3 
animals/genotype  
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In an attempt to identify the tissue layer in which these a-SMA cells reside, IHC 
co-stains with markers of the fibrosa (collagen 1 a1) and spongiosa (versican) were 
performed and revealed an imperfect overlap between a-SMA expressing cells and either 
of these markers (Figure 3.14, and 3.15). The altered distribution of a-SMA in the 
conditional heterozygote and knockout correlates with areas of lower versican expression 
in the valve tips (Figure 3.14). Although some overlap is evident between collagen and 
a-SMA expressing cells in control mitral leaflets, this expression is limited to the middle 
of the mitral tip. The DHH heterozygote and knockout mice fail to show this pattern and 
the cells that express a-SMA in this region do not appear to appreciably overlap (Figure 
3.15). Loss of one allele of Dhh was sufficient to generate these molecular changes 
indicating that gene dosage of this growth factor is critical. These data suggest that a-
SMA positive VICs likely mark a unique sub-population of endothelial-derived cells 
within the tips of the mitral valves. This hypothesis was further tested by performing IHC 
on WT1 lineage traced mice, which labels epicardially derived cells (EPDCs)187. 
Consistent with a-SMA marking a novel population of endothelially derived cells within 
the mitral leaflet tips, expression is not observed within EPDCs of the anterior or 




Figure 3.14: Conditional Dhh ablation affects a-SMA distribution in vivo. 
Immunofluorescence staining shows a-SMA (red) expression does not overlap with 
versican (green). Distribution and organization of a-SMA was affected in conditional 
knockouts (NfatC1Cre(+);Dhhf/f) and heterozygous (NfatC1Cre(+);Dhhf/+) mitral valves 





Figure 3.15: VICs that produce a-SMA are distinct from collagen producing VICs. 
Similar to results observed in Figure 3.14, immunofluorescence staining shows a-SMA 
(red) expression does not completely overlap with collagen (green). Although some 
overlap is detected (arrow), a-SMA appear to largely be excluded from collagen 
expressing cells. In the conditional knockouts (NfatC1Cre(+);Dhhf/f) and heterozygous 
(NfatC1Cre(+);Dhhf/+) mitral valves, a-SMA distribution was affected and appears in a 




Figure 3.16: a-SMA producing VICs are not epicardially derived. IHC staining of 
E15.5 hearts from WT1-Cre ROSA-eGFP (Wt1Cre(+); Rosaf/+) lineage trace mice for 
Hoechst (blue), a-SMA (red) and GFP (green). VICs expressing a-SMA were GFP 
negative, and thus not derived from the epicardial lineage. 
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Our data demonstrate a critical role for DHH signaling through the primary cilium 
in the regulation of collagen gel compaction (Figures 3.9-3.11) and a-SMA organization 
(Figure 3.12 and 3.13). Anisotropic filamentous actin is required for force generation 
and remodeling of ECM188-195. Thus, we tested whether DHH could induce organized, 
anisotropic a-SMA filaments. Immunocytochemistry of unstimulated cVICs in serum-
starved cultures revealed prominent a-SMA expression. This expression was primarily 
restricted to the cell periphery with a notable lack of mature actin filaments (Figure 
3.17A). Under DHH stimulated conditions, however, we observed a profound increase in 
anisotropic, a-SMA filaments that were well organized within the VICs (Figure 3.17A’). 
To test if this organization was dependent on active Hedgehog signaling, the Smoothened 
inhibitor, Cyclopamine was used. ICC of cyclopamine-treated cultures revealed a 
complete loss of filamentous a-SMA staining with no discernible difference in 
organization between DHH-treated and controls (Figure 3.17B, B’). The actin 
depolymerizing agent, Cytochalasin D gave a similar response with no evidence of 
mature filamentous actin between DHH-treated and controls (Figure 3.17C, C’). These 
data further demonstrate a role of DHH signaling through the primary cilium in 




Figure 3.17: DHH stimulates a-SMA organization through Smoothened-dependent 
TIAM1-RAC1 activation. (A, A’) Serum starved cVICs (HH30-31) display a-SMA 
expression along the cell periphery. Addition of DHH (1µg/ml) to cVICs induces a rapid 
reorganization of a-SMA stress fibers. (B,B’) Addition of the Smoothened inhibitor 
completely blocks this DHH-mediated actin effect as does depolymerization of the actin 
cytoskeleton with cytochalasin D (C,C’). (D) Co-immunoprecipitation showed that HH 
treatment from DHH ligand or HH-containing untreated media results in the loss of SMO 
and TIAM1 binding. This effect is inhibited by cyclopamine (Cyclo), cytochalasin D 
(CytoD), or HH antibodies (Abs). Inputs for each of the co-IP experiments are shown to 
the right and display relatively equal presence of SMO protein in the lysate (E) DHH 
treatment activates the TIAM1 target kinase RAC1 (RAC1-GTP) in cVICs, (F) inducing 
a greater than 50-fold increase within 10 minutes. n=4 
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To gain mechanistic insight into how DHH might regulate smooth muscle actin 
polymerization through the primary cilium, we investigated the involvement of RAC1 
activation. RAC1 is a member of the p21 Rho-family of small GTPases that are master 
regulators of actin cytoskeletal rearrangements111,185,196. Recent data has suggested that 
RAC1 is activated by the small GEF, TIAM1 (T cell lymphoma Invasion and 
Metastasis)197. As TIAM1 has been shown to interact with Smoothened and upon 
Hedgehog stimulation197, function as a GEF for RAC1 to polymerize actin, we initially 
tested by Co-immunoprecipitation (Co-IP) whether this interaction was functioning in our 
culture models (Figure 3.17D). In full serum containing media (containing each 
Hedgehog ligand and/or spiked with additional DHH protein), we detected no appreciable 
interaction between TIAM1 and Smoothened. However, following treatment of the 
cultures with antibodies against each of the Hedgehog ligands, this interaction was 
observed. Similarly, cyclopamine, which binds to Smoothened and induces an inactive 
confirmation of Smoothened, resulted in retention of a Smoothened-TIAM1 interaction 
by Co-IP. Treatment with the actin depolymerizing agent, cytochalasin D also led to an 
interaction between TIAM1 and Smoothened (Figure 3.17D). These data suggested that 
DHH is required for the release of a TIAM1-Smoothened interaction leading to RAC1 
activation and a-SMA polymerization. Consistent with this hypothesis, stimulation of 
serum-starved cells with DHH resulted in a significant increase in RAC1-GTP (Figure 
3.17E, F), which is required for a-SMA maturation. Loss of RAC1-GTP activation was 




Figure 3.18. Loss of Dhh reduces RAC1 activation. Immunohistochemical stains 
revealed that conditional knockout of Dhh (NfatC1Cre(+);Dhhf/f) resulted in less RAC1-




Mitral valve prolapse is a common disease affecting 2.5% of the general public 
with a poorly understood etiology. Until recently, studies on MVP have been relegated to 
end-stage phenotyping. These studies have led to the understanding of the molecular and 
structural phenotypes of a myxomatous valve198-200. In these abnormal, biomechanically 
inferior tissues, there is very little phenotypic similarity with unaffected valves in terms 
of their structural organization. The intricately organized ECM composition of elastin, 
proteoglycans and collagen that is observed in normal mitral valves is lost in MVP 
patients. However, the blurring of these ECM boundaries in diseased tissues is not the 
only difference. Cell phenotypes are also altered between a normal and MVP disease 
valve with evidence of increased inflammatory cells201,202 and myofibroblasts presence, 
escalation of robust cellular activity, and overall lack of cellular quiescence199. How the 
valve tissue progresses to this stage of disease in MVP patients is unknown. Recent 
genetic discoveries have pointed to primary cilia as causative to MVP in affected families 
as well as in the population86,121,203,204. Uncovering how primary cilia function will likely 
provide key insight into mechanisms that go awry in MVP patients.  
Although it is now clear that primary cilia are required for valve development and 
can cause myxomatous valve disease and MVP in mouse models and in patients with 
disease, the function of these cellular antennae in the valves have remained elusive. The 
classical signaling of Hedgehog through the primary cilium to regulate GLI transcription 
factors is by far the most common mechanism of function. However, it is becoming clear 
that this signaling cascade, which ends in GLI transcriptional target gene regulation, is far 
more complex and can function through different mechanisms depending on cell-context. 
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In this study, for example, we found no evidence to support a Hedgehog-cilia-GLI 
pathway in two independent cilia-deficient genetic models. This contradicts previous 
reports of Ift88205 and Dzip1206-210 deletion, which showed a profound effect on GLI 
repressor versus activator forms with consequences on modulation of GLI transcriptional 
targets. The differences between our study and other previous reports likely reside in the 
context of the interrogated tissue-type, cell-type and cell-ECM microenvironment. 
Another main difference may reside in the ligand itself. Whereas most reports focus on 
Sonic Hedgehog (SHH) as the major driver of cilia-dependent signaling in most cells 
within the body, our data do not support a role for SHH in the valves. RNAseq and RT-
PCR revealed the presence of Dhh mRNA within the developing mitral valves and not 
Shh or Ihh. Previous reports have shown that, although the affinity for Patched is similar 
between the Hedgehog ligands, their potencies to stimulate the canonical pathway are 
very different with a potency of Shh>>Ihh>>Dhh111. Thus, the decision to function 
through a canonical (GLI-dependent) or non-canonical pathway likely resides in the type 
of Hedgehog ligand present, concentration gradient within the tissue and diffusivity of 
the ligand. Our data showing activation of ciliated VIC’s in close proximity to the highest 
degree of DHH expressing endocardial cells lend support to this hypothesis of a limited 
concentration gradient and/or restricted diffusion rate (Figure 3.2). 
For Hedgehog to function through the primary cilia, it must bind to its cognate 
receptor, Patched at the ciliary base. This binding induces a conformation change that de-
represses Patched inhibition of the GPCR, Smoothened, which then traverses into the 
ciliary axoneme. Theoretically, knocking out Smoothened should show a similar 
phenotype in the valves compared to valves in Ift88, Dhh, and Dzip1 mouse models. 
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Although previous reports have stated no valve phenotype in the Tie2Cre;Smoothened 
floxed mouse211, our studies using the NfatC1Cre resulted in a robust abnormal mitral 
morphological phenotype (Figure 3.19) and changes in the ECM such as decreased 
collagen (Figure 3.20) and versican (Figure 3.21) as have been reported in cilia 
knockout (Ift88 and Dzip1) mouse models. As has been reported in Ift88 and Dzip1 mice 
and the Exoc5 mouse from Chapter 2 of this dissertation, both NfatC1Cre(+);Dhhf/f and 
NfatC1Cre(+);Smof/f mice show increases in the prevalence of bicuspid aortic valve 
morphology (Figure 3.22). NfatC1Cre(+);Dhhf/f mice had a 50% incidence of BAV with 
3/6 mice having right non-coronary (RNC) fusions (Figure 3.22B), as did 1/3 of 
NfatC1Cre(+);Smof/f mice (Figure 3.22C). The reason for the differences between our 
work and previous reports are unclear but may reside either in the type of Cre used, the 
degree of persistent Smoothened expression in the valves, or technical differences 




Figure 3.19: Conditional Smo ablation results in dysmorphic valves. H&E’s of 
conditional Smo knockout mice at P0 (NfatC1Cre(+);Smof/f). Enlarged anterior leaflets 
(arrows) are observed compared to littermate controls. AL, PL = Anterior and posterior 




Figure 3.20: Conditional Smoothened knockouts show alterations to collagen. (A) 
Control mitral valves stained for collagen (red), MF20 (green), and nuclei (blue) show 





Figure 3.21: Conditional Smoothened knockouts show alterations to versican. (A) 
Control mitral valves stained for versican (red), MF20 (green), and nuclei (blue) show 





Figure 3.22: Conditional knockouts of Dhh and Smo show increased prevalence of 
BAV. (A) Low and high magnification images of H&E stained control P0 aortic valve 
with the right coronary (RC) and left coronary (LC) cusps visible. (B) Conditional 
knockouts of Dhh had an increased prevalence (50%, 3/6 animals) of right-non-coronary 
RNC cusp fusion. (C) Similarly, RNC cusp fusion was noted in aortic valves of 
conditional Smo knockouts (33%, 1/3 animals). 
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Within the valves, primary cilia and Desert Hedgehog are only observed during 
development. It is becoming recognized that during fetal morphogenesis, cardiac valves 
need to be reshaped and reorganized to conform to the growing heart and increasing 
hemodynamic demands. Although still poorly understood, various groups have proposed 
a need for actin-driven mechanics to reshape the valve185,212-214. Consistent with this 
theory, we show that DHH expression is capable of regulating collagen gel remodeling in 
vitro, which is primarily dependent on actin kinetics since dismantling the actin 
cytoskeleton completely abrogates compaction. Our previous reports on cilia-deficient 
valves86 and our current findings in vivo also highlight a function for primary cilia and 
DHH signaling in the regulation of fetal valve remodeling. Mechanistically, we focused 
on pathways that are known to be involved in VIC compaction, including the regulation 
of a-SMA. Typically, a-SMA is viewed as a myofibroblast marker that is activated 
during disease processes. This view is oversimplified as we detect a-SMA to be 
expressed in unique temporal-spatial patterns during valve development. Thus, 
categorizing a-SMA solely as a myofibroblast marker is not necessarily correct as it is 
expressed within valve interstitial cells that appear phenotypically identical to their 
neighboring cells. As a-SMA positive cells do not label exclusively with collagen or 
proteoglycan markers, respectively, we are unable to characterize them as a specific cell 
type. As such, our in vivo and in vitro data suggest that they likely represent a novel 
DHH-responsive cell type within the tips of the valves. Upon stimulation by DHH, these 
cells undergo a robust re-organization of the contractile a-SMA cytoskeleton. Genetic 
perturbation of primary cilia or Dhh as well as pharmacological disruption of 
Smoothened function do not result in a change in a-SMA expression levels (Figure 
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3.23), but rather a change in the distribution and organization of the actin architecture. As 
we show, this change in actin organization appears to be driven by a complex kinase 
cascade involving TIAM1 and RAC1.  
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Figure 3.23: Total a-SMA protein expression is not affected by DHH, cyclopamine 
or cytochalasin D. (A) Western analyses of cVICs entombed within collagen gels that 
had been treated for 24 hours with DHH, Hedgehog antibodies, cyclopamine, or 
cytochalasin D. (B-C) Bands from panel A were normalized against total protein amounts 
from collagen gels via ponceau staining and presented as normalized band intensities in 




How organizing the actin cytoskeleton into anisotropic arrays of a-SMA leads to 
ECM remodeling is not well understood. It is logical to propose that actin organization 
results in shape changes that establish long, thinned fibroblasts. As these fibroblasts are 
connected to the ECM via integrins and other receptors, the ECM passively adopts a 
stratification similar to the cells. In this way, the cellular-ECM syncytium acquire an 
aligned shape within the valve tissue. With this perspective, stating that a-SMA functions 
to promote “contraction” of VICs is incorrect and care should be placed on the 
description of such. Additionally, the presence of bonafide acto-myosin contractile cables 
within the valve interstitial cells has not yet been fully described, and as such further 
questions the contractibility of these cells. Rather, it is more likely that a-SMA induces 
cell shape changes and the ECM attached to the VICs through integrins becomes 
passively remodeled or re-organized. Previous TEM studies have shown that the neonatal 
valve and mature adult valve do indeed have longitudinal arrays of cell-ECM along the 
tension points of the valve ranging from annulus fibrosae to chordae tendineae10. Thus, 
blocking VIC shape changes, integrin-mediated cell-ECM interactions, and/or cell-cell 
adhesions would likely disrupt cell-ECM alignment and result in a phenotypically 
enlarged, or uncompacted tissue during development. In addition to our current data, 
recent findings from various in vivo mouse models, including perturbations of other 
genes that cause MVP (such as FLNA and DCHS1) and in vitro 3D models that 
incorporate tension64-67,215, support this hypothesis. 
 The concept that MVP, which is usually diagnosed in aged adults can be rooted in 
developmental defects may seem paradoxical. However, based on this report, in addition 
to manuscripts by us and others, we now recognize that MVP has at least two major 
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disease phases that represent cause and effect: 1) disease inception that occurs during 
development121,216-219 and 2) disease pathogenesis that occurs over the lifespan of the 
affected individual201,202. This is akin to a house being built with a faulty structure that 
will take time to fail. As such, myxomatous valve disease and MVP must then, by 
definition, be congenital in nature and influenced by secondary defects (e.g. 
inflammation, etc.) in valve homeostasis after birth. We posit that valves in MVP patients 
are not biomechanically inferior because they “degenerate” (as is current dogma), as this 
would imply destruction of a properly built structure. Rather, valves in MVP patients are 
never built properly during development and hence they “generate” a myxomatous 
phenotype over time. This distinction is crucial as it places a critical need in 
understanding how valves are constructed during development with the goal of being able 
to rectify or correct a tissue that is being built improperly. Herein we have identified a 
novel mechanism by which Desert Hedgehog signals through the primary cilium in a 
paracrine, non-cell autonomous manner to activate and stabilize the cytoskeleton (Figure 
3.24). When perturbed, the actin cytoskeleton is organized improperly resulting in 
developmental valve defects and generation of a myxomatous valve phenotype later in 
life. As cilia gene defects are common in MVP patients, this study sheds new light on 
how these structures are functioning in normal valves and the damaging consequences 
that ciliogenic signaling defects have on actin organization. Finding new methods for 
organizing and/or stabilizing the actin cytoskeleton may prove beneficial in blunting 





Figure 3.24: Model of DHH-cilia signaling in valve development. In normal 
embryonic valves, the endocardium (endo) releases DHH ligand, which acts on ciliated 
mesenchyme (mes). Upon binding to patched (PTCH1), Smoothened is de-repressed, 
which leads to TIAM1 activation of RAC1 (RAC1-GTP). RAC1-GTP consequentially 
activates actin, which promotes its organization, collagen remodeling and tissue thinning 
and elongation during fetal gestation. In the absence of DHH or in the context of cilia 
gene variants as seen in patients with MVP, the Hedgehog signal is not received, and 
actin organization fails to occur resulting in a defective valve remodeling and poor 












4.1 Ciliogenesis and Valve Disease 
Mitral valve prolapse (MVP) and bicuspid aortic valve (BAV) are cardiac valve 
diseases that affect a combined 3-4% of the human population, and represent a significant 
economic and healthcare burden for those affected. These diseases are frequently 
heritable and sometimes occur as part of a syndrome with known genetic causes such as 
in Alström and Marfan syndromes. However, in many non-syndromic cases of MVP and 
BAV, the specific origin of the pathogenesis is unknown, and is likely the consequence of 
a complex landscape of molecular interactions. Both conditions can lead to a progressive 
disruption of cardiac function due to deleterious tissue remodeling, and currently result in 
thousands of surgeries each year to correct or replace the damaged valves. Understanding 
the mechanisms underlying these disorders is paramount to developing new intervention 
strategies and improving patient outcomes. 
Previous work by our lab and others has shown that primary cilia are important 
regulators of valvulogenesis, and that their perturbation is broadly attributable to some 
incidences of heritable valve disease. However, many questions about the underlying 
mechanisms of their contribution remain unanswered. In an effort to reduce the 
knowledge gap, this dissertation work focused on two main questions related to primary 
cilia and cardiac valve development: 1) how are primary cilia in heart valves generated 
and 2) what is their function in valvulogenesis? These questions are particularly 
important because pathway discoveries in these areas could identify new therapeutic 
targets for drug discovery or predictive biomarkers.  
To explore the first question, we hypothesized that generating cilia (ciliogenesis) 
is a necessary part of valvulogenesis and that perturbing ciliogenic trafficking through 
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disruption of the exocyst would inhibit ciliogenesis and negatively influence valve 
morphogenesis. We tested this hypothesis in a variety of model systems that targeted a 
key exocyst linker protein, EXOC5, as a method to disrupt exocyst function. This 
included experimentation with exoc5-/- zebrafish and conditional endocardial and 
endothelial specific cre mouse models of Exoc5 ablation. Data showed that disruption of 
the exocyst complex in mice resulted in shorter and less prevalent cilia in both aortic and 
mitral cushions, confirming the exocyst is necessary for normal ciliogenesis in heart 
valves. Further, results demonstrated that disruption to this pathway lead to the 
development of dysmorphic aortic and mitral valves in mice and arterial stenosis in 
zebrafish. We also demonstrated a link between variants in the ciliome, including 
members of the exocyst complex, and human BAV. These data, taken together, connect 
the exocyst to ciliogenesis and the development of cardiac valve diseases, but questions 
remain and further experimentation should be undertaken to build upon these findings. 
One of the first avenues of future studies should be to definitively link exocyst 
perturbation to anomalous valvulogenesis through its role in ciliary trafficking. As was 
previously mentioned in Chapter 1, the exocyst has multiple functions within a cell, and 
though we were able to link Exoc5 ablation to shorter cilia and dysmorphic valves, we 
did not prove the valve phenotype was caused solely by disrupted ciliogenesis. Both 
zebrafish and mouse models displayed conduction irregularities that seem more 
reasonably related to the exocyst’s role in membrane polarity and cell junction 
maintenance. Further, Ift88 conditional knockout mice, which show almost complete loss 
of cilia in the heart valves, are not embryonic lethal like the Exoc5 conditional knockout 
(cKO) mice indicating involvement of non-ciliary pathways in the Exoc5 cKOs 
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phenotype. However, there is no doubt that the exocyst contributes to ciliogenesis and 
valvulogenesis in the heart, which makes it an exciting subject of future cardiac research. 
Much as was demonstrated with the VxPx cilia targeting sequence rescue experiments in 
zebrafish, more definitive connections between the exocyst’s role in ciliogenesis and 
valvulogenesis will be able to be drawn with the newly generated VxPx Exoc5 mutant 
mice in the Lipschutz lab. If similar phenotyping and morphometric analysis is conducted 
with these new mice, comparisons to the data from this study should reveal a clearer 
picture of the exocyst’s ciliary vs non-ciliary role in heart disease. 
Another avenue for future study is a computational analysis of the similarities and 
differences in transcript profiles between all of our cilia perturbation models, including 
the Exoc5 mice, to look for alterations in similar pathway families between cKO lines 
compared to controls. All of our murine models of cilia perturbation share a similar range 
of phenotypes that broadly encompass a disruption to extracellular matrix organization 
and expression, which leads to valve abnormalities including bicuspid aortic valves 
and/or myxomatous mitral valves. Similarly, our models of MVP, including Dchs1 
conditional and global knockout mice, and Flna cKO mice, all demonstrate a disruption 
to ciliogenesis. The fact that multiple genetic perturbations produce analogous 
phenotypes indicates that it is not so much the specific part of the ciliary machinery that 
is mutated, but rather that the ciliome has been disrupted at all. Gene Ontology (GO) 
enrichment analysis of RNAseq data sets already collected from Ift88 and Dzip1 mice can 
be leveraged in combination with future RNAseq data from other cilia perturbation 
models to identify functional changes shared between mouse lines that might point to a 
unifying hypothesis of the disease phenotype. 
 138 
4.2 DHH-Cilia Signaling 
It is not just the construction of a cilium that is important to proper 
valvulogenesis. As we showed in our Dhh conditional knockout studies, the cilium can be 
adequately assembled (Figure 3.6) and still result in pathogenic phenotypes if the 
signaling mechanisms are ataxic. For this reason, we approached our second question 
regarding cilia functionality through examination of its role as a signaling coordinator. 
We hypothesized that one of the primary roles of cilia in the valve was to coordinate 
Desert Hedgehog (DHH) signaling to remodel the mitral valve during development. We 
tested this hypothesis through employing cre-mediated Dhh ablation in mice to 
specifically target DHH generating cells (VECs), but not impact cilia generating cells 
(VICs). Our results demonstrated that DHH-cilia signaling operates through a paracrine 
crosstalk mechanism in which the DHH producing endocardial cells influence the 
behavior of a subset of ciliated interstitial cells to remodel the mitral valve through 
activation of a-SMA organization. We further demonstrated that Dhh deficient mice also 
have a higher incidence of bicuspid aortic valves, implicating the role of this signaling 
pathway in aortic valve development as well. These data, taken together lead to the 
conclusion that part of the function of cilia in valvulogenesis is to coordinate the 
remodeling response to Dhh signaling that contributes to the maturation of the cardiac 
valves. 
There are still many questions that remain unanswered about the role of DHH 
signaling during valve development. For example, our findings point to a role for non-
canonical (GLI-independent) Hedgehog signaling in valve remodeling, but we also know 
that the interstitial cell population expresses GLI transcripts and proteins. Though we did 
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not find consistent, significant differences in GLI processing at P0, some Gli transcripts 
showed a trend towards significance and it seems an unlikely waste of cellular energy 
resources to continually produce GLI proteins that are not in use. This begs the question 
of is there a yet undescribed canonical signaling role for DHH in valvulogenesis? Our 
expression studies are suggestive of one, and future work may benefit from investigating 
GLI signaling in the valve further. It is possible that changes to GLI processing are 
transient and the signal has remained undetected in our current body of work. It is also 
possible that canonical DHH signaling only occurs discretely during embryogenesis, and 
thus our postnatal leaflet analysis is too late to reveal its influence. It could also be the 
case that GLI-dependent signaling is ligand gradient-dependent, and only takes place in a 
small leaflet region. Because of these various possibilities and others, canonical DHH 
signaling is still a worthy target of future study that may yet reveal insights into the 
regulation of valve development. 
Future studies should also be conducted to further refine our knowledge of the 
DHH-cilia-SMA non-canonical type II pathway. Preliminary IHC data at P0 in 
conditional Smoothened knockout mice (NfatC1Cre(+);Smof/f) has demonstrated a potential 
link to the involvement of PIP kinase activity in wildtype mice that is disrupted in Smo 
cKOs (Figure 4.1A), as well as disruptions to the actin-binding protein, alpha actinin 
(Figure 4.1B). It is my hypothesis that RAC1 activation through TIAM1 dissociation 
from SMO may activate the kinase, PIP5K1b. This kinase is known to localize to the 
plasma membrane to phosphorylate PI(4)P to create PIP2. PIP2 is known to remove 
capping proteins from G-actin that allow actin nucleation and cytoskeletal polymerization 
(Figure 4.2). Confirmation of this signaling cascade would help to expand our 
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knowledge about the mechanism underlying Type II non-canonical DHH signaling and 
would provide valuable insight into heart valve development.  
The DHH-cilia-SMA signaling findings also invite an exciting array of new 
questions about the importance of cilia in coordination of cytoskeletal rearrangements 
during valve morphogenesis. Since cilia are present on interstitial cells throughout 
valvulogenesis, it is logical to think that they could similarly coordinate a variety of 
different cytoskeletal components in response to non-Hedgehog stimuli throughout 
development. For example, following EMT cilia may be able to regulate actin or tubulin 
stabilization states to promote cell migration or proliferation as has been observed in 
studies on fibroblast behavior220 and organs such as the lungs221 and kidneys222,223. These 
ciliary functions may have been missed in our conditional Ift88 mouse models due to the 
onset timing and dosages of the Cres employed. Future studies could leverage in vitro 
models of cilia loss to overcome this potential limitation and interrogate other potential 






Figure 4.1: Preliminary evidence suggests alterations to PIP signaling and 
cytoskeletal remodeling in conditional Smoothened knockout mice. (A) High 
resolution confocal images of immunohistochemical stains of the anterior leaflet tips of 
P0 NfatC1Cre(+);Smof/f mice display a reduction of PIP5K1b expression compared to 
controls. (B) Smoothened conditional knockout mice also had a reduction in the 




Figure 4.2: Model of potential mechanism for DHH induction of SMA organization 
in cardiac valves. This model represents a hypothesis of the potential mechanism for 
DHH-cilia-SMA signaling. In the presence of Hedgehog ligand, TIAM1 is released from 
its complex with Smoothened, and acts as a GEF for RAC1. RAC1 then activates 
PIP5K1b signaling which results in the phosphorylation of PI4P to create PIP2. PIP2 is 
known to participate in the organization of the actin cytoskeleton. 
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4.3 Concluding Discussion 
There are several frequently asked questions that arise from the work presented in 
this dissertation and from the previous work in our lab. First, in the case of MVP, how is 
this adult phenotype associated with disruptions in cilia when cilia are only 
developmentally expressed on mitral valves? Second, if valve disease is caused by a 
disruption to ciliogenesis or disrupted cilia signaling, and cilia are present on almost all 
cell types, why do we not see similar pathogenic phenotypes in other organs in human 
MVP or BAV patients? Third, why do our mouse models only have disease in the valves 
of the left side of the heart? Fourth, why do human MVP patients not have a higher 
incidence of BAV, and BAV patients a higher incidence of MVP like the mice? These 
four questions have been repeated at conferences, committee meetings, and other 
presentations of this work, and while the definitive answers will require rigorous future 
experimentation, I want to conclude this dissertation with a brief elucidation of my 
speculations.  
To answer the first question, we need to consider the role of cilia in the 
development of normal heart valves. As was described in Chapter 3, cilia can act as 
coordinators of tissue remodeling through signaling cascades that guide cellular 
phenotype and organization. Previous studies by our lab and others have also shown that 
cilia signaling is associated with the regulation of extra cellular matrix (ECM) production 
and localization85,86,224,225. Taken together, these observations support the idea that 
primary cilia act to create and organize the scaffolding that underlies a developing heart 
valve. All of these events happen during valvulogenesis, but a dysregulation of these 
processes can have lasting consequences throughout a lifetime. It is perhaps easiest to 
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understand this concept by considering the construction of two buildings. One building is 
carefully designed and assembled by attentive craftsmen that utilize high quality 
materials, and the other is haphazardly thrown together by disorganized contractors using 
subpar supplies. These two buildings may look similar at the completion of construction, 
and the second building will likely continue to be structurally sound for several years. 
However, over time, as the buildings are utilized by their occupants and exposed to the 
environment, the shoddy building will begin to degrade and require repairs, while the 
first building will remain intact much longer. The same applies to the construction of 
heart valves. If the formation of the valve is faulty due to defects in cilia that lead to the 
dysregulation of ECM constituents and/or lack of cellular alignment, it may function for a 
while, but eventually the improper structural configuration will lead to tissue degradation 
and mechanical failure. 
The answer to the second question of why we observe cardiac defects in valve 
disease patients but lack significant disruption to other ciliated organs builds upon the 
concept of structural insufficiency from the first question and adds consideration of the 
local environment of the heart. In both BAV and MVP we observe a disruption to the 
valve scaffolding that stems from aberrant ECM production and/or organization. This 
faulty architecture leads to the development of enlarged and thickened valves that are 
unable to maintain biomechanical competence over time. The weakened template is then 
also exposed to sheer stress, modulating hemodynamic pressures, and continuous 
mechanical activity. Many quality studies have demonstrated the sensitivity of an 
otherwise healthy valve to alterations in cardiac pressure226-228, so it is easy to imagine 
how flawed valve structure could degrade under these conditions. Other organs, such as 
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the brain or kidneys, do not experience this level of mechanical stress, and generally 
maintain pressures between 5-20 mmHg depending on the organ in question. In 
comparison, the valves on the left side of the heart routinely experience 100-120 mmHg 
of pressure during systole. So while it is possible that individuals with congenital diseases 
such as BAV and MVP may have structural insufficiencies in tissues comprising their 
other organs, those tissues are not subjected to the same chronic flagellation, and 
consequently do not develop a detectable disease phenotype. It is therefore reasonable to 
hypothesize that a combination of structural disarray and repetitive kinetics is required 
for valves to lose their functional competence. To test this hypothesis, future studies 
should investigate the role of biomechanics in our genetic models of valve disease. For 
example, one could imagine a setup in which dissected P0 mitral valves could be 
subjected to atomic force microscopy to assess the stress response between genotypes of 
the different models of cilia disruption.  
The third question of why our mouse models lack right-heart valve diseases has 
an answer that closely aligns with the previous consideration. Though it is true that the 
semilunar valves and atrioventricular valves on the left side of the heart arise from the 
same progenitor population as their counterparts on the right side of the heart, they do not 
exist in a similar environment following cardiac septation. As previously mentioned, the 
left-heart valves are exposed to pressures >100 mmHg, while the right-heart valves 
normally remain <25 mmHg. That means beat by beat, the left heart routinely has 4x the 
pressure load of the right heart over an entire human life time. In addition to the 
differences pressure has on mechanical load and stress, it can also lead to molecular 
changes within the cells that comprise the valve leaflets. Studies have shown that there 
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are chamber-specific transcriptional profiles during development229 and differential 
expression of MMPs and their inhibitors between valves230, so it logical to conclude that 
VIC populations diverge as the valves mature in their respective locations. The 
divergence of VIC populations would likely lead to differential cilia signaling during 
development that could further help to explain the lack of right-sided disease in our 
mouse models. To test this hypothesis, it would be useful to create an atlas of 
transcriptional profiles for ciliome constituents in VICs throughout development. Once 
assembled, this information could then be used to create testable hypotheses to examine 
differential expression of the ciliome between valves on opposing sides of the heart. 
Fourth, why do our mice frequently have both BAV and MVP, but similar 
comorbidity is not often observed in humans? First, while most individuals with mitral 
valve prolapse have normal aortic valves, coexistence of both valve conditions has been 
reported in humans231. It is also interesting to note that in a recent study of BAV-MVP 
co-occurrence, prolapsing anterior leaflets (AL) were twice as common as prolapsing 
posterior leaflets (PL) in patients with BAV232. This is in opposition to findings in 
patients with MVP alone, in which prolapse of the PL is most common, but more closely 
matches our mouse models which have a greater prevalence of AL prolapse. Because 
BAV can be detected at birth and MVP does not develop until adulthood, it might then be 
logical to consider that MVP results as a downstream consequence of aortic 
malformation. This may indeed be true in some cases, however, if this were the sole 
explanation, one would also expect MVP to be more common in the general BAV 
population. One should also consider that the affected cell populations in most of our 
murine models of valve disease are limited to endocardial cells and their derivatives, 
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whereas genetic mutations would be globally expressed in affected humans. However, 
this answer is also somewhat unsatisfactory as aortic mitral valves arise from different 
endocardial cushions in different regions of the heart, though it is worth noting that 
endocardial cells and their derivatives do comprise the majority populations in both 
mitral and aortic valves. Aortic valves, unlike mitral valves, also have cellular 
contributions from many different cell populations (neural crest, myocardium, 
endocardium and SHF), and the communication and integration of these different cell 
types is required for cusp formation. As a final point, it is important to consider the most 
obvious explanation, which is that a mouse is not a human. As was mentioned in the 
introduction of this dissertation, there are anatomical differences between mammal 
hearts, structural differences in the layers of the valves, and signaling differences between 
species. Perhaps the multi-layered molecular landscape of human heart valves conveys a 
protective quality that is lacking in their rodent relatives, or perhaps the accelerated 
murine heart rate renders their tissue more sensitive to biomechanical forces and thus 
more vulnerable to both conditions. For now, the answer to this question remains elusive, 
but should persist in the subconscious of future studies. 
Finally, I want to briefly to discuss the potential translational impact of this 
dissertation work. Understanding mechanisms by which cilia influence valve 
development not only gives us a greater knowledge of valvulogenesis, but also of cardiac 
valve disease origins and progression. This work specifically outlined two pathways, 
exocyst trafficking/signaling and Desert Hedgehog signaling, that have influence over the 
success of valve development in our animal models, and in the case of the exocyst, a 
genetic link to human BAV disease. This knowledge allows for the potential of drug 
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discovery by identifying receptors and signaling cascades that could be pharmaceutically 
targeted in future work to help patients with CAVD, BAV, or MVP. For drug discovery 
to be effective, scientists need to know how the druggable targets function in vivo233, 
which is one of the ways that basic science research, like the work presented in this 
dissertation, is critical to advancing translational medicine. Further, by identifying cilia 
gene variants in the human BAV population, future work can build upon our findings to 
potentially identify the causative genetic perturbations that increase disease risk. As an 
example of how our discoveries could progress from bench to bedside, consider that 
exocyst disruption was associated with BAV and CAVD in our mouse models. Future 
studies could build upon this finding to develop a personalized medicine approach to 
identify BAV patients with mutations in components of the exocyst signaling pathway. 
These patients could then be monitored more closely for CAVD development, and 
pharmaceutical interventions could be utilized at earlier disease timepoints, potentially 
eliminating or delaying the need for surgical intervention. It is also possible that 
knowledge about the aberrant ERK signaling described in Chapter 2 could be leveraged 
to treat CAVD patients with MEK inhibitors to reduce their disease progression.  
These are just a few examples of potential translational applications, and many 
questions remain to be answered before this dissertation work can be applied to affect 
clinical outcomes for patients. However, considerable progress has been made towards 
increasing our knowledge about the origin and mechanisms of human heart valve disease. 
Building upon discoveries in the lab that connected primary cilia to valvular diseases, the 
work presented here has identified a previously unrecognized contribution for the exocyst 
trafficking complex in the generation of cilia in the heart, and demonstrated a novel role 
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for cilia, DHH, and a-SMA in the coordination of valve remodeling. Future studies will 
be able to leverage these data to further refine our knowledge about the genetic and 
molecular landscape of valve development in a continued effort to find new therapies to 










Human BAV Genetic Studies 
Data from 480 white patients with BAV were collected with institutional review board 
approval, and written individual patient consents were genotyped with the Omni2.5 chip, 
yielding 2,379,855 genetic markers. From the Framingham Heart Study cohort, available 
at dbGap, 2477 white patients without BAV were genotyped, using the HumanOmni5.0 
bead chip with 4,271,233 genetic markers from dbGaP, and used as controls. Quality 
control of the genotype data from both cohorts was performed by jointly and separately 
recalling all genotypes using GenomeStudio and PLINK. We considered markers with a 
minor allele frequency >1% and performed extensive principal components–based 
filtering for population stratification. After merging cases and controls and further quality 
control, we used 452 BAV cases and 1834 white controls for a common set of 1,355,128 
single-nucleotide polymorphisms (SNPs). Genotyping of the 15 most significant SNPs 
identified in the Discovery cohort, including those containing EXOC4,6,8, was 
performed upon a Replication cohort of 1679 BAV cases and 894 control patients 
undergoing coronary artery bypass grafting. These studies were approved by the 
institutional review board at Harvard University. 
Pathway Analysis 
Pathway analysis was performed using GeNets for the 33 genes ±150 kb from the 15 
SNPs that were used for the Replication Study. GeNets statistically tested the 
connectivity of our gene set and then visualized how the significantly enriched pathways 
from the Molecular Significant Data Base, a collection of annotated gene sets for use 
with GSEA software (MSigDB database v6.2 updated July 2018), intersected with our 
gene set. To find any significant pathway between the genes, we ran the 33 genes of 
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interest in the web-based program and identified the 
PID_ARF6_TRAFFICKINGPATHWAY. The number of candidate genes in this 
pathway was 49. The p-value of 1.48x10-05 indicated that the network was significantly 
more connected than one would expect for a gene set of this size and the global 
connectivity of its genes, i.e., the degree distribution of the genes in the entire network. 
Animal Approval 
All experiments on zebrafish and mice were approved by the Institutional Animal Care 
and Use Committee of the Medical University of South Carolina and the Ralph H. 
Johnson Veterans Administration Medical Center. 
Zebrafish Husbandry and Genotyping 
Adult zebrafish were maintained and raised in an Aquatic Habitats recirculating water 
system (Tecniplast) in a 14:10-hour light-dark cycle. The exoc5 mutant line was 
purchased from the Zebrafish International Resource Center (exoc5-sa23168). The exoc5 
C377T point-nonsense mutation was verified by polymerase chain reaction and direct 
sequencing of both strands in heterozygote adults and mutant larvae progeny. Genomic 
DNA from clipped fins, or whole 3.5 dpf zebrafish, was extracted in 50 μL 1x lysis buffer 
(10 mmol/L Tris-HCl pH 8.0, 50 mmol/L KCl, 0.3% Tween 20, 0.3% NP-40), denatured 
at 98°C for 10 minutes, and digested at 55ºC for 6 hours with 10 μg/mL proteinase K, and 
the reaction was stopped at 98ºC for 10 minutes. The polymerase chain reaction primers 
were as follows: forward primer, 5′-CTATATAGACATGGAGCGGCAAT-3′; reverse 
primer: 5′-CCAACAATTCCTCACCTTCC-3′. Sequencing was performed by Genewiz 
with the forward polymerase chain reaction primer. The CRISPR (clustered regularly 
interspaced short palindromic repeats) mutant exoc5 zebrafish line was generated with 
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the assistance of Dr John Parant in Core B of the University of Alabama at Birmingham 
P30 Hepatorenal Fibrocystic Disease Core Center. The CRISPR mutation was identified 
as a 13-bp insertion in exon 4, leading to a frameshift and premature stop codon. To 
confirm the mutation, genomic DNA from clipped fins or whole 3 dpf zebrafish with 
phenotypes was extracted and processed as described above. The polymerase chain 
reaction primers were as follows: forward primer, 5′-CAAAGGTAGCCTTCCAGCAC-
3′; reverse primer: 5′-CCTCTGTCTCGGGGTATTGA-3′. Sequencing was performed by 
Eurofins with the forward primer, 5′-TCCAGCATGTTTTTCTGGTG-3′ (Eurofins.com). 
Zebrafish Western Blot Analysis 
Dechorionated zebrafish embryos at 3.5 or 4 dpf were homogenized in sodium dodecyl 
sulfate buffer containing protease inhibitor cocktail (Sigma) and phosphatase inhibitor 
(ThermoScientific) to perform Western blot analysis. The homogenized lysates were 
boiled for 5 minutes at 95°C followed by centrifugation at 13,500 rpm for 20 minutes at 
4°C, and the supernatants were collected and mixed with 3x Laemmli sample buffer for 
the protein electrophoresis. The protein samples were separated on NuPage 4-12% Bis-
Tris gels (Novex) and then transferred to a nitrocellulose membrane (Novex). The 
antibodies included rabbit polyclonal anti-EXOC5 that were generated by the Lipschutz 
lab, mouse anti-EXOC4 (Enzo), and mouse anti-GAPDH monoclonal antibody (Sigma), 
all at 1:1000 dilution. Secondary antibodies were from Jackson Immunoresearch 
Laboratories and Thermo Fisher Scientific. 
EXOC5 Mutant mRNA Rescue Experiments 
For rescue experiments of zebrafish exoc5 mutants, capped and polyadenylated mRNA of 
wild-type (WT) and ciliary-targeting sequence mutated human EXOC5 was synthesized 
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in vitro using the mMESSAGE mMACHINE kit (Ambion). Two doses of EXOC5 
mRNA (low: 100 pg or high: 250 pg) were injected, using a Sutter Instruments 
microinjector, into 100 embryos at the 1-cell stage. At 3.5 dpf, 12 randomly selected 
larvae were imaged and individually genotyped by direct sequencing as outlined above. 
Site-Directed Mutagenesis 
To inhibit the ciliary targeting sequence VxPx in human EXOC5, the QuikChange Site-
Directed Mutagenesis Kit (Stratagene, No. 200518) was used for in vitro site-directed 
mutagenesis of proline 668 to alanine. The primers were 5′-CTTCTGGTA GTTGCCGC 
AGA TAATTTAAAGCAAGTCTGC-3′ and 5′-GCAGACTTGCTT T AA ATTA TCTG 
CGGCAACTACCAGAAG-3′. Plasmid pcDNA3-hEXOC5 was used as the template. 
Sequencing confirmed the specific amino acid change. 
Mouse Husbandry and Genotyping 
Animals were kept in a 12-hour light-dark cycle with food and water ad libitum. 
Genotyping was performed by Transnetyx (transnetyx.com) or in-house with the KAPA 
Mouse Genotyping Kit (Kapabiosystems, # KK7301). 







Exoc5f/f GCCTGTAACTCACAGAGATC GCTGGCATTCTAAGTCATGG 






Tie2Cre CCCTGTGCTCAGACAGAAATGAGA CGCATAACCAGTGAAACAGCATTGC 
Dhhf/f TGGGTGTTCCTTACAATCCGC CAACCACTGGACCGAAGGAGGAA 
Dhh∆ TACGGTTCTCTCTGATTGTGATGAGGTC CAACCACTGGACCGAAGGAGGAA 
NfatC1enCre CCTGGAAAATGCTTCTGTCCG CAGGGTGTTATAAGCAATCCC 
Smof/f GAAAGCTGGCCCCAGACTTTCG AGTACCAGCAGCAGCAACTGC 
Ift88f/f GGTCCTAACAAGTAAGCCCAGTGTT GCCTCCTGTTTCTTGACAACAGTG 
Dzip1f/f GCCAAAGTGGTTTGCCTGACA GCAGGTTAAACACTCATATAGC 
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Conditional Mouse Lines 
All mouse lines utilized in this work were gifts to Dr. Russell Norris or purchased from 
Jackson Laboratories. Gifted mice include: Exoc5 (Dr. Joshua Lipschutz), NfatC1enCre(+) 
and NfatC1Cre(+) (Dr. Bin Zhou), and Dhh (Dr. Marie-Ange Renault). 
3D Reconstructions and Morphometrics 
3D reconstructions were generated from H&E images as previously described from P0 
neonatal mice for aortic and/or mitral valve analyses. Littermate controls were used as 
comparisons for phenotypic measurements (n=4 controls for each cHet or cKO group). 
Valve volumes were quantified with Imaris 9.2 software from the rendered 3D 
reconstruction. Length and thickness measurements were taken from the H&E images 
with Fiji (Image J) measuring tools. Length was measured along the entire vertical axis of 
each leaflet from the beginning, middle, and end of the valve. Thickness was measured in 
3-4 evenly spaced intervals along the leaflet length to account for overall thickness from 
the leaflet hinge to tip. Each thickness measurement was taken across the horizontal axis 
on each 5µm section of each leaflet of the valve. 3D reconstruction of IHC’s from valves 
were created from high-resolution confocal z-stacks using the Imaris 9.2 software. 
Mouse Immunohistochemistry and Fluorescence Imaging 
Immunohistochemical and fluorescence stains were performed on 5μm, paraffin-
embedded sections from E10.5, E13.5, E14.5, E15.5, E16.5, P0, and adult (6.5-weeks to 
18-months) wild type and conditional Exoc5, conditional Dhh, conditional Smo, 
conditional Ift88, and conditional Dzip1 mice as previously described. Primary antibodies 
and their dilutions include acetylated alpha-tubulin (Sigma, #T6793, 1:500), alpha-
smooth muscle actin (Sigma, #A2547, 1:500; Cell Signaling, #19245, 1:500), ARL13B 
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(Protein Tech, #17711-1-AP, 1:500), CD31 (ARP, #DIA-310), cleaved Caspase 3 
(Epitomics, #1476-1, 1:100), cleaved NOTCH1 (Cell Signaling, # 4147, 1:200), Collagen 
Telo (a generous gift from Dr. Stanley Hoffman, 1:250), DHH (Santa Cruz, #sc-271168, 
1:50), Elastin (Abcam, #ab77804, 1:250), ERK1/2 (extracellular signal–regulated kinases 
1/2; Cell Signaling, #4695, 1:50), phospho-ERK1/2 (phosphorylated extracellular signal–
regulated kinases 1/2; Cell Signaling, No.4370, 1:40), RUNX2 (Abcam, # ab192256, 
1:250), Smoothened (Novus, #NSL2666, 1:100), Versican (a generous gift from Dr. 
Stanley Hoffman, 1:250), γ-tubulin (Abcam, #T6793, 1:1000). Secondary antibodies 
were all purchased from Invitrogen, used at 1:100 dilution, and included Alexa Fluors: 
488 (#A-11029, #A-11034), 568 (#A-11004, #A-11036), and Cy5 (#A-10524) at 1:100. 
Nuclei were stained with Hoechst (Life Technologies, #H3569, 1:10,000). Slides were 
coverslipped using Invitrogen SlowFade Gold Antifade Reagent (#S36936). Images were 
captured using a Leica TCS SP5 AOBS Confocal Microscope System and LAS AF 
v2.6.3 Build 8173 Acquisition and Analysis Software, Zeiss Axioscope M2, or Olympus 
BH-2 brightfield microscope. 
Histology Quantifications 
Cilia Length 
Measurements were taken from z-stack confocal images using Imaris 9.0 software as 
previously described. Measurements were taken from all visible aortic cusps in the tissue 
section: n=3 animals/genotype (>1500 cells total) with slides selected from the front, 





Cells were counted using the open-source software, CellProfiler. A pipeline was created 
to separate the channels of florescent images and then count the total number of 
pERK/ERK-positive cells (red channel) and the total number cells (blue channel). 
Histological sections from similar regions of aortic valve were selected (n=3 
animals/genotype), and images were edited to include only cells from the aortic cusps 
before counting. 
Cell Density 
These measurements were taken from H&E images of P0 mitral valves. Total cell 
numbers were counted using Cellprofiler. A pipeline was created to generate binary 
images from edited H&E images containing only the valve leaflets to count nuclei per 
section. Cell density was then manually recorded by tallying nuclei within three 25.4mm2 
areas taken from equally spaced areas within the anterior mitral leaflets. (n=3 
animals/genotype.) 
Echocardiography 
Echocardiographic images were acquired in the parasternal long-axis, short-axis, and 
apical views (40 MHz probe, Visualsonics 2100, Fujifilm, Canada). Two-dimensional 
images were used for quantification of the diameter of the aortic root. Pulse wave and 
color Doppler modes in conjunction with timing of the cardiac cycle (electrocardiogram) 
were used to visualize flow patterns at the aortic valves. A total of 5 conditional 





Guide slides from adult mice were stained using a standard alizarin red protocol from 
IHC World (ihcworld.com). A total of 13 conditional heterozygous mice (6 with tricuspid 
aortic valve and 7 with BAV) and 4 control mice were stained and imaged. 
Movats Pentachrome Staining 
Movats staining was performed on 5µm sections of wildtype, Exoc5 conditional 
heterozygotes (NfatC1Cre(+);Exoc5f/+), globally ablated Dhh, and Dhh conditional 
knockout (NfatC1enCre(+);Dhhf/f) adult mitral valve tissue. Tissue sections were 
deparaffinized with xylenes and hydrated through graded ethanol to distilled water. 
Sections were incubated in Bouin’s Fluid at 60°C for 1 hour. This was followed by a 5-
minute wash in running water and a 20-minute incubation in 1% alcian blue at room 
temperature. Slides were then dipped 5 times in de-ioinzed water and incubated in 
alkaline alcohol for 10 minutes at 56°C. This was followed by a 2-minute wash in 
running water and a 15-minute room temperature incubation in Orcein-Verhoeff stain 
(0.2% Orcein, 5% alcoholic hematoxylin, 10% ferric chloride, 12% Lugol’s iodine). 
Slides were washed for 3 minutes in running water and stained with woodstain scarlet-
acid fuchsin for 2 minutes and 30 seconds. This was followed by incubations in 0.5% 
acetic acid (30 seconds), 5% phosphotungstic acid (9 minutes), 0.5% acetic acid (30 
seconds), and 3 times in 100% EtOH (1 minute each). Slides were then incubated in 
alcoholic saffron for 20 minutes at room temperature. Finally, slides were dehydrated 
using two 5-minute incubations in 100% EtOH and three 5-minute incubations in xylenes 




Cell lysates were collected with non-ionic lysis buffer (25mM Tris pH7.4, 150mM NaCl, 
1% Igepal, 5% Glycerol) containing 1X protease and phosphatase inhibitor cocktail 
(Thermo Fisher Scientific, #1861281), snap frozen with liquid nitrogen, and then stored 
at -80°C until ready for use. Equal amounts of protein (300µg/sample) were then loaded 
into 1.5ml tubes with 20ul of A/G agarose beads (50% agarose, Pierce, #20421) and 
volumes were equalized to 1ml with lysis buffer. Samples were rotated at 4°C for 30 
minutes to pre-clear the lysates. After centrifugation to pellet the beads, the supernatant 
was collected and split between two tubes for the co-IP. One tube contained 10µl A/G 
agarose beads with 3µl normal mouse IgG (400µg/ml, Santa Cruz, #sc-2025) and the 
other contained 10µl of agarose beads conjugated to EXOC4 (generated by Dr. Joshua 
Lipschutz), Flag M2 (Sigma, #F1804), or TIAM1 antibody (500µg/ml, 25% agarose, 
Santa Cruz, #sc-393315 AC). Samples were rotated for 16 hours at 4°C. Supernatant was 
removed and beads were washed 6 times with 500µl of lysis buffer containing protease 
inhibitor. Each wash step included centrifuging to pellet the beads for 2 minutes at 14,000 
X g and rotating the beads for 5 minutes at 4°C. All supernatant was removed to leave 
dry beads. Protein was then eluted at 98°C for 5 minutes in 15µl 2x SDS laemmli buffer 
(125mM Tris pH7, 10% Glycerol, 2% SDS, 5% b-mercaptoethanol, and 0.05% 
bromophenol blue diluted in H20), and used for Western blot analysis. n=4 
RT-PCR 
Reverse transcribed RNA isolated from immortalized mouse mitral valve interstitial cells 
(mVICs) was used for RT-PCR analyses of Gli1, Gli2, Gli3, Smoothened, Patched 1, 
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Patched 2, Shh, Ihh, Dhh and Hprt (Quantabio, Inc). The mVICs were a kind gift of Dr. 
Joey Barnett (Vanderbilt University) and previously published. Primer sequences used: 
Patched 1: Forward: 5’-TAATGCTGCGACAACTCAGG-3’, Reverse: 5’-
GGCTGGAGTCTGAGAACTGG-3’, Patched 2: Forward: 5’-
CTTGACTGCTTCTGGGAAGG-3’; Reverse: 5-‘GCCAGCATAAGCAGATAGCC-3’, 
Smoothened: Forward: 5’-CTGGGAGTCGGTTTTAATGG-3’; Reverse: 5’-
ACACGTTGTAGCGCAAAGG-3’, Gli1: Forward: 5’-
CGGAGTTCAGTCAAATTAAC-3’; Reverse: 5’-CATCTGAGGTTGGGAATCC-3’, 
Gli2: Forward: 5’-AGCCTTCACCCACCTTCTTG-3’; Reverse: 5’-
TGGGCGCAGGCCCTCAGC-3’, Gli3: Forward: 5’-CCTTCTGAGTCCTCACAGAG-
3’; Reverse: 5’-GACTAGGGTTGTTCCTTCCG-3’, HPRT: Forward: 5’-
GCGATGATGAACCAGGTTA-3’; Reverse: 5’-GTTGAGAGATCATCTCCACC-3’, 
Shh: Forward: 5’-CAAAAAGCTGACCCCTTTAGC-3’; Reverse: 5’-
CGTCTCGATCACGTAGAAGACC-3’, Ihh: Forward: 5’-
CTTGCCTACAAGCAGTTCAGC-3’; Reverse: 5’-TGCTGGTTCTGTATGATTGTCC-
3’, Dhh: Forward: 5’-CTTCAAGGATGAGGAGAACAGC-3’; Reverse: 5’-
TGACTCTCTAGAACCGCGTAGC-3’. 
RNAseq 
Mitral leaflets were dissected from P0 wildtype mice (n=3) and RNA was isolated using 
MicroRNeasy (Qiagen). Purity and quantification was determined by Bioanalyzer and the 
library preparation was done using the SMART-Seq v4 RNA-seq kit (Clontech 
Laboratories) per manufacturer instructions. The analysis was conducted on an OnRamp 
Bioinformatics Genomics research platform as previously described. 
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In situ Hybridizations 
In situ hybridizations were performed as previously described and amplified with primers 
containing a SP6 RNA polymerase site engineered onto the 3’ end of the reverse primer 
(5’-CGATCATTTAGGTGACACTATAGAAGAACCCCACTCACAGTTGGTATG-3’, 
SP6 site underlined) or a T7 RNA polymerase site engineered onto the 3’ end (Forward 
5’-CGATCTAATACGACTCACTATAGGGAAGGACAGAAGTCCTCCAAGC-3’, T7 
site underlined.) n=3/timepoint 
Mouse Western Blot Analysis 
All Western blots were performed in a Bio-Rad mini blot electrophoresis chamber with 
semi-dry transfer in a Bio-Rad Trans-blot Turbo Transfer system. Protein samples were 
prepared using a 2x SDS Laemmli buffer (125mM Tris pH7, 10% Glycerol, 2% SDS, 5% 
b-mercaptoethanol, and .05% bromophenol blue) and boiled at 98°C for 5 minutes prior 
to loading. Proteins were separated in 4-20% Mini-PROTEAN TGX Stain-Free Protein 
Gels (Bio-rad, #456-8093) and transferred to Trans-Blot Turbo Mini Nitrocellulose 
Transfer Packs (Bio-rad, #170-4158). Membranes were blocked in 5% nonfat milk (Bio-
rad, #170-6404) diluted in 1X Tris Buffered Saline, 0.1% Tween 20 (TBST) for 1 hour 
and incubated in primary antibodies at 4°C overnight with rotation. The next morning the 
membranes were rinsed 5 times with TBST and incubated at room temperature for 1 hour 
in secondary antibody. The membranes were then rinsed 5 times in TBST for 10 minutes 
each and imaged on a Bio-Rad ChemiDoc MP system with SuperSignal West Femto 
Maximum Sensitivity Substrate (ThermoFisher, #34096) or Pierce ECL Western Blotting 
Substrate (ThermoFisher, #32209) as appropriate. Primary antibodies and their dilutions 
included: GLI3 (Origene, #TA337186, 1:1000), RAC1 monoclonal antibody 
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(Cytoskeleton Inc., #ARC03, 1:500) and Smoothened (GeneTex, #GTX60154, 1:1000). 
All secondary antibodies were purchased from Sigma and were used at 1:7500. These 
included: Anti-mouse IgG HRP antibody (#A9044) and Anti-rabbit IgG HRP antibody 
(#A9169). 
Chicken Valve Dissection/Cell Culture Treatment Groups 
Eggs were purchased from Charles River Labs (#10100326) and incubated in a rotating 
egg incubator at 37°C with 55% humidity until Hamburger Hamilton Stage 30-31 
(HH30-31), a stage of active valve remodeling. Embryos were then removed from the 
shell, and the mitral valves were dissected from the heart and stored in sterile PBS until 
all eggs were dissected. Mitral valves were pooled, and cells were dissociated with 
Trypsin containing EDTA (Corning, #25-053-CL). Cells were cultured in 100 mm dishes 
from Sigma (#93100), and maintained in M199 medium (Hyclone, #SH30253.01) 
supplemented with 5% heat-inactivated chicken serum (Bioworld, #30611183-1), 1% 
Pen-Strep (Life Technologies, 15070-063), and 0.1% Insulin-Transferrin-Selenium (ITS) 
(Gibco, #41400-045). Treatment groups for cell experiments included: Untreated, DHH 
(1µg/ml) of recombinant mouse DHH C23II N-Terminus ligand (Novus Biologicals, 
#NBP2-35175), Antibodies (0.5µg/ml) against SHH (Santa Cruz, #sc-365112), IHH 
(Santa Cruz, #sc-166685), and DHH (Santa Cruz, #sc-271168), Cyclopamine 25µM 
(Tocris, #1623), and Cytochalasin D 1µM (Sigma, #C8273). All treatments, unless 
otherwise specified, were performed in low serum containing media: M199, 0.1% 




Hydrogel Remodeling Assay 
Collagen hydrogels were made with serum-free M199 media (Hyclone, #SH30253.01) 
and 1.5mg/ml Rat Tail Collagen I (Corning, #354236). Fetal chick mitral valve interstitial 
cells (cVICs) (stage HH30-31) were added to the M199/Collagen mixture after it was 
neutralized with 1N NaOH at a concentration of 3x105 cells per hydrogel. 400µl of 
cell/hydrogel mixture was added to each well of a 4-well plate (Thermo Scientific, 
#176740) and allowed to polymerize at 37°C for approximately 1 hour. After hydrogels 
solidified, 500µl of chick valve culture media was added to the top of the gels without 
detaching them and then incubated overnight at 37°C. The next morning, the culture 
media was aspirated and the gels were rinsed twice with sterile 1X Phosphate Buffered 
Saline (PBS). Treatments were then added in low serum containing media and hydrogels 
were detached from the well walls with a sterile pipette tip. Gels were imaged every hour 
for 8 hours and again at 24 hours (timepoints: 1, 2, 3, 4, 5, 6, 7, 8 and 24 hours). 
Following compaction, hydrogels were collected and embedded in paraffin for sectioning 
and immunostaining. The hydrogel assay for Figure 3.10 was conducted in the same 
manner with the exception of using serum free media containing 1% Pen-Strep and 0.1% 
ITS during treatment. n=4 hydrogels/treatment group 
Immunocytochemistry 
cVICs were seeded into 4-well, collagen-coated chamber slides and cultured with normal 
media at 37°C for 16 hours. Cells were serum starved for 5 hours and treated in serum 
free media for 2 hours. Media was aspirated and cells were fixed in 4% 
paraformaldehyde (PFA) for 15 minutes and permeabilized in 0.1% Triton-X for 5 
minutes. Fixed cells were washed twice in PBS and blocked with 1% bovine serum 
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albumin (BSA) in PBS for 1 hour at room temperature. Cells were incubated in primary 
antibody diluted in 1% BSA for 16 hours at 4°C or 1.5 hours at room temperature as 
necessary, washed twice with PBS and incubated in secondary antibody for 1 hour at 
room temperature. Slides were washed three times for 5 minutes in PBS, including a 
wash step with Hoechst (Life Technologies, #H3569, 1:10,000). Slides were coverslipped 
with Invitrogen SlowFade Gold Antifade Reagent (#S36936). Primary antibodies and 
their dilutions included: acetylated tubulin (Sigma, #T6793, 1:500), alpha-smooth muscle 
actin (Sigma, #A2547, 1:500), Collagen Telo (a generous gift from Dr. Stanley Hoffman, 
1:250). Secondary antibodies were purchased from Invitrogen, used at a 1:100 dilution, 
and included fluorophores 488, 568, and Cy5. n=4 slide chambers/treatment group 
RAC1 Activation Assay 
RAC1 activation was performed on HH30 chicken VICs per manufacturers 
recommendations (Cytoskeleton, Inc., #BK035). Serum starved VICs were treated with 
1µg/ml of recombinant mouse DHH C23II N-Terminus ligand (Novus Biologicals, 
NBP2-35175) for 5, 10, 15, and 30 minutes. Proteins were isolated from treated and 
untreated control cells with kit buffers as indicated by instructions. n=4 replicates 
Statistical Analysis 
Unless otherwise stated, all error bars are shown as means ± SD, and a Student’s t-test 
was used to detect statistically significant differences between groups/genotypes. P-
values are listed in the figure legend for each image. Graphs were generated by SPSS 
v24, SPSS v25, or Excel. Boxplots depict data quartiles and the error bars on these graphs 
represent the 95% confidence interval. 
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Genome-Wide Association Studies 
A logistic regression analysis based on an additive genetic model was performed for 
association analysis adjusted for sex and 8 principal component analyses using PLINK. 
Additional statistical analyses are described above and in the text of the article. 
Cilia Length 
A generalized linear mixed model was used to compare the likelihood of cilia presence 
across genotypes by using a logit link function and litter, mouse, and genotype by litter 
interaction as random effects in the model. For mice with cilia present, mixed-model 
ANOVA was used to compare mouse average cilia length across genotypes, with litter 




1 Tyser, R. C. et al. Calcium handling precedes cardiac differentiation to initiate the 
first heartbeat. Elife 5, doi:10.7554/eLife.17113 (2016). 
 
2 Bier, E. & Bodmer, R. Drosophila, an emerging model for cardiac disease. Gene 
342, 1-11, doi:10.1016/j.gene.2004.07.018 (2004). 
 
3 Sade, R. M. Brain death, cardiac death, and the dead donor rule. J. S. C. Med. 
Assoc. 107, 146-149 (2011). 
 
4 Isogai, S., Horiguchi, M. & Weinstein, B. M. The vascular anatomy of the 
developing zebrafish: an atlas of embryonic and early larval development. Dev. 
Biol. 230, 278-301, doi:10.1006/dbio.2000.9995 (2001). 
 
5 Nigam, H. C. Structure and function of the truncus arteriosus of the Indian frog 
Rana tigerina (Daud). Proc Ani Sci 92, 55-63, 
doi:https://doi.org/10.1007/BF03186171 (1983). 
 
6 Poelmann, R. E. et al. Outflow tract septation and the aortic arch system in 
reptiles: lessons for understanding the mammalian heart. Evodevo 8, 9, 
doi:10.1186/s13227-017-0072-z (2017). 
 
7 Stephenson, A., Adams, J. W. & Vaccarezza, M. The vertebrate heart: an 
evolutionary perspective. J. Anat. 231, 787-797, doi:10.1111/joa.12687 (2017). 
 
8 Olson, E. N. Gene regulatory networks in the evolution and development of the 
heart. Science 313, 1922-1927, doi:10.1126/science.1132292 (2006). 
 
9 Zhou, P. & Pu, W. T. Recounting Cardiac Cellular Composition. Circ. Res. 118, 
368-370, doi:10.1161/CIRCRESAHA.116.308139 (2016). 
 
10 de Vlaming, A. et al. Atrioventricular valve development: new perspectives on an 
old theme. Differentiation 84, 103-116, doi:10.1016/j.diff.2012.04.001 (2012). 
 
11 Hu, W., Polinsky, P., Sadoun, E., Rosenfeld, M. E. & Schwartz, S. M. 
Atherosclerotic lesions in the common coronary arteries of ApoE knockout mice. 
Cardiovasc. Pathol. 14, 120-125, doi:10.1016/j.carpath.2005.02.004 (2005). 
 
12 Spannbauer, A. et al. Large Animal Models of Heart Failure With Reduced 
Ejection Fraction (HFrEF). Front Cardiovasc Med 6, 117, 
doi:10.3389/fcvm.2019.00117 (2019). 
 
13 Riehle, C. & Bauersachs, J. Small animal models of heart failure. Cardiovasc. 
Res. 115, 1838-1849, doi:10.1093/cvr/cvz161 (2019). 
 167 
14 Milani-Nejad, N. & Janssen, P. M. Small and large animal models in cardiac 
contraction research: advantages and disadvantages. Pharmacol. Ther. 141, 235-
249, doi:10.1016/j.pharmthera.2013.10.007 (2014). 
 
15 Olson, E. N. & Srivastava, D. Molecular pathways controlling heart development. 
Science 272, 671-676, doi:10.1126/science.272.5262.671 (1996). 
 
16 de Boer, B. A., van den Berg, G., de Boer, P. A., Moorman, A. F. & Ruijter, J. M. 
Growth of the developing mouse heart: an interactive qualitative and quantitative 
3D atlas. Dev. Biol. 368, 203-213, doi:10.1016/j.ydbio.2012.05.001 (2012). 
 
17 Kuhn, E. N. & Wu, S. M. Origin of cardiac progenitor cells in the developing and 
postnatal heart. J. Cell. Physiol. 225, 321-325, doi:10.1002/jcp.22281 (2010). 
 
18 Tam, P. P., Parameswaran, M., Kinder, S. J. & Weinberger, R. P. The allocation 
of epiblast cells to the embryonic heart and other mesodermal lineages: the role of 
ingression and tissue movement during gastrulation. Development 124, 1631-1642 
(1997). 
 
19 Redkar, A., Montgomery, M. & Litvin, J. Fate map of early avian cardiac 
progenitor cells. Development 128, 2269-2279 (2001). 
 
20 Abu-Issa, R., Waldo, K. & Kirby, M. L. Heart fields: one, two or more? Dev. 
Biol. 272, 281-285, doi:10.1016/j.ydbio.2004.05.016 (2004). 
 
21 Moorman, A. F., Christoffels, V. M., Anderson, R. H. & van den Hoff, M. J. The 
heart-forming fields: one or multiple? Philos. Trans. R. Soc. Lond. B Biol. Sci. 
362, 1257-1265, doi:10.1098/rstb.2007.2113 (2007). 
 
22 Snarr, B. S. et al. Isl1 expression at the venous pole identifies a novel role for the 
second heart field in cardiac development. Circ. Res. 101, 971-974, 
doi:10.1161/CIRCRESAHA.107.162206 (2007). 
 
23 Verzi, M. P., McCulley, D. J., De Val, S., Dodou, E. & Black, B. L. The right 
ventricle, outflow tract, and ventricular septum comprise a restricted expression 
domain within the secondary/anterior heart field. Dev. Biol. 287, 134-145, 
doi:10.1016/j.ydbio.2005.08.041 (2005). 
 
24 Waldo, K. L. et al. Conotruncal myocardium arises from a secondary heart field. 
Development 128, 3179-3188 (2001). 
 
25 Laugwitz, K. L., Moretti, A., Caron, L., Nakano, A. & Chien, K. R. Islet1 
cardiovascular progenitors: a single source for heart lineages? Development 135, 
193-205, doi:10.1242/dev.001883 (2008). 
 168 
26 Arguello, C., de la Cruz, M. V. & Gomez, C. S. Experimental study of the 
formation of the heart tube in the chick embryo. J. Embryol. Exp. Morphol. 33, 1-
11 (1975). 
 
27 van den Berg, G. et al. A caudal proliferating growth center contributes to both 
poles of the forming heart tube. Circ. Res. 104, 179-188, 
doi:10.1161/CIRCRESAHA.108.185843 (2009). 
 
28 Christoffels, V. M. et al. Chamber formation and morphogenesis in the 
developing mammalian heart. Dev. Biol. 223, 266-278, 
doi:10.1006/dbio.2000.9753 (2000). 
 
29 Slough, J., Cooney, L. & Brueckner, M. Monocilia in the embryonic mouse heart 
suggest a direct role for cilia in cardiac morphogenesis. Dev. Dyn. 237, 2304-
2314, doi:10.1002/dvdy.21669 (2008). 
 
30 Wessels, A. et al. Spatial distribution of "tissue-specific" antigens in the 
developing human heart and skeletal muscle. III. An immunohistochemical 
analysis of the distribution of the neural tissue antigen G1N2 in the embryonic 
heart; implications for the development of the atrioventricular conduction system. 
Anat. Rec. 232, 97-111, doi:10.1002/ar.1092320111 (1992). 
 
31 Person, A. D., Klewer, S. E. & Runyan, R. B. Cell biology of cardiac cushion 
development. Int. Rev. Cytol. 243, 287-335, doi:10.1016/S0074-7696(05)43005-3 
(2005). 
 
32 Combs, M. D. & Yutzey, K. E. Heart valve development: regulatory networks in 
development and disease. Circ. Res. 105, 408-421, 
doi:10.1161/CIRCRESAHA.109.201566 (2009). 
 
33 Butcher, J. T. & Markwald, R. R. Valvulogenesis: the moving target. Philos. 
Trans. R. Soc. Lond. B Biol. Sci. 362, 1489-1503, doi:10.1098/rstb.2007.2130 
(2007). 
 
34 Runyan, R. B. & Markwald, R. R. Invasion of mesenchyme into three-
dimensional collagen gels: a regional and temporal analysis of interaction in 
embryonic heart tissue. Dev. Biol. 95, 108-114, doi:10.1016/0012-
1606(83)90010-6 (1983). 
 
35 Eisenberg, L. M. & Markwald, R. R. Molecular regulation of atrioventricular 




36 MacGrogan, D. et al. How to make a heart valve: from embryonic development to 
bioengineering of living valve substitutes. Cold Spring Harb. Perspect. Med. 4, 
a013912, doi:10.1101/cshperspect.a013912 (2014). 
 
37 Snarr, B. S., Kern, C. B. & Wessels, A. Origin and fate of cardiac mesenchyme. 
Dev. Dyn. 237, 2804-2819, doi:10.1002/dvdy.21725 (2008). 
 
38 Wessels, A. & Sedmera, D. Developmental anatomy of the heart: a tale of mice 
and man. Physiol. Genomics 15, 165-176, 
doi:10.1152/physiolgenomics.00033.2003 (2003). 
 
39 Rivera-Feliciano, J. et al. Development of heart valves requires Gata4 expression 
in endothelial-derived cells. Development 133, 3607-3618, 
doi:10.1242/dev.02519 (2006). 
 
40 von Gise, A. & Pu, W. T. Endocardial and epicardial epithelial to mesenchymal 
transitions in heart development and disease. Circ. Res. 110, 1628-1645, 
doi:10.1161/CIRCRESAHA.111.259960 (2012). 
 
41 Gittenberger-de Groot, A. C., Vrancken Peeters, M. P., Mentink, M. M., Gourdie, 
R. G. & Poelmann, R. E. Epicardium-derived cells contribute a novel population 
to the myocardial wall and the atrioventricular cushions. Circ. Res. 82, 1043-
1052, doi:10.1161/01.res.82.10.1043 (1998). 
 
42 Lim, J. & Thiery, J. P. Epithelial-mesenchymal transitions: insights from 
development. Development 139, 3471-3486, doi:10.1242/dev.071209 (2012). 
 
43 Hutson, M. R. & Kirby, M. L. Model systems for the study of heart development 
and disease. Cardiac neural crest and conotruncal malformations. Semin. Cell 
Dev. Biol. 18, 101-110, doi:10.1016/j.semcdb.2006.12.004 (2007). 
 
44 Lie-Venema, H. et al. Origin, fate, and function of epicardium-derived cells 
(EPDCs) in normal and abnormal cardiac development. ScientificWorldJournal 7, 
1777-1798, doi:10.1100/tsw.2007.294 (2007). 
 
45 Epstein, J. A. et al. Migration of cardiac neural crest cells in Splotch embryos. 
Development 127, 1869-1878 (2000). 
 
46 Nakamura, T., Colbert, M. C. & Robbins, J. Neural crest cells retain 
multipotential characteristics in the developing valves and label the cardiac 




47 Wessels, A. et al. Epicardially derived fibroblasts preferentially contribute to the 
parietal leaflets of the atrioventricular valves in the murine heart. Dev. Biol. 366, 
111-124, doi:10.1016/j.ydbio.2012.04.020 (2012). 
 
48 David, T. E., Ivanov, J., Armstrong, S., Christie, D. & Rakowski, H. A 
comparison of outcomes of mitral valve repair for degenerative disease with 
posterior, anterior, and bileaflet prolapse. J. Thorac. Cardiovasc. Surg. 130, 1242-
1249, doi:10.1016/j.jtcvs.2005.06.046 (2005). 
 
49 Fernandez, B. et al. Bicuspid aortic valves with different spatial orientations of 
the leaflets are distinct etiological entities. J. Am. Coll. Cardiol. 54, 2312-2318, 
doi:10.1016/j.jacc.2009.07.044 (2009). 
 
50 Briggs, L. E., Kakarla, J. & Wessels, A. The pathogenesis of atrial and 
atrioventricular septal defects with special emphasis on the role of the dorsal 
mesenchymal protrusion. Differentiation 84, 117-130, 
doi:10.1016/j.diff.2012.05.006 (2012). 
 
51 Burns, T., Yang, Y., Hiriart, E. & Wessels, A. The Dorsal Mesenchymal 
Protrusion and the Pathogenesis of Atrioventricular Septal Defects. J Cardiovasc 
Dev Dis 3, doi:10.3390/jcdd3040029 (2016). 
 
52 Snarr, B. S., Wirrig, E. E., Phelps, A. L., Trusk, T. C. & Wessels, A. A 
spatiotemporal evaluation of the contribution of the dorsal mesenchymal 
protrusion to cardiac development. Dev. Dyn. 236, 1287-1294, 
doi:10.1002/dvdy.21074 (2007). 
 
53 Eley, L. et al. A novel source of arterial valve cells linked to bicuspid aortic valve 
without raphe in mice. Elife 7, doi:10.7554/eLife.34110 (2018). 
 
54 Lewandowski, S. L., Janardhan, H. P. & Trivedi, C. M. Histone Deacetylase 3 
Coordinates Deacetylase-independent Epigenetic Silencing of Transforming 
Growth Factor-beta1 (TGF-beta1) to Orchestrate Second Heart Field 
Development. J. Biol. Chem. 290, 27067-27089, doi:10.1074/jbc.M115.684753 
(2015). 
 
55 Ma, Q., Zhou, B. & Pu, W. T. Reassessment of Isl1 and Nkx2-5 cardiac fate maps 
using a Gata4-based reporter of Cre activity. Dev. Biol. 323, 98-104, 
doi:10.1016/j.ydbio.2008.08.013 (2008). 
 
56 Anstine, L. J., Horne, T. E., Horwitz, E. M. & Lincoln, J. Contribution of Extra-




57 Deb, A. et al. Bone marrow-derived myofibroblasts are present in adult human 
heart valves. J. Heart Valve Dis. 14, 674-678 (2005). 
 
58 Hajdu, Z. et al. Recruitment of bone marrow-derived valve interstitial cells is a 
normal homeostatic process. J. Mol. Cell. Cardiol. 51, 955-965, 
doi:10.1016/j.yjmcc.2011.08.006 (2011). 
 
59 Visconti, R. P. et al. An in vivo analysis of hematopoietic stem cell potential: 
hematopoietic origin of cardiac valve interstitial cells. Circ. Res. 98, 690-696, 
doi:10.1161/01.RES.0000207384.81818.d4 (2006). 
 
60 Tanaka, K. et al. Age-associated aortic stenosis in apolipoprotein E-deficient 
mice. J. Am. Coll. Cardiol. 46, 134-141, doi:10.1016/j.jacc.2005.03.058 (2005). 
 
61 Vincentelli, A. et al. In vivo autologous recellularization of a tissue-engineered 
heart valve: are bone marrow mesenchymal stem cells the best candidates? J. 
Thorac. Cardiovasc. Surg. 134, 424-432, doi:10.1016/j.jtcvs.2007.05.005 (2007). 
 
62 Weber, B., Emmert, M. Y. & Hoerstrup, S. P. Stem cells for heart valve 
regeneration. Swiss Med. Wkly. 142, w13622, doi:10.4414/smw.2012.13622 
(2012). 
 
63 Hinton, R. B., Jr. et al. Extracellular matrix remodeling and organization in 
developing and diseased aortic valves. Circ. Res. 98, 1431-1438, 
doi:10.1161/01.RES.0000224114.65109.4e (2006). 
 
64 Canty, E. G. & Kadler, K. E. Collagen fibril biosynthesis in tendon: a review and 
recent insights. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 133, 979-985, 
doi:10.1016/s1095-6433(02)00212-x (2002). 
 
65 Canty, E. G. et al. Actin filaments are required for fibripositor-mediated collagen 
fibril alignment in tendon. J. Biol. Chem. 281, 38592-38598, 
doi:10.1074/jbc.M607581200 (2006). 
 
66 Kadler, K. Matrix loading: assembly of extracellular matrix collagen fibrils during 
embryogenesis. Birth Defects Res C Embryo Today 72, 1-11, 
doi:10.1002/bdrc.20002 (2004). 
 
67 Kadler, K. E., Holmes, D. F., Trotter, J. A. & Chapman, J. A. Collagen fibril 
formation. Biochem. J. 316 ( Pt 1), 1-11, doi:10.1042/bj3160001 (1996). 
 
68 Oosthoek, P. W., Wenink, A. C., Macedo, A. J. & Gittenberger-de Groot, A. C. 
The parachute-like asymmetric mitral valve and its two papillary muscles. J. 
Thorac. Cardiovasc. Surg. 114, 9-15, doi:10.1016/S0022-5223(97)70111-9 
(1997). 
 172 
69 Oosthoek, P. W. et al. Development of the atrioventricular valve tension 
apparatus in the human heart. Anat. Embryol. (Berl.) 198, 317-329, 
doi:10.1007/s004290050187 (1998). 
 
70 Lamers, W. H., Viragh, S., Wessels, A., Moorman, A. F. & Anderson, R. H. 
Formation of the tricuspid valve in the human heart. Circulation 91, 111-121, 
doi:10.1161/01.cir.91.1.111 (1995). 
 
71 de Lange, F. J. et al. Lineage and morphogenetic analysis of the cardiac valves. 
Circ. Res. 95, 645-654, doi:10.1161/01.RES.0000141429.13560.cb (2004). 
 
72 Martin, P. S. et al. Embryonic Development of the Bicuspid Aortic Valve. J 
Cardiovasc Dev Dis 2, 248-272, doi:10.3390/jcdd2040248 (2015). 
 
73 Koefoed, K., Veland, I. R., Pedersen, L. B., Larsen, L. A. & Christensen, S. T. 
Cilia and coordination of signaling networks during heart development. 
Organogenesis 10, 108-125, doi:10.4161/org.27483 (2014). 
 
74 Satir, P. & Christensen, S. T. Overview of structure and function of mammalian 
cilia. Annu. Rev. Physiol. 69, 377-400, 
doi:10.1146/annurev.physiol.69.040705.141236 (2007). 
 
75 Clement, C. A. et al. TGF-beta signaling is associated with endocytosis at the 
pocket region of the primary cilium. Cell Rep 3, 1806-1814, 
doi:10.1016/j.celrep.2013.05.020 (2013). 
 
76 Goetz, S. C. & Anderson, K. V. The primary cilium: a signalling centre during 
vertebrate development. Nat Rev Genet 11, 331-344, doi:10.1038/nrg2774 (2010). 
 
77 Ezratty, E. J. et al. A role for the primary cilium in Notch signaling and epidermal 
differentiation during skin development. Cell 145, 1129-1141, 
doi:10.1016/j.cell.2011.05.030 (2011). 
 
78 Dawe, H. R., Farr, H. & Gull, K. Centriole/basal body morphogenesis and 
migration during ciliogenesis in animal cells. J. Cell Sci. 120, 7-15, 
doi:10.1242/jcs.03305 (2007). 
 
79 Seeley, E. S. & Nachury, M. V. The perennial organelle: assembly and 
disassembly of the primary cilium. J. Cell Sci. 123, 511-518, 
doi:10.1242/jcs.061093 (2010). 
 
80 Kubo, A., Sasaki, H., Yuba-Kubo, A., Tsukita, S. & Shiina, N. Centriolar 
satellites: molecular characterization, ATP-dependent movement toward 
centrioles and possible involvement in ciliogenesis. J. Cell Biol. 147, 969-980, 
doi:10.1083/jcb.147.5.969 (1999). 
 173 
81 Mennella, V., Agard, D. A., Huang, B. & Pelletier, L. Amorphous no more: 
subdiffraction view of the pericentriolar material architecture. Trends Cell Biol. 
24, 188-197, doi:10.1016/j.tcb.2013.10.001 (2014). 
 
82 Betleja, E., Nanjundappa, R., Cheng, T. & Mahjoub, M. R. A novel Cep120-
dependent mechanism inhibits centriole maturation in quiescent cells. Elife 7, 
doi:10.7554/eLife.35439 (2018). 
 
83 Garcia-Gonzalo, F. R. et al. Phosphoinositides Regulate Ciliary Protein 
Trafficking to Modulate Hedgehog Signaling. Dev. Cell 34, 400-409, 
doi:10.1016/j.devcel.2015.08.001 (2015). 
 
84 Fulmer, D. et al. Defects in the Exocyst-Cilia Machinery Cause Bicuspid Aortic 
Valve Disease and Aortic Stenosis. Circulation 140, 1331-1341, 
doi:10.1161/CIRCULATIONAHA.119.038376 (2019). 
 
85 Toomer, K. A. et al. A role for primary cilia in aortic valve development and 
disease. Dev. Dyn. 246, 625-634, doi:10.1002/dvdy.24524 (2017). 
 
86 Toomer, K. A. et al. Primary cilia defects causing mitral valve prolapse. Sci. 
Transl. Med. 11, doi:10.1126/scitranslmed.aax0290 (2019). 
 
87 Narita, K. et al. Proteomic analysis of multiple primary cilia reveals a novel mode 
of ciliary development in mammals. Biol Open 1, 815-825, 
doi:10.1242/bio.20121081 (2012). 
 
88 Ecder, T. & Schrier, R. W. Cardiovascular abnormalities in autosomal-dominant 
polycystic kidney disease. Nat Rev Nephrol 5, 221-228, 
doi:10.1038/nrneph.2009.13 (2009). 
 
89 Lumiaho, A. et al. Mitral valve prolapse and mitral regurgitation are common in 
patients with polycystic kidney disease type 1. Am. J. Kidney Dis. 38, 1208-1216, 
doi:10.1053/ajkd.2001.29216 (2001). 
 
90 Huangfu, D. et al. Hedgehog signalling in the mouse requires intraflagellar 
transport proteins. Nature 426, 83-87, doi:10.1038/nature02061 (2003). 
 
91 Wicking, C. & McGlinn, E. The role of hedgehog signalling in tumorigenesis. 
Cancer Lett. 173, 1-7, doi:10.1016/s0304-3835(01)00676-0 (2001). 
 
92 Shin, J. O. et al. Temporal and spatial expression patterns of Hedgehog receptors 
in the developing inner and middle ear. Int. J. Dev. Biol. 61, 557-563, 
doi:10.1387/ijdb.170155jb (2017). 
 174 
93 Yatsuzuka, A. et al. GPR17 is an essential regulator for the temporal adaptation of 
sonic hedgehog signalling in neural tube development. Development 146, 
doi:10.1242/dev.176784 (2019). 
 
94 Garcia-Morales, D. et al. Dynamic Hh signalling can generate temporal 
information during tissue patterning. Development 146, doi:10.1242/dev.176933 
(2019). 
 
95 Varjosalo, M. & Taipale, J. Hedgehog: functions and mechanisms. Genes Dev. 
22, 2454-2472, doi:10.1101/gad.1693608 (2008). 
 
96 Marigo, V., Davey, R. A., Zuo, Y., Cunningham, J. M. & Tabin, C. J. 
Biochemical evidence that patched is the Hedgehog receptor. Nature 384, 176-
179, doi:10.1038/384176a0 (1996). 
 
97 Stone, D. M. et al. The tumour-suppressor gene patched encodes a candidate 
receptor for Sonic hedgehog. Nature 384, 129-134, doi:10.1038/384129a0 (1996). 
 
98 Byrne, E. F., Luchetti, G., Rohatgi, R. & Siebold, C. Multiple ligand binding sites 
regulate the Hedgehog signal transducer Smoothened in vertebrates. Curr. Opin. 
Cell Biol. 51, 81-88, doi:10.1016/j.ceb.2017.10.004 (2018). 
 
99 Raleigh, D. R. et al. Cilia-Associated Oxysterols Activate Smoothened. Mol. Cell 
72, 316-327 e315, doi:10.1016/j.molcel.2018.08.034 (2018). 
 
100 Pusapati, G. V. et al. G protein-coupled receptors control the sensitivity of cells to 
the morphogen Sonic Hedgehog. Sci Signal 11, doi:10.1126/scisignal.aao5749 
(2018). 
 
101 Ramsbottom, S. A. & Pownall, M. E. Regulation of Hedgehog Signalling Inside 
and Outside the Cell. J Dev Biol 4, 23, doi:10.3390/jdb4030023 (2016). 
 
102 Zhang, B. et al. Patched1-ArhGAP36-PKA-Inversin axis determines the ciliary 
translocation of Smoothened for Sonic Hedgehog pathway activation. Proc. Natl. 
Acad. Sci. U. S. A. 116, 874-879, doi:10.1073/pnas.1804042116 (2019). 
 
103 Ding, Q. et al. Mouse suppressor of fused is a negative regulator of sonic 
hedgehog signaling and alters the subcellular distribution of Gli1. Curr. Biol. 9, 
1119-1122, doi:10.1016/s0960-9822(99)80482-5 (1999). 
 
104 Tukachinsky, H., Lopez, L. V. & Salic, A. A mechanism for vertebrate Hedgehog 
signaling: recruitment to cilia and dissociation of SuFu-Gli protein complexes. J. 
Cell Biol. 191, 415-428, doi:10.1083/jcb.201004108 (2010). 
 
 175 
105 Humke, E. W., Dorn, K. V., Milenkovic, L., Scott, M. P. & Rohatgi, R. The 
output of Hedgehog signaling is controlled by the dynamic association between 
Suppressor of Fused and the Gli proteins. Genes Dev. 24, 670-682, 
doi:10.1101/gad.1902910 (2010). 
 
106 Li, S., Ma, G., Wang, B. & Jiang, J. Hedgehog induces formation of PKA-
Smoothened complexes to promote Smoothened phosphorylation and pathway 
activation. Sci Signal 7, ra62, doi:10.1126/scisignal.2005414 (2014). 
 
107 Chen, Y. et al. Dual Phosphorylation of suppressor of fused (Sufu) by PKA and 
GSK3beta regulates its stability and localization in the primary cilium. J. Biol. 
Chem. 286, 13502-13511, doi:10.1074/jbc.M110.217604 (2011). 
 
108 Brennan, D., Chen, X., Cheng, L., Mahoney, M. & Riobo, N. A. Noncanonical 
Hedgehog signaling. Vitam. Horm. 88, 55-72, doi:10.1016/B978-0-12-394622-
5.00003-1 (2012). 
 
109 Pathi, S. et al. Comparative biological responses to human Sonic, Indian, and 
Desert hedgehog. Mech. Dev. 106, 107-117, doi:10.1016/s0925-4773(01)00427-0 
(2001). 
 
110 Barnes, E. A., Heidtman, K. J. & Donoghue, D. J. Constitutive activation of the 
shh-ptc1 pathway by a patched1 mutation identified in BCC. Oncogene 24, 902-
915, doi:10.1038/sj.onc.1208240 (2005). 
 
111 Chinchilla, P., Xiao, L., Kazanietz, M. G. & Riobo, N. A. Hedgehog proteins 
activate pro-angiogenic responses in endothelial cells through non-canonical 
signaling pathways. Cell Cycle 9, 570-579, doi:10.4161/cc.9.3.10591 (2010). 
 
112 Polizio, A. H. et al. Heterotrimeric Gi proteins link Hedgehog signaling to 
activation of Rho small GTPases to promote fibroblast migration. J. Biol. Chem. 
286, 19589-19596, doi:10.1074/jbc.M110.197111 (2011). 
 
113 Hoffmann, A. D., Peterson, M. A., Friedland-Little, J. M., Anderson, S. A. & 
Moskowitz, I. P. sonic hedgehog is required in pulmonary endoderm for atrial 
septation. Development 136, 1761-1770, doi:10.1242/dev.034157 (2009). 
 
114 Briggs, L. E. et al. Wnt/beta-catenin and sonic hedgehog pathways interact in the 
regulation of the development of the dorsal mesenchymal protrusion. Dev. Dyn. 
245, 103-113, doi:10.1002/dvdy.24339 (2016). 
 
115 Wiegering, A., Ruther, U. & Gerhardt, C. The Role of Hedgehog Signalling in the 
Formation of the Ventricular Septum. J Dev Biol 5, doi:10.3390/jdb5040017 
(2017). 
 176 
116 Levine, R. A. et al. Mitral valve disease--morphology and mechanisms. Nat. Rev. 
Cardiol. 12, 689-710, doi:10.1038/nrcardio.2015.161 (2015). 
 
117 Brazile, B. et al. On the bending properties of porcine mitral, tricuspid, aortic, and 
pulmonary valve leaflets. J. Long. Term Eff. Med. Implants 25, 41-53, 
doi:10.1615/jlongtermeffmedimplants.2015011741 (2015). 
 
118 Shah, P. M. Current concepts in mitral valve prolapse--diagnosis and 
management. J. Cardiol. 56, 125-133, doi:10.1016/j.jjcc.2010.06.004 (2010). 
 
119 Nkomo, V. T. et al. Burden of valvular heart diseases: a population-based study. 
Lancet 368, 1005-1011, doi:10.1016/S0140-6736(06)69208-8 (2006). 
 
120 Levine, R. A., Triulzi, M. O., Harrigan, P. & Weyman, A. E. The relationship of 
mitral annular shape to the diagnosis of mitral valve prolapse. Circulation 75, 
756-767, doi:10.1161/01.cir.75.4.756 (1987). 
 
121 Durst, R. et al. Mutations in DCHS1 cause mitral valve prolapse. Nature 525, 
109-113, doi:10.1038/nature14670 (2015). 
 
122 Mirabel, M. et al. What are the characteristics of patients with severe, 
symptomatic, mitral regurgitation who are denied surgery? Eur. Heart J. 28, 
1358-1365, doi:10.1093/eurheartj/ehm001 (2007). 
 
123 Del Val, D. et al. Early Experience With Transcatheter Mitral Valve 
Replacement: A Systematic Review. J Am Heart Assoc 8, e013332, 
doi:10.1161/JAHA.119.013332 (2019). 
 
124 Fedak, P. W. et al. Clinical and pathophysiological implications of a bicuspid 
aortic valve. Circulation 106, 900-904, doi:10.1161/01.cir.0000027905.26586.e8 
(2002). 
 
125 Sievers, H. H. & Schmidtke, C. A classification system for the bicuspid aortic 
valve from 304 surgical specimens. J. Thorac. Cardiovasc. Surg. 133, 1226-1233, 
doi:10.1016/j.jtcvs.2007.01.039 (2007). 
 
126 Mahadevia, R. et al. Bicuspid aortic cusp fusion morphology alters aortic three-
dimensional outflow patterns, wall shear stress, and expression of aortopathy. 
Circulation 129, 673-682, doi:10.1161/CIRCULATIONAHA.113.003026 (2014). 
 
127 Liu, T. et al. Bicuspid Aortic Valve: An Update in Morphology, Genetics, 
Biomarker, Complications, Imaging Diagnosis and Treatment. Front. Physiol. 9, 
1921, doi:10.3389/fphys.2018.01921 (2018). 
 
 177 
128 Tzemos, N. et al. Outcomes in adults with bicuspid aortic valves. JAMA 300, 
1317-1325, doi:10.1001/jama.300.11.1317 (2008). 
 
129 Michelena, H. I. et al. Incidence of aortic complications in patients with bicuspid 
aortic valves. JAMA 306, 1104-1112, doi:10.1001/jama.2011.1286 (2011). 
 
130 Rajamannan, N. M., Gersh, B. & Bonow, R. O. Calcific aortic stenosis: from 
bench to the bedside--emerging clinical and cellular concepts. Heart 89, 801-805, 
doi:10.1136/heart.89.7.801 (2003). 
 
131 Lindman, B. R. et al. Calcific aortic stenosis. Nat Rev Dis Primers 2, 16006, 
doi:10.1038/nrdp.2016.6 (2016). 
 
132 Kari, F. A., Beyersdorf, F. & Siepe, M. Pathophysiological implications of 
different bicuspid aortic valve configurations. Cardiol. Res. Pract. 2012, 735829, 
doi:10.1155/2012/735829 (2012). 
 
133 De Mozzi, P., Longo, U. G., Galanti, G. & Maffulli, N. Bicuspid aortic valve: a 
literature review and its impact on sport activity. Br. Med. Bull. 85, 63-85, 
doi:10.1093/bmb/ldn002 (2008). 
 
134 Wu, B. & Guo, W. The Exocyst at a Glance. J. Cell Sci. 128, 2957-2964, 
doi:10.1242/jcs.156398 (2015). 
 
135 Choi, S. Y. et al. Cdc42 and sec10 Are Required for Normal Retinal Development 
in Zebrafish. Invest. Ophthalmol. Vis. Sci. 56, 3361-3370, doi:10.1167/iovs.14-
15692 (2015). 
 
136 Zuo, X., Guo, W. & Lipschutz, J. H. The exocyst protein Sec10 is necessary for 
primary ciliogenesis and cystogenesis in vitro. Mol. Biol. Cell 20, 2522-2529, 
doi:10.1091/mbc.E08-07-0772 (2009). 
 
137 Seixas, C. et al. Arl13b and the exocyst interact synergistically in ciliogenesis. 
Mol. Biol. Cell 27, 308-320, doi:10.1091/mbc.E15-02-0061 (2016). 
 
138 Zuo, X. et al. The exocyst acting through the primary cilium is necessary for renal 
ciliogenesis, cystogenesis, and tubulogenesis. J. Biol. Chem. 294, 6710-6718, 
doi:10.1074/jbc.RA118.006527 (2019). 
 
139 Fogelgren, B. et al. Urothelial Defects from Targeted Inactivation of Exocyst 
Sec10 in Mice Cause Ureteropelvic Junction Obstructions. PLoS One 10, 
e0129346, doi:10.1371/journal.pone.0129346 (2015). 
 
 178 
140 Lobo, G. P. et al. The exocyst is required for photoreceptor ciliogenesis and 
retinal development. J. Biol. Chem. 292, 14814-14826, 
doi:10.1074/jbc.M117.795674 (2017). 
 
141 Martin-Urdiroz, M., Deeks, M. J., Horton, C. G., Dawe, H. R. & Jourdain, I. The 
Exocyst Complex in Health and Disease. Front Cell Dev Biol 4, 24, 
doi:10.3389/fcell.2016.00024 (2016). 
 
142 Mizuno, S. et al. Peri-implantation lethality in mice carrying megabase-scale 
deletion on 5qc3.3 is caused by Exoc1 null mutation. Sci. Rep. 5, 13632, 
doi:10.1038/srep13632 (2015). 
 
143 Dixon-Salazar, T. J. et al. Exome sequencing can improve diagnosis and alter 
patient management. Sci. Transl. Med. 4, 138ra178, 
doi:10.1126/scitranslmed.3003544 (2012). 
 
144 Gilboa, S. M. et al. Congenital Heart Defects in the United States: Estimating the 
Magnitude of the Affected Population in 2010. Circulation 134, 101-109, 
doi:10.1161/CIRCULATIONAHA.115.019307 (2016). 
 
145 Michelena, H. I. et al. Bicuspid aortic valve: identifying knowledge gaps and 
rising to the challenge from the International Bicuspid Aortic Valve Consortium 
(BAVCon). Circulation 129, 2691-2704, 
doi:10.1161/CIRCULATIONAHA.113.007851 (2014). 
 
146 van der Linde, D. et al. Birth prevalence of congenital heart disease worldwide: a 
systematic review and meta-analysis. J. Am. Coll. Cardiol. 58, 2241-2247, 
doi:10.1016/j.jacc.2011.08.025 (2011). 
 
147 Reller, M. D., Strickland, M. J., Riehle-Colarusso, T., Mahle, W. T. & Correa, A. 
Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J. 
Pediatr. 153, 807-813, doi:10.1016/j.jpeds.2008.05.059 (2008). 
 
148 Mordi, I. & Tzemos, N. Bicuspid aortic valve disease: a comprehensive review. 
Cardiol. Res. Pract. 2012, 196037, doi:10.1155/2012/196037 (2012). 
 
149 Bonachea, E. M. et al. Rare GATA5 sequence variants identified in individuals 
with bicuspid aortic valve. Pediatr. Res. 76, 211-216, doi:10.1038/pr.2014.67 
(2014). 
 
150 Garg, V. et al. Mutations in NOTCH1 cause aortic valve disease. Nature 437, 
270-274, doi:10.1038/nature03940 (2005). 
 
 179 
151 Giusti, B. et al. Genetic Bases of Bicuspid Aortic Valve: The Contribution of 
Traditional and High-Throughput Sequencing Approaches on Research and 
Diagnosis. Front. Physiol. 8, 612, doi:10.3389/fphys.2017.00612 (2017). 
 
152 Pepe, G. et al. Identification of fibrillin 1 gene mutations in patients with bicuspid 
aortic valve (BAV) without Marfan syndrome. BMC Med. Genet. 15, 23, 
doi:10.1186/1471-2350-15-23 (2014). 
 
153 Karp, N., Grosse-Wortmann, L. & Bowdin, S. Severe aortic stenosis, bicuspid 
aortic valve and atrial septal defect in a child with Joubert Syndrome and Related 
Disorders (JSRD) - a case report and review of congenital heart defects reported 
in the human ciliopathies. Eur. J. Med. Genet. 55, 605-610, 
doi:10.1016/j.ejmg.2012.07.010 (2012). 
 
154 Liu, Q. et al. The proteome of the mouse photoreceptor sensory cilium complex. 
Mol. Cell. Proteomics 6, 1299-1317, doi:10.1074/mcp.M700054-MCP200 (2007). 
 
155 Choi, S. Y. et al. Cdc42 deficiency causes ciliary abnormalities and cystic 
kidneys. J. Am. Soc. Nephrol. 24, 1435-1450, doi:10.1681/ASN.2012121236 
(2013). 
 
156 Zuo, X., Fogelgren, B. & Lipschutz, J. H. The small GTPase Cdc42 is necessary 
for primary ciliogenesis in renal tubular epithelial cells. J. Biol. Chem. 286, 
22469-22477, doi:10.1074/jbc.M111.238469 (2011). 
 
157 Lipschutz, J. H. & Mostov, K. E. Exocytosis: the many masters of the exocyst. 
Curr. Biol. 12, R212-214, doi:10.1016/s0960-9822(02)00753-4 (2002). 
 
158 Stoetzel, C. et al. A mutation in VPS15 (PIK3R4) causes a ciliopathy and affects 
IFT20 release from the cis-Golgi. Nat Commun 7, 13586, 
doi:10.1038/ncomms13586 (2016). 
 
159 Fogelgren, B. et al. The exocyst protein Sec10 interacts with Polycystin-2 and 
knockdown causes PKD-phenotypes. PLoS Genet. 7, e1001361, 
doi:10.1371/journal.pgen.1001361 (2011). 
 
160 Mazelova, J. et al. Ciliary targeting motif VxPx directs assembly of a trafficking 
module through Arf4. EMBO J. 28, 183-192, doi:10.1038/emboj.2008.267 
(2009). 
 
161 Wu, B. et al. Endocardial cells form the coronary arteries by angiogenesis through 
myocardial-endocardial VEGF signaling. Cell 151, 1083-1096, 
doi:10.1016/j.cell.2012.10.023 (2012). 
 180 
162 Gu, X. & Masters, K. S. Role of the MAPK/ERK pathway in valvular interstitial 
cell calcification. Am. J. Physiol. Heart Circ. Physiol. 296, H1748-1757, 
doi:10.1152/ajpheart.00099.2009 (2009). 
 
163 Munjal, C. et al. Inhibition of MAPK-Erk pathway in vivo attenuates aortic valve 
disease processes in Emilin1-deficient mouse model. Physiol Rep 5, 
doi:10.14814/phy2.13152 (2017). 
 
164 Sadaba, J. R. et al. Role for Galectin-3 in Calcific Aortic Valve Stenosis. J Am 
Heart Assoc 5, doi:10.1161/JAHA.116.004360 (2016). 
 
165 Roberts, W. C. & Ko, J. M. Frequency by decades of unicuspid, bicuspid, and 
tricuspid aortic valves in adults having isolated aortic valve replacement for aortic 
stenosis, with or without associated aortic regurgitation. Circulation 111, 920-
925, doi:10.1161/01.CIR.0000155623.48408.C5 (2005). 
 
166 Grisanti, L., Revenkova, E., Gordon, R. E. & Iomini, C. Primary cilia maintain 
corneal epithelial homeostasis by regulation of the Notch signaling pathway. 
Development 143, 2160-2171, doi:10.1242/dev.132704 (2016). 
 
167 Tsao, P. N. et al. Notch signaling controls the balance of ciliated and secretory 
cell fates in developing airways. Development 136, 2297-2307, 
doi:10.1242/dev.034884 (2009). 
 
168 Prigent, M. et al. ARF6 controls post-endocytic recycling through its downstream 
exocyst complex effector. J. Cell Biol. 163, 1111-1121, 
doi:10.1083/jcb.200305029 (2003). 
 
169 Levine, R. A., Jerosch-Herold, M. & Hajjar, R. J. Mitral Valve Prolapse: A 
Disease of Valve and Ventricle. J. Am. Coll. Cardiol. 72, 835-837, 
doi:10.1016/j.jacc.2018.07.006 (2018). 
 
170 Delling, F. N. et al. Evolution of Mitral Valve Prolapse: Insights From the 
Framingham Heart Study. Circulation 133, 1688-1695, 
doi:10.1161/CIRCULATIONAHA.115.020621 (2016). 
 
171 Delling, F. N. et al. Mild expression of mitral valve prolapse in the Framingham 
offspring: expanding the phenotypic spectrum. J. Am. Soc. Echocardiogr. 27, 17-
23, doi:10.1016/j.echo.2013.09.015 (2014). 
 
172 Freed, L. A. et al. Mitral valve prolapse in the general population: the benign 
nature of echocardiographic features in the Framingham Heart Study. J. Am. Coll. 
Cardiol. 40, 1298-1304, doi:10.1016/s0735-1097(02)02161-7 (2002). 
 
 181 
173 Freed, L. A. et al. Prevalence and clinical outcome of mitral-valve prolapse. N. 
Engl. J. Med. 341, 1-7, doi:10.1056/NEJM199907013410101 (1999). 
 
174 Levine, R. A. et al. Three-dimensional echocardiographic reconstruction of the 
mitral valve, with implications for the diagnosis of mitral valve prolapse. 
Circulation 80, 589-598, doi:10.1161/01.cir.80.3.589 (1989). 
 
175 Basso, C. et al. Arrhythmic Mitral Valve Prolapse and Sudden Cardiac Death. 
Circulation 132, 556-566, doi:10.1161/CIRCULATIONAHA.115.016291 (2015). 
 
176 Devereux, R. B., Kramer-Fox, R. & Kligfield, P. Mitral valve prolapse: causes, 
clinical manifestations, and management. Ann. Intern. Med. 111, 305-317, 
doi:10.7326/0003-4819-111-4-305 (1989). 
 
177 Perloff, J. K. & Child, J. S. Clinical and epidemiologic issues in mitral valve 
prolapse: overview and perspective. Am. Heart J. 113, 1324-1332, 
doi:10.1016/0002-8703(87)90961-6 (1987). 
 
178 Lum, L. & Beachy, P. A. The Hedgehog response network: sensors, switches, and 
routers. Science 304, 1755-1759, doi:10.1126/science.1098020 (2004). 
 
179 Lum, L. et al. Hedgehog signal transduction via Smoothened association with a 
cytoplasmic complex scaffolded by the atypical kinesin, Costal-2. Mol. Cell 12, 
1261-1274, doi:10.1016/s1097-2765(03)00426-x (2003). 
 
180 Caradu, C. et al. Restoring Endothelial Function by Targeting Desert Hedgehog 
Downstream of Klf2 Improves Critical Limb Ischemia in Adults. Circ. Res. 123, 
1053-1065, doi:10.1161/CIRCRESAHA.118.313177 (2018). 
 
181 Wu, B. et al. Nfatc1 coordinates valve endocardial cell lineage development 
required for heart valve formation. Circ. Res. 109, 183-192, 
doi:10.1161/CIRCRESAHA.111.245035 (2011). 
 
182 Dai, P. et al. Sonic Hedgehog-induced activation of the Gli1 promoter is mediated 
by GLI3. J. Biol. Chem. 274, 8143-8152, doi:10.1074/jbc.274.12.8143 (1999). 
 
183 Sasaki, H., Nishizaki, Y., Hui, C., Nakafuku, M. & Kondoh, H. Regulation of 
Gli2 and Gli3 activities by an amino-terminal repression domain: implication of 
Gli2 and Gli3 as primary mediators of Shh signaling. Development 126, 3915-
3924 (1999). 
 
184 Wang, B., Fallon, J. F. & Beachy, P. A. Hedgehog-regulated processing of Gli3 
produces an anterior/posterior repressor gradient in the developing vertebrate 
limb. Cell 100, 423-434, doi:10.1016/s0092-8674(00)80678-9 (2000). 
 182 
185 Gould, R. A. et al. Cyclic Mechanical Loading Is Essential for Rac1-Mediated 
Elongation and Remodeling of the Embryonic Mitral Valve. Curr. Biol. 26, 27-
37, doi:10.1016/j.cub.2015.11.033 (2016). 
 
186 Taipale, J. et al. Effects of oncogenic mutations in Smoothened and Patched can 
be reversed by cyclopamine. Nature 406, 1005-1009, doi:10.1038/35023008 
(2000). 
 
187 Horne, T. E. et al. Dynamic Heterogeneity of the Heart Valve Interstitial Cell 
Population in Mitral Valve Health and Disease. J Cardiovasc Dev Dis 2, 214-232, 
doi:10.3390/jcdd2030214 (2015). 
 
188 Versaevel, M., Grevesse, T. & Gabriele, S. Spatial coordination between cell and 
nuclear shape within micropatterned endothelial cells. Nat Commun 3, 671, 
doi:10.1038/ncomms1668 (2012). 
 
189 Farsi, J. M. & Aubin, J. E. Microfilament rearrangements during fibroblast-
induced contraction of three-dimensional hydrated collagen gels. Cell Motil. 4, 
29-40, doi:10.1002/cm.970040105 (1984). 
 
190 D'Addario, M., Arora, P. D., Ellen, R. P. & McCulloch, C. A. Interaction of p38 
and Sp1 in a mechanical force-induced, beta 1 integrin-mediated transcriptional 
circuit that regulates the actin-binding protein filamin-A. J. Biol. Chem. 277, 
47541-47550, doi:10.1074/jbc.M207681200 (2002). 
 
191 D'Addario, M., Arora, P. D., Ellen, R. P. & McCulloch, C. A. Regulation of 
tension-induced mechanotranscriptional signals by the microtubule network in 
fibroblasts. J. Biol. Chem. 278, 53090-53097, doi:10.1074/jbc.M309027200 
(2003). 
 
192 D'Addario, M. et al. Cytoprotection against mechanical forces delivered through 
beta 1 integrins requires induction of filamin A. J. Biol. Chem. 276, 31969-31977, 
doi:10.1074/jbc.M102715200 (2001). 
 
193 Ehrlicher, A. J., Nakamura, F., Hartwig, J. H., Weitz, D. A. & Stossel, T. P. 
Mechanical strain in actin networks regulates FilGAP and integrin binding to 
filamin A. Nature 478, 260-263, doi:10.1038/nature10430 (2011). 
 
194 Sandbo, N. & Dulin, N. Actin cytoskeleton in myofibroblast differentiation: 






195 Lim, S. M., Trzeciakowski, J. P., Sreenivasappa, H., Dangott, L. J. & Trache, A. 
RhoA-induced cytoskeletal tension controls adaptive cellular remodeling to 
mechanical signaling. Integr. Biol. (Camb.) 4, 615-627, doi:10.1039/c2ib20008b 
(2012). 
 
196 Duval, D. et al. Valvular dystrophy associated filamin A mutations reveal a new 
role of its first repeats in small-GTPase regulation. Biochim. Biophys. Acta 1843, 
234-244, doi:10.1016/j.bbamcr.2013.10.022 (2014). 
 
197 Sasaki, N., Kurisu, J. & Kengaku, M. Sonic hedgehog signaling regulates actin 
cytoskeleton via Tiam1-Rac1 cascade during spine formation. Mol. Cell. 
Neurosci. 45, 335-344, doi:10.1016/j.mcn.2010.07.006 (2010). 
 
198 Rabkin, E. et al. Activated interstitial myofibroblasts express catabolic enzymes 
and mediate matrix remodeling in myxomatous heart valves. Circulation 104, 
2525-2532, doi:10.1161/hc4601.099489 (2001). 
 
199 Rabkin-Aikawa, E., Farber, M., Aikawa, M. & Schoen, F. J. Dynamic and 
reversible changes of interstitial cell phenotype during remodeling of cardiac 
valves. J. Heart Valve Dis. 13, 841-847 (2004). 
 
200 Hjortnaes, J. et al. Comparative Histopathological Analysis of Mitral Valves in 
Barlow Disease and Fibroelastic Deficiency. Semin. Thorac. Cardiovasc. Surg. 
28, 757-767, doi:10.1053/j.semtcvs.2016.08.015 (2016). 
 
201 Sauls, K. et al. Increased Infiltration of Extra-Cardiac Cells in Myxomatous Valve 
Disease. J Cardiovasc Dev Dis 2, 200-213, doi:10.3390/jcdd2030200 (2015). 
 
202 Hulin, A. et al. Macrophage Transitions in Heart Valve Development and 
Myxomatous Valve Disease. Arterioscler. Thromb. Vasc. Biol. 38, 636-644, 
doi:10.1161/ATVBAHA.117.310667 (2018). 
 
203 Dina, C. et al. Genetic association analyses highlight biological pathways 
underlying mitral valve prolapse. Nat. Genet. 47, 1206-1211, 
doi:10.1038/ng.3383 (2015). 
 
204 Yu, M. et al. Genome-Wide Association Study-Driven Gene-Set Analyses, 
Genetic, and Functional Follow-Up Suggest GLIS1 as a Susceptibility Gene for 
Mitral Valve Prolapse. Circ Genom Precis Med 12, e002497, 
doi:10.1161/CIRCGEN.119.002497 (2019). 
 
205 Liu, A., Wang, B. & Niswander, L. A. Mouse intraflagellar transport proteins 
regulate both the activator and repressor functions of Gli transcription factors. 




206 Wang, C., Low, W. C., Liu, A. & Wang, B. Centrosomal protein DZIP1 regulates 
Hedgehog signaling by promoting cytoplasmic retention of transcription factor 
GLI3 and affecting ciliogenesis. J. Biol. Chem. 288, 29518-29529, 
doi:10.1074/jbc.M113.492066 (2013). 
 
207 Tay, S. Y. et al. The iguana/DZIP1 protein is a novel component of the ciliogenic 
pathway essential for axonemal biogenesis. Dev. Dyn. 239, 527-534, 
doi:10.1002/dvdy.22199 (2010). 
 
208 Kim, H. R., Richardson, J., van Eeden, F. & Ingham, P. W. Gli2a protein 
localization reveals a role for Iguana/DZIP1 in primary ciliogenesis and a 
dependence of Hedgehog signal transduction on primary cilia in the zebrafish. 
BMC Biol. 8, 65, doi:10.1186/1741-7007-8-65 (2010). 
 
209 Wolff, C. et al. iguana encodes a novel zinc-finger protein with coiled-coil 
domains essential for Hedgehog signal transduction in the zebrafish embryo. 
Genes Dev. 18, 1565-1576, doi:10.1101/gad.296004 (2004). 
 
210 Sekimizu, K. et al. The zebrafish iguana locus encodes Dzip1, a novel zinc-finger 
protein required for proper regulation of Hedgehog signaling. Development 131, 
2521-2532, doi:10.1242/dev.01059 (2004). 
 
211 Goddeeris, M. M. et al. Intracardiac septation requires hedgehog-dependent 
cellular contributions from outside the heart. Development 135, 1887-1895, 
doi:10.1242/dev.016147 (2008). 
 
212 Butcher, J. T., McQuinn, T. C., Sedmera, D., Turner, D. & Markwald, R. R. 
Transitions in early embryonic atrioventricular valvular function correspond with 
changes in cushion biomechanics that are predictable by tissue composition. Circ. 
Res. 100, 1503-1511, doi:10.1161/CIRCRESAHA.107.148684 (2007). 
 
213 Butcher, J. T., Norris, R. A., Hoffman, S., Mjaatvedt, C. H. & Markwald, R. R. 
Periostin promotes atrioventricular mesenchyme matrix invasion and remodeling 
mediated by integrin signaling through Rho/PI 3-kinase. Dev. Biol. 302, 256-266, 
doi:10.1016/j.ydbio.2006.09.048 (2007). 
 
214 Yalcin, H. C., Shekhar, A., McQuinn, T. C. & Butcher, J. T. Hemodynamic 
patterning of the avian atrioventricular valve. Dev. Dyn. 240, 23-35, 
doi:10.1002/dvdy.22512 (2011). 
 
215 Kapacee, Z. et al. Tension is required for fibripositor formation. Matrix Biol. 27, 
371-375, doi:10.1016/j.matbio.2007.11.006 (2008). 
 
 185 
216 Toomer, K. et al. Filamin-A as a Balance between Erk/Smad Activities During 
Cardiac Valve Development. Anat Rec (Hoboken) 302, 117-124, 
doi:10.1002/ar.23911 (2019). 
 
217 Lincoln, J. & Yutzey, K. E. Molecular and developmental mechanisms of 
congenital heart valve disease. Birth Defects Res. A Clin. Mol. Teratol. 91, 526-
534, doi:10.1002/bdra.20799 (2011). 
 
218 Sauls, K. et al. Developmental basis for filamin-A-associated myxomatous mitral 
valve disease. Cardiovasc. Res. 96, 109-119, doi:10.1093/cvr/cvs238 (2012). 
 
219 Duval, D. et al. MVP-Associated Filamin A Mutations Affect FlnA-PTPN12 
(PTP-PEST) Interactions. J Cardiovasc Dev Dis 2, 233-247, 
doi:10.3390/jcdd2030233 (2015). 
 
220 Christensen, S. T., Veland, I. R., Schwab, A., Cammer, M. & Satir, P. Analysis of 
primary cilia in directional cell migration in fibroblasts. Methods Enzymol. 525, 
45-58, doi:10.1016/B978-0-12-397944-5.00003-1 (2013). 
 
221 McGowan, S. E. & McCoy, D. M. Platelet-derived growth factor-A and sonic 
hedgehog signaling direct lung fibroblast precursors during alveolar septal 
formation. Am. J. Physiol. Lung Cell Mol. Physiol. 305, L229-239, 
doi:10.1152/ajplung.00011.2013 (2013). 
 
222 Han, S. J. et al. Deficiency of primary cilia in kidney epithelial cells induces 
epithelial to mesenchymal transition. Biochem. Biophys. Res. Commun. 496, 450-
454, doi:10.1016/j.bbrc.2018.01.079 (2018). 
 
223 Rodriguez-Ribera, L., Slattery, C., Mc Morrow, T., Marcos, R. & Pastor, S. 
Reactive carbonyl compounds impair wound healing by vimentin collapse and 
loss of the primary cilium. Food Chem. Toxicol. 108, 128-138, 
doi:10.1016/j.fct.2017.07.055 (2017). 
 
224 Seeger-Nukpezah, T. & Golemis, E. A. The extracellular matrix and ciliary 
signaling. Curr. Opin. Cell Biol. 24, 652-661, doi:10.1016/j.ceb.2012.06.002 
(2012). 
 
225 Villalobos, E. et al. Fibroblast Primary Cilia Are Required for Cardiac Fibrosis. 
Circulation 139, 2342-2357, doi:10.1161/CIRCULATIONAHA.117.028752 
(2019). 
 
226 Tuzun, E. et al. Assessment of aortic valve pressure overload and leaflet functions 
in an ex vivo beating heart loaded with a continuous flow cardiac assist device. 
Eur. J. Cardiothorac. Surg. 45, 377-383, doi:10.1093/ejcts/ezt355 (2014). 
 
 186 
227 Rahimi, K. et al. Elevated blood pressure and risk of mitral regurgitation: A 
longitudinal cohort study of 5.5 million United Kingdom adults. PLoS Med. 14, 
e1002404, doi:10.1371/journal.pmed.1002404 (2017). 
 
228 Singh, J. P. et al. Prevalence and clinical determinants of mitral, tricuspid, and 
aortic regurgitation (the Framingham Heart Study). Am. J. Cardiol. 83, 897-902, 
doi:10.1016/s0002-9149(98)01064-9 (1999). 
 
229 Tabibiazar, R., Wagner, R. A., Liao, A. & Quertermous, T. Transcriptional 
profiling of the heart reveals chamber-specific gene expression patterns. Circ. 
Res. 93, 1193-1201, doi:10.1161/01.RES.0000103171.42654.DD (2003). 
 
230 Dreger, S. A., Taylor, P. M., Allen, S. P. & Yacoub, M. H. Profile and 
localization of matrix metalloproteinases (MMPs) and their tissue inhibitors 
(TIMPs) in human heart valves. J. Heart Valve Dis. 11, 875-880; discussion 880 
(2002). 
 
231 Roberts, W. C., Zafar, S., Ko, J. M., Carry, M. M. & Hebeler, R. F. Combined 
congenitally bicuspid aortic valve and mitral valve prolapse causing pure 
regurgitation. Proc. (Bayl. Univ. Med. Cent.) 26, 30-32, 
doi:10.1080/08998280.2013.11928908 (2013). 
 
232 Padang, R. et al. Coexistent bicuspid aortic valve and mitral valve prolapse: 
epidemiology, phenotypic spectrum, and clinical implications. Eur. Heart J. 
Cardiovasc. Imaging 20, 677-686, doi:10.1093/ehjci/jey166 (2019). 
 
233 Perry, C. J. & Lawrence, A. J. Hurdles in Basic Science Translation. Front. 
Pharmacol. 8, 478, doi:10.3389/fphar.2017.00478 (2017). 
 
